ZA200508847B - Novel methods for the treatment of inflammatory diseases - Google Patents
Novel methods for the treatment of inflammatory diseases Download PDFInfo
- Publication number
- ZA200508847B ZA200508847B ZA200508847A ZA200508847A ZA200508847B ZA 200508847 B ZA200508847 B ZA 200508847B ZA 200508847 A ZA200508847 A ZA 200508847A ZA 200508847 A ZA200508847 A ZA 200508847A ZA 200508847 B ZA200508847 B ZA 200508847B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- compound according
- compound
- aryl
- hydrogen
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 68
- 238000000034 method Methods 0.000 title claims description 66
- 208000027866 inflammatory disease Diseases 0.000 title claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 231
- 125000000217 alkyl group Chemical group 0.000 claims description 130
- 239000003862 glucocorticoid Substances 0.000 claims description 96
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 90
- 201000010099 disease Diseases 0.000 claims description 84
- 229910052739 hydrogen Inorganic materials 0.000 claims description 83
- 239000001257 hydrogen Substances 0.000 claims description 67
- 150000002431 hydrogen Chemical class 0.000 claims description 57
- 125000003342 alkenyl group Chemical group 0.000 claims description 47
- 102000004127 Cytokines Human genes 0.000 claims description 40
- 108090000695 Cytokines Proteins 0.000 claims description 40
- 229910052799 carbon Inorganic materials 0.000 claims description 37
- 230000004071 biological effect Effects 0.000 claims description 36
- 230000000694 effects Effects 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 34
- 125000000304 alkynyl group Chemical group 0.000 claims description 33
- 125000003118 aryl group Chemical group 0.000 claims description 32
- -1 mono-substituted methylene Chemical group 0.000 claims description 31
- 230000002401 inhibitory effect Effects 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 26
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 25
- 235000000346 sugar Nutrition 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 229940002612 prodrug Drugs 0.000 claims description 21
- 239000000651 prodrug Substances 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
- NAVXWOJDWMVTHF-UHFFFAOYSA-N 4-[2-(2-hydroxyethoxy)-1,3-dioxolan-2-yl]-2-methylphenol Chemical compound C1=C(O)C(C)=CC(C2(OCCO)OCCO2)=C1 NAVXWOJDWMVTHF-UHFFFAOYSA-N 0.000 claims description 17
- 150000003431 steroids Chemical class 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 15
- 150000001721 carbon Chemical group 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 238000011321 prophylaxis Methods 0.000 claims description 12
- WEAGCQRXAUJTKK-UHFFFAOYSA-N 2-ethyl-2-(4-methoxyphenyl)-1,3-dioxolane Chemical compound C=1C=C(OC)C=CC=1C1(CC)OCCO1 WEAGCQRXAUJTKK-UHFFFAOYSA-N 0.000 claims description 11
- SEBSCXLWNCIHNW-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-1,3-thiazolidine Chemical compound C1=C(OC)C(OC)=CC=C1C1SCCN1 SEBSCXLWNCIHNW-UHFFFAOYSA-N 0.000 claims description 10
- SJJBGUKAMAMLBQ-UHFFFAOYSA-N 2-hexyl-2-(4-methylphenyl)-1,3-dithiolane Chemical compound C=1C=C(C)C=CC=1C1(CCCCCC)SCCS1 SJJBGUKAMAMLBQ-UHFFFAOYSA-N 0.000 claims description 10
- KWVQAQAGCKSKKD-UHFFFAOYSA-N 4-[2-(2-hydroxyethoxy)-1,3-dioxolan-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C1(OCCO)OCCO1 KWVQAQAGCKSKKD-UHFFFAOYSA-N 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 208000019553 vascular disease Diseases 0.000 claims description 10
- IDLQZSAXYMNZIS-UHFFFAOYSA-N 2-(4-thiophen-2-ylphenyl)-1,3-oxathiolane Chemical compound O1CCSC1C1=CC=C(C=2SC=CC=2)C=C1 IDLQZSAXYMNZIS-UHFFFAOYSA-N 0.000 claims description 9
- BSLYORCAGNIGOR-UHFFFAOYSA-N 4-(1,3-thiazolidin-2-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1SCCN1 BSLYORCAGNIGOR-UHFFFAOYSA-N 0.000 claims description 9
- 208000006673 asthma Diseases 0.000 claims description 9
- VIJTVHWVRFFLIY-UHFFFAOYSA-N 2-(4-bromophenyl)-2-butyl-1,3-dioxolane Chemical compound C=1C=C(Br)C=CC=1C1(CCCC)OCCO1 VIJTVHWVRFFLIY-UHFFFAOYSA-N 0.000 claims description 8
- DQBXDUBUXIXTDA-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-ethyl-4-methyl-1,3-dioxolane Chemical compound C=1C=C(Cl)C=CC=1C1(CC)OCC(C)O1 DQBXDUBUXIXTDA-UHFFFAOYSA-N 0.000 claims description 8
- OEXWUSCPOOBKNK-UHFFFAOYSA-N 2-fluoro-5-(5-methyl-1,3-oxathiolan-2-yl)benzonitrile Chemical compound O1C(C)CSC1C1=CC=C(F)C(C#N)=C1 OEXWUSCPOOBKNK-UHFFFAOYSA-N 0.000 claims description 8
- VUDFXBXBTDOYQG-UHFFFAOYSA-N 2-hexyl-2-(4-methylphenyl)-1,3-dioxolane Chemical compound C=1C=C(C)C=CC=1C1(CCCCCC)OCCO1 VUDFXBXBTDOYQG-UHFFFAOYSA-N 0.000 claims description 8
- AQXQCWAXQJVTKU-UHFFFAOYSA-N 4-(1,3-dioxolan-2-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1OCCO1 AQXQCWAXQJVTKU-UHFFFAOYSA-N 0.000 claims description 8
- LKLWIAFVELDTQD-UHFFFAOYSA-N 4-(5-methyl-2-octyl-1,3-oxathiolan-2-yl)phenol Chemical compound C=1C=C(O)C=CC=1C1(CCCCCCCC)OC(C)CS1 LKLWIAFVELDTQD-UHFFFAOYSA-N 0.000 claims description 8
- KRIXHPHSQAZTRK-UHFFFAOYSA-N 5-(5,5-diethyl-1,3-dioxan-2-yl)-2-fluorobenzonitrile Chemical compound O1CC(CC)(CC)COC1C1=CC=C(F)C(C#N)=C1 KRIXHPHSQAZTRK-UHFFFAOYSA-N 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- SESLENFVZILGIS-UHFFFAOYSA-N 2-(4-bromophenyl)-2-ethyl-1,3-oxathiolane Chemical compound C=1C=C(Br)C=CC=1C1(CC)OCCS1 SESLENFVZILGIS-UHFFFAOYSA-N 0.000 claims description 7
- YHMUSIBVYIZADU-UHFFFAOYSA-N 2-(4-bromophenyl)thiazolidine Chemical compound C1=CC(Br)=CC=C1C1SCCN1 YHMUSIBVYIZADU-UHFFFAOYSA-N 0.000 claims description 7
- ARBGBCQCAFWNDH-UHFFFAOYSA-N 2-methoxy-4-(1,3-thiazolidin-2-yl)phenol Chemical compound C1=C(O)C(OC)=CC(C2SCCN2)=C1 ARBGBCQCAFWNDH-UHFFFAOYSA-N 0.000 claims description 7
- NGKHBJGPSIJYFU-UHFFFAOYSA-N 2-methyl-2-(4-methylphenyl)-1,3-dithiolane Chemical compound C1=CC(C)=CC=C1C1(C)SCCS1 NGKHBJGPSIJYFU-UHFFFAOYSA-N 0.000 claims description 7
- VSFZZQZBZSRIHI-UHFFFAOYSA-N 4-(5-methyl-1,3-oxathiolan-2-yl)benzonitrile Chemical compound O1C(C)CSC1C1=CC=C(C#N)C=C1 VSFZZQZBZSRIHI-UHFFFAOYSA-N 0.000 claims description 7
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 7
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 7
- 208000011231 Crohn disease Diseases 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 7
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 7
- 206010046851 Uveitis Diseases 0.000 claims description 7
- 230000003143 atherosclerotic effect Effects 0.000 claims description 7
- 125000004970 halomethyl group Chemical group 0.000 claims description 7
- 201000006417 multiple sclerosis Diseases 0.000 claims description 7
- 229910052727 yttrium Inorganic materials 0.000 claims description 7
- PHFZPCUENVTYTD-UHFFFAOYSA-N 2,6-dimethoxy-3-[4-(trifluoromethoxy)phenyl]pyridine Chemical compound COC1=NC(OC)=CC=C1C1=CC=C(OC(F)(F)F)C=C1 PHFZPCUENVTYTD-UHFFFAOYSA-N 0.000 claims description 6
- NDWKSWPMFTZWSX-UHFFFAOYSA-N 2-(3,4,5-trimethoxyphenyl)-1,3-oxathiolane Chemical compound COC1=C(OC)C(OC)=CC(C2SCCO2)=C1 NDWKSWPMFTZWSX-UHFFFAOYSA-N 0.000 claims description 6
- LZQULKMXHWGIBE-UHFFFAOYSA-N 2-(3,5-dimethoxyphenyl)-2-hexyl-1,3-dioxolane Chemical compound C=1C(OC)=CC(OC)=CC=1C1(CCCCCC)OCCO1 LZQULKMXHWGIBE-UHFFFAOYSA-N 0.000 claims description 6
- LUJXDUNPTBPHKA-UHFFFAOYSA-N 2-(4-bromophenyl)-2-butyl-4-propyl-1,3-oxathiane Chemical compound C=1C=C(Br)C=CC=1C1(CCCC)OCCC(CCC)S1 LUJXDUNPTBPHKA-UHFFFAOYSA-N 0.000 claims description 6
- YAFZHHREETZBER-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-methyl-1,3-dioxane Chemical compound C=1C=C(Cl)C=CC=1C1(C)OCCCO1 YAFZHHREETZBER-UHFFFAOYSA-N 0.000 claims description 6
- YMBUWFFNNVVGFS-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-methyl-1,3-dithiolane Chemical compound C=1C=C(Cl)C=CC=1C1(C)SCCS1 YMBUWFFNNVVGFS-UHFFFAOYSA-N 0.000 claims description 6
- OQFUUZFCTONCOU-UHFFFAOYSA-N 2-(4-methoxyphenyl)-1,3-thiazolidine Chemical compound C1=CC(OC)=CC=C1C1SCCN1 OQFUUZFCTONCOU-UHFFFAOYSA-N 0.000 claims description 6
- DOXCRHCGPFQNJT-UHFFFAOYSA-N 2-(4-thiophen-2-ylphenyl)-1,3-thiazolidine Chemical compound N1CCSC1C1=CC=C(C=2SC=CC=2)C=C1 DOXCRHCGPFQNJT-UHFFFAOYSA-N 0.000 claims description 6
- RSLPSONLCVSXRB-UHFFFAOYSA-N 2-methoxy-4-(1,3-oxathiolan-2-yl)phenol Chemical compound C1=C(O)C(OC)=CC(C2SCCO2)=C1 RSLPSONLCVSXRB-UHFFFAOYSA-N 0.000 claims description 6
- SVHWGVTWTUENJY-UHFFFAOYSA-N 2-methyl-2-(4-methylphenyl)-1,3-dioxane Chemical compound C1=CC(C)=CC=C1C1(C)OCCCO1 SVHWGVTWTUENJY-UHFFFAOYSA-N 0.000 claims description 6
- UGCRLXAUNINWGL-UHFFFAOYSA-N 2-methyl-2-(4-methylphenyl)-1,3-dioxolane Chemical compound C1=CC(C)=CC=C1C1(C)OCCO1 UGCRLXAUNINWGL-UHFFFAOYSA-N 0.000 claims description 6
- WFUJZBUDBNHCCP-UHFFFAOYSA-N 2-methyl-2-(4-nitrophenyl)-1,3-dioxane Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C1(C)OCCCO1 WFUJZBUDBNHCCP-UHFFFAOYSA-N 0.000 claims description 6
- HHXVQNVADPECCD-UHFFFAOYSA-N 2-methyl-2-(4-nitrophenyl)-1,3-dioxolane Chemical compound C=1C=C([N+]([O-])=O)C=CC=1C1(C)OCCO1 HHXVQNVADPECCD-UHFFFAOYSA-N 0.000 claims description 6
- ORPJXNXMVFMTMH-UHFFFAOYSA-N 4-(1,3-oxathiolan-2-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1SCCO1 ORPJXNXMVFMTMH-UHFFFAOYSA-N 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- XKLPCZOGHLMPMJ-UHFFFAOYSA-N 1-(3-methylbutyl)-4-(4-methylphenyl)pyrazole Chemical compound C1=NN(CCC(C)C)C=C1C1=CC=C(C)C=C1 XKLPCZOGHLMPMJ-UHFFFAOYSA-N 0.000 claims description 5
- NNNQMZNJWISROL-UHFFFAOYSA-N 2,6-dimethoxy-3-[4-(trifluoromethyl)phenyl]pyridine Chemical compound COC1=NC(OC)=CC=C1C1=CC=C(C(F)(F)F)C=C1 NNNQMZNJWISROL-UHFFFAOYSA-N 0.000 claims description 5
- GOYWGNGKHQRSJF-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-methyl-1,3-dioxolane Chemical compound C=1C=C(Cl)C=CC=1C1(C)OCCO1 GOYWGNGKHQRSJF-UHFFFAOYSA-N 0.000 claims description 5
- NBNWRXAIBYMACK-UHFFFAOYSA-N 2-(4-methoxyphenyl)-1,3-oxathiolane Chemical compound C1=CC(OC)=CC=C1C1SCCO1 NBNWRXAIBYMACK-UHFFFAOYSA-N 0.000 claims description 5
- NYTUDOKVKPJSOI-UHFFFAOYSA-N 2-(4-methylphenyl)-4,5-dihydro-1,3-oxazole Chemical compound C1=CC(C)=CC=C1C1=NCCO1 NYTUDOKVKPJSOI-UHFFFAOYSA-N 0.000 claims description 5
- WFRILQSDAUCMBA-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]butan-1-ol Chemical compound C=1C=C(F)C=CC=1C1(CCCCO)OCCO1 WFRILQSDAUCMBA-UHFFFAOYSA-N 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 125000004104 aryloxy group Chemical group 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- LMNFUGMCVMHJGP-UHFFFAOYSA-N 2-bromo-4-[2-(2-hydroxyethoxy)-1,3-dioxolan-2-yl]-6-methylphenol Chemical compound BrC1=C(O)C(C)=CC(C2(OCCO)OCCO2)=C1 LMNFUGMCVMHJGP-UHFFFAOYSA-N 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- JNCKNTOSZFOACM-UHFFFAOYSA-N 1-methoxy-4-[4-(trifluoromethoxy)phenyl]benzene Chemical group C1=CC(OC)=CC=C1C1=CC=C(OC(F)(F)F)C=C1 JNCKNTOSZFOACM-UHFFFAOYSA-N 0.000 claims description 3
- RJDGOJYDQPRINZ-UHFFFAOYSA-N 2-(4-chlorophenyl)-4,5-dihydro-1,3-oxazole Chemical compound C1=CC(Cl)=CC=C1C1=NCCO1 RJDGOJYDQPRINZ-UHFFFAOYSA-N 0.000 claims description 3
- PSXMDNYXVDFBJU-UHFFFAOYSA-N 4-(4-methoxyphenyl)-1-(3-methylbutyl)pyrazole Chemical compound C1=CC(OC)=CC=C1C1=CN(CCC(C)C)N=C1 PSXMDNYXVDFBJU-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 8
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 3
- VQGHOUODWALEFC-UHFFFAOYSA-N 2-phenylpyridine Chemical compound C1=CC=CC=C1C1=CC=CC=N1 VQGHOUODWALEFC-UHFFFAOYSA-N 0.000 claims 2
- XSSTWZINYCULLM-UHFFFAOYSA-N 4-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]butanoic acid Chemical compound C=1C=C(F)C=CC=1C1(CCCC(=O)O)OCCO1 XSSTWZINYCULLM-UHFFFAOYSA-N 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- JVZRCNQLWOELDU-UHFFFAOYSA-N gamma-Phenylpyridine Natural products C1=CC=CC=C1C1=CC=NC=C1 JVZRCNQLWOELDU-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 104
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 93
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 93
- 239000000243 solution Substances 0.000 description 93
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 87
- 239000003921 oil Substances 0.000 description 71
- 235000019198 oils Nutrition 0.000 description 70
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 66
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 61
- 210000004027 cell Anatomy 0.000 description 60
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 44
- 229910052757 nitrogen Inorganic materials 0.000 description 38
- 239000007787 solid Substances 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 238000002360 preparation method Methods 0.000 description 35
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 32
- 229940037128 systemic glucocorticoids Drugs 0.000 description 32
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 31
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 31
- 102000000589 Interleukin-1 Human genes 0.000 description 29
- 108010002352 Interleukin-1 Proteins 0.000 description 29
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 29
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 28
- 230000005764 inhibitory process Effects 0.000 description 26
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
- 239000002904 solvent Substances 0.000 description 24
- 238000003818 flash chromatography Methods 0.000 description 23
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- 125000005843 halogen group Chemical group 0.000 description 22
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 21
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 20
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- 239000012267 brine Substances 0.000 description 20
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 20
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 20
- 230000037396 body weight Effects 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 19
- 229940125904 compound 1 Drugs 0.000 description 19
- 230000035755 proliferation Effects 0.000 description 19
- 229910052938 sodium sulfate Inorganic materials 0.000 description 19
- 235000011152 sodium sulphate Nutrition 0.000 description 19
- 210000002950 fibroblast Anatomy 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 16
- 239000010410 layer Substances 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 14
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 14
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 14
- 102000004889 Interleukin-6 Human genes 0.000 description 13
- 108090001005 Interleukin-6 Proteins 0.000 description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
- 230000001419 dependent effect Effects 0.000 description 13
- 229940100601 interleukin-6 Drugs 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- 102000003390 tumor necrosis factor Human genes 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 11
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- 239000005557 antagonist Substances 0.000 description 10
- 229960003957 dexamethasone Drugs 0.000 description 10
- 239000012071 phase Substances 0.000 description 10
- 238000010992 reflux Methods 0.000 description 10
- 230000035939 shock Effects 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- 239000011592 zinc chloride Substances 0.000 description 10
- 235000005074 zinc chloride Nutrition 0.000 description 10
- 150000001408 amides Chemical class 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 229940125782 compound 2 Drugs 0.000 description 9
- 238000001816 cooling Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- 239000013543 active substance Substances 0.000 description 8
- 239000012298 atmosphere Substances 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000002792 vascular Effects 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 125000001309 chloro group Chemical group Cl* 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 125000001153 fluoro group Chemical group F* 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000002540 macrophage Anatomy 0.000 description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 description 7
- 229910000029 sodium carbonate Inorganic materials 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 6
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 229940126657 Compound 17 Drugs 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 6
- 125000002252 acyl group Chemical group 0.000 description 6
- 150000001299 aldehydes Chemical class 0.000 description 6
- 230000008485 antagonism Effects 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 125000001246 bromo group Chemical group Br* 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- 208000002849 chondrocalcinosis Diseases 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000012259 ether extract Substances 0.000 description 6
- 230000001524 infective effect Effects 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- RIHUULLOFMRSPU-UHFFFAOYSA-N methyl 4-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]butanoate Chemical compound C=1C=C(F)C=CC=1C1(CCCC(=O)OC)OCCO1 RIHUULLOFMRSPU-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 208000002574 reactive arthritis Diseases 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 6
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 5
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 5
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 5
- 208000009386 Experimental Arthritis Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000020411 cell activation Effects 0.000 description 5
- 238000002648 combination therapy Methods 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 208000037803 restenosis Diseases 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 229940104230 thymidine Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical class C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- WZWIQYMTQZCSKI-UHFFFAOYSA-N 4-cyanobenzaldehyde Chemical compound O=CC1=CC=C(C#N)C=C1 WZWIQYMTQZCSKI-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- 108090000672 Annexin A5 Proteins 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 4
- 208000002177 Cataract Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000001132 Osteoporosis Diseases 0.000 description 4
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 4
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 229960002714 fluticasone Drugs 0.000 description 4
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 229960004584 methylprednisolone Drugs 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 229960005205 prednisolone Drugs 0.000 description 4
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 4
- 229960004618 prednisone Drugs 0.000 description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 3
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 3
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 3
- BUZYGTVTZYSBCU-UHFFFAOYSA-N 1-(4-chlorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C=C1 BUZYGTVTZYSBCU-UHFFFAOYSA-N 0.000 description 3
- CYZHVLKQVXBTCS-UHFFFAOYSA-N 1-(4-methylphenyl)heptan-1-one Chemical compound CCCCCCC(=O)C1=CC=C(C)C=C1 CYZHVLKQVXBTCS-UHFFFAOYSA-N 0.000 description 3
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 3
- FETFXNFGOYOOSP-UHFFFAOYSA-N 1-sulfanylpropan-2-ol Chemical compound CC(O)CS FETFXNFGOYOOSP-UHFFFAOYSA-N 0.000 description 3
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 3
- 206010003267 Arthritis reactive Diseases 0.000 description 3
- 208000012657 Atopic disease Diseases 0.000 description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 3
- 208000020084 Bone disease Diseases 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 3
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 description 3
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 229940126639 Compound 33 Drugs 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 201000009273 Endometriosis Diseases 0.000 description 3
- 206010014824 Endotoxic shock Diseases 0.000 description 3
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 3
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- 201000005569 Gout Diseases 0.000 description 3
- 208000009329 Graft vs Host Disease Diseases 0.000 description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 3
- 208000029523 Interstitial Lung disease Diseases 0.000 description 3
- 208000019693 Lung disease Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 208000016604 Lyme disease Diseases 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 108010048043 Macrophage Migration-Inhibitory Factors Proteins 0.000 description 3
- 102100037791 Macrophage migration inhibitory factor Human genes 0.000 description 3
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 208000012902 Nervous system disease Diseases 0.000 description 3
- 208000022873 Ocular disease Diseases 0.000 description 3
- 206010030216 Oesophagitis Diseases 0.000 description 3
- 208000010191 Osteitis Deformans Diseases 0.000 description 3
- 208000027868 Paget disease Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- 208000018262 Peripheral vascular disease Diseases 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000033464 Reiter syndrome Diseases 0.000 description 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
- 208000025747 Rheumatic disease Diseases 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 208000006045 Spondylarthropathies Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- 201000009594 Systemic Scleroderma Diseases 0.000 description 3
- 206010042953 Systemic sclerosis Diseases 0.000 description 3
- 208000011622 Testicular disease Diseases 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 206010047112 Vasculitides Diseases 0.000 description 3
- 206010047115 Vasculitis Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 3
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
- 201000010105 allergic rhinitis Diseases 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 238000002399 angioplasty Methods 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000009267 bronchiectasis Diseases 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- AIXMJTYHQHQJLU-UHFFFAOYSA-N chembl210858 Chemical compound O1C(CC(=O)OC)CC(C=2C=CC(O)=CC=2)=N1 AIXMJTYHQHQJLU-UHFFFAOYSA-N 0.000 description 3
- 230000007882 cirrhosis Effects 0.000 description 3
- 208000019425 cirrhosis of liver Diseases 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 229940125797 compound 12 Drugs 0.000 description 3
- 229940126142 compound 16 Drugs 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 208000018631 connective tissue disease Diseases 0.000 description 3
- 208000021921 corneal disease Diseases 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 208000037329 crystal arthropathy Diseases 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 3
- 201000001981 dermatomyositis Diseases 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- 231100000284 endotoxic Toxicity 0.000 description 3
- 230000002346 endotoxic effect Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 208000024908 graft versus host disease Diseases 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 201000006334 interstitial nephritis Diseases 0.000 description 3
- 201000004614 iritis Diseases 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 208000027202 mammary Paget disease Diseases 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 229960003151 mercaptamine Drugs 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 208000037819 metastatic cancer Diseases 0.000 description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 206010028417 myasthenia gravis Diseases 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- ZJVAWPKTWVFKHG-UHFFFAOYSA-N p-Methoxypropiophenone Chemical compound CCC(=O)C1=CC=C(OC)C=C1 ZJVAWPKTWVFKHG-UHFFFAOYSA-N 0.000 description 3
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 201000006292 polyarteritis nodosa Diseases 0.000 description 3
- 208000005987 polymyositis Diseases 0.000 description 3
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 201000000306 sarcoidosis Diseases 0.000 description 3
- 208000010157 sclerosing cholangitis Diseases 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 201000005671 spondyloarthropathy Diseases 0.000 description 3
- 239000012258 stirred mixture Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 206010043778 thyroiditis Diseases 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WQADWIOXOXRPLN-UHFFFAOYSA-N 1,3-dithiane Chemical compound C1CSCSC1 WQADWIOXOXRPLN-UHFFFAOYSA-N 0.000 description 2
- IMLSAISZLJGWPP-UHFFFAOYSA-N 1,3-dithiolane Chemical compound C1CSCS1 IMLSAISZLJGWPP-UHFFFAOYSA-N 0.000 description 2
- 150000004865 1,3-dithiolanes Chemical class 0.000 description 2
- STYJKBMRWQQJIS-UHFFFAOYSA-N 1-(4-bromophenyl)pentan-1-one Chemical compound CCCCC(=O)C1=CC=C(Br)C=C1 STYJKBMRWQQJIS-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- SEAOBYFQWJFORM-UHFFFAOYSA-N 1-bromo-4-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=C(Br)C=C1 SEAOBYFQWJFORM-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- VZGDCNFVMWRPOW-UHFFFAOYSA-N 2,6-dimethoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC(OC)=CC=C1B1OC(C)(C)C(C)(C)O1 VZGDCNFVMWRPOW-UHFFFAOYSA-N 0.000 description 2
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 2
- MOFRJTLODZILCR-UHFFFAOYSA-N 2-fluoro-5-formylbenzonitrile Chemical compound FC1=CC=C(C=O)C=C1C#N MOFRJTLODZILCR-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- TYZFMFVWHZKYSE-UHFFFAOYSA-N 3-mercaptohexanol Chemical compound CCCC(S)CCO TYZFMFVWHZKYSE-UHFFFAOYSA-N 0.000 description 2
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- YQYGPGKTNQNXMH-UHFFFAOYSA-N 4-nitroacetophenone Chemical compound CC(=O)C1=CC=C([N+]([O-])=O)C=C1 YQYGPGKTNQNXMH-UHFFFAOYSA-N 0.000 description 2
- UECDQUOWFRTJOH-UHFFFAOYSA-N 4-thiophen-2-ylbenzaldehyde Chemical compound C1=CC(C=O)=CC=C1C1=CC=CS1 UECDQUOWFRTJOH-UHFFFAOYSA-N 0.000 description 2
- ZBQROUOOMAMCQW-UHFFFAOYSA-N 5-(4-fluorophenyl)-5-oxopentanoic acid Chemical compound OC(=O)CCCC(=O)C1=CC=C(F)C=C1 ZBQROUOOMAMCQW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- KCBAMQOKOLXLOX-BSZYMOERSA-N CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O Chemical compound CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)CCCCCCCCCCNCCCONC(=O)C4=C(C(=C(C=C4)F)F)NC5=C(C=C(C=C5)I)F)O KCBAMQOKOLXLOX-BSZYMOERSA-N 0.000 description 2
- QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 2
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 101000605127 Homo sapiens Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 206010022941 Iridocyclitis Diseases 0.000 description 2
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000007239 Wittig reaction Methods 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 2
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- 230000002152 alkylating effect Effects 0.000 description 2
- 201000004612 anterior uveitis Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229960002537 betamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 231100000223 dermal penetration Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000003843 furanosyl group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 238000005567 liquid scintillation counting Methods 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- TVNYNMWSTIOQCP-UHFFFAOYSA-N methyl 5-(4-fluorophenyl)-5-oxopentanoate Chemical compound COC(=O)CCCC(=O)C1=CC=C(F)C=C1 TVNYNMWSTIOQCP-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 108020004017 nuclear receptors Proteins 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 2
- JZBXYOOARNRUME-UHFFFAOYSA-N p-hydroxynonanophenone Chemical compound CCCCCCCCC(=O)C1=CC=C(O)C=C1 JZBXYOOARNRUME-UHFFFAOYSA-N 0.000 description 2
- LPNBBFKOUUSUDB-UHFFFAOYSA-N p-toluic acid Chemical compound CC1=CC=C(C(O)=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-N 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 2
- 206010035653 pneumoconiosis Diseases 0.000 description 2
- 239000002861 polymer material Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000012342 propidium iodide staining Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- 235000012141 vanillin Nutrition 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 2
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- QYYZXEPEVBXNNA-QGZVFWFLSA-N (1R)-2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide Chemical compound C(C)(=O)N1[C@H](C2=CC=C(C=C2C1)S(=O)(=O)C)C(=O)NC1=CC=C(C=C1)C(C(F)(F)F)(C(F)(F)F)O QYYZXEPEVBXNNA-QGZVFWFLSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- 125000006091 1,3-dioxolane group Chemical class 0.000 description 1
- WJJSZTJGFCFNKI-UHFFFAOYSA-N 1,3-oxathiolane Chemical class C1CSCO1 WJJSZTJGFCFNKI-UHFFFAOYSA-N 0.000 description 1
- FMEATOMLFIVSDA-UHFFFAOYSA-N 1-(3,5-dimethoxyphenyl)heptan-1-one Chemical compound CCCCCCC(=O)C1=CC(OC)=CC(OC)=C1 FMEATOMLFIVSDA-UHFFFAOYSA-N 0.000 description 1
- YFNOUGJZNHTYAD-UHFFFAOYSA-N 1-(3-methylbutyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(CCC(C)C)C=C1B1OC(C)(C)C(C)(C)O1 YFNOUGJZNHTYAD-UHFFFAOYSA-N 0.000 description 1
- UOMOSYFPKGQIKI-UHFFFAOYSA-N 1-(4-bromophenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(Br)C=C1 UOMOSYFPKGQIKI-UHFFFAOYSA-N 0.000 description 1
- XLQSXGGDTHANLN-UHFFFAOYSA-N 1-bromo-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(Br)C=C1 XLQSXGGDTHANLN-UHFFFAOYSA-N 0.000 description 1
- ZBTMRBYMKUEVEU-UHFFFAOYSA-N 1-bromo-4-methylbenzene Chemical compound CC1=CC=C(Br)C=C1 ZBTMRBYMKUEVEU-UHFFFAOYSA-N 0.000 description 1
- VFWCMGCRMGJXDK-UHFFFAOYSA-N 1-chlorobutane Chemical class CCCCCl VFWCMGCRMGJXDK-UHFFFAOYSA-N 0.000 description 1
- ANOOTOPTCJRUPK-UHFFFAOYSA-N 1-iodohexane Chemical compound CCCCCCI ANOOTOPTCJRUPK-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- VKEBWCZVWZDPKV-UHFFFAOYSA-N 2-(4-methylphenyl)-1,3-dithiolane Chemical compound C1=CC(C)=CC=C1C1SCCS1 VKEBWCZVWZDPKV-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- VFUDDKHMYGQRAP-UHFFFAOYSA-N 2-methylbenzenesulfonate;pyridin-1-ium Chemical compound C1=CC=NC=C1.CC1=CC=CC=C1S(O)(=O)=O VFUDDKHMYGQRAP-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- BAKYASSDAXQKKY-UHFFFAOYSA-N 4-Hydroxy-3-methylbenzaldehyde Chemical compound CC1=CC(C=O)=CC=C1O BAKYASSDAXQKKY-UHFFFAOYSA-N 0.000 description 1
- QJPJQTDYNZXKQF-UHFFFAOYSA-N 4-bromoanisole Chemical compound COC1=CC=C(Br)C=C1 QJPJQTDYNZXKQF-UHFFFAOYSA-N 0.000 description 1
- ZRYZBQLXDKPBDU-UHFFFAOYSA-N 4-bromobenzaldehyde Chemical compound BrC1=CC=C(C=O)C=C1 ZRYZBQLXDKPBDU-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
- ZRDUKPHQUPBKHQ-UHFFFAOYSA-N 5-phenyl-1h-pyrimidin-6-one Chemical compound OC1=NC=NC=C1C1=CC=CC=C1 ZRDUKPHQUPBKHQ-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 101150026868 CHS1 gene Proteins 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010011655 Cushingoid Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- WQZGKKKJIJFFOK-WHZQZERISA-N D-aldose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-WHZQZERISA-N 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108700011498 Glucocorticoid Receptor Deficiency Proteins 0.000 description 1
- 229940123037 Glucocorticoid antagonist Drugs 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 244000148687 Glycosmis pentaphylla Species 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000725401 Homo sapiens Cytochrome c oxidase subunit 2 Proteins 0.000 description 1
- 101000950847 Homo sapiens Macrophage migration inhibitory factor Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- 101710041373 KIAA0753 Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- 101100221809 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cpd-7 gene Proteins 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 235000021319 Palmitoleic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 description 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Chemical class 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100023399 Protein moonraker Human genes 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 102000003800 Selectins Human genes 0.000 description 1
- 108090000184 Selectins Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 206010047073 Vascular fragility Diseases 0.000 description 1
- 206010047486 Virilism Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- WGCOQYDRMPFAMN-ZDUSSCGKSA-N [(3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxypiperidin-1-yl]-pyrimidin-5-ylmethanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CCC1)C(=O)C=1C=NC=NC=1 WGCOQYDRMPFAMN-ZDUSSCGKSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001263 acyl chlorides Chemical class 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical class CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229920013641 bioerodible polymer Polymers 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- OPHUWKNKFYBPDR-UHFFFAOYSA-N copper lithium Chemical compound [Li].[Cu] OPHUWKNKFYBPDR-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 150000008050 dialkyl sulfates Chemical class 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 229940008406 diethyl sulfate Drugs 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 150000004862 dioxolanes Chemical group 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- 101150025236 dmaW gene Proteins 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000294 dose-dependent toxicity Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000003635 glucocorticoid antagonist Substances 0.000 description 1
- 208000026352 glucocorticoid resistance Diseases 0.000 description 1
- 235000021312 gluten Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- UWYVPFMHMJIBHE-OWOJBTEDSA-N hydroxymaleic acid group Chemical group O/C(/C(=O)O)=C/C(=O)O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002951 idosyl group Chemical class C1([C@@H](O)[C@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 102000002467 interleukin receptors Human genes 0.000 description 1
- 108010093036 interleukin receptors Proteins 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 231100000794 masculinization Toxicity 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 108010077055 methylated bovine serum albumin Proteins 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229950007856 mofetil Drugs 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- HHQJWDKIRXRTLS-UHFFFAOYSA-N n'-bromobutanediamide Chemical compound NC(=O)CCC(=O)NBr HHQJWDKIRXRTLS-UHFFFAOYSA-N 0.000 description 1
- VOVZXURTCKPRDQ-CQSZACIVSA-N n-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide Chemical compound C1[C@H](O)CCN1C1=NC=C(C(=O)NC=2C=CC(OC(F)(F)Cl)=CC=2)C=C1C1=CC=NN1 VOVZXURTCKPRDQ-CQSZACIVSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000007896 negative regulation of T cell activation Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- XULSCZPZVQIMFM-IPZQJPLYSA-N odevixibat Chemical compound C12=CC(SC)=C(OCC(=O)N[C@@H](C(=O)N[C@@H](CC)C(O)=O)C=3C=CC(O)=CC=3)C=C2S(=O)(=O)NC(CCCC)(CCCC)CN1C1=CC=CC=C1 XULSCZPZVQIMFM-IPZQJPLYSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical class C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Chemical class 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920000128 polypyrrole Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- XRVCFZPJAHWYTB-UHFFFAOYSA-N prenderol Chemical compound CCC(CC)(CO)CO XRVCFZPJAHWYTB-UHFFFAOYSA-N 0.000 description 1
- 229950006800 prenderol Drugs 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003132 pyranosyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000011973 solid acid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000005156 substituted alkylene group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 125000005323 thioketone group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES
The present invention relates generally to the treatment of diseases or conditions resulting from cellular activation, such as inflammatory or cancerous diseases or conditions. In particular, the invention relates to the use of phenyl substituted cyclic derivatives to inhibit the cytokine or biological activity of macrophage migration inhibitory factor (MIF), and diseases or conditions wherein MIF cytokine or biological activity is implicated.
MIF is the first identified T-cell-derived soluble lymphokine. MIF was first described as a soluble factor with the ability to modify the migration of macrophages . The molecule responsible for the biological actions ascribed to MIF was identified and cloned in 1989 @,
Initially found to activate macrophages at inflammatory sites, it has been shown to possess pluripotential actions in the immune system. MIF has been shown to be expressed in human diseases which include inflammation, injury, ischaemia or malignancy. MIF also has a unique relationship with glucocorticoids by overriding their anti-inflammatory effects.
Recent studies have indicated that monoclonal antibody antagonism of MIF may be useful in the treatment of sepsis, certain types of cancers and delayed type hypersensitivity.
Antibody antagonism of MIF has also been shown to have activity in adjuvant- or collagen-induced arthritis animal models and other models of inflammatory and immune diseases.
Although antibody antagonism of MIF is one potential way to provide therapeutic treatments, such biological molecules can be expensive to prepare on a commercial basis and further, can be limited in the way they are administered (generally by injection) and do not readily lend themselves to formulations for administration by other means eg oral administration.
Small molecule inhibitors may overcome one or more such difficulties connected with the use of biological therapeutic treatments. There exists a need, therefore, for small molecule inhibitors of the cytokine or biological activity of MIF. Small molecule inhibitors of the cytokine or biological activity of MIF would have therapeutic effects in a broad range of diseases, whether given alone or in combination with other therapies.
Further, glucocorticoids have been used to treat human diseases for over fifty years and are effective in a range of diseases which include inflammation, injury, ischaemia or malignancy. Although debate continues in relation to their impact on disease progression, their influence on symptoms and signs of inflammation, especially in the short term, can be dramatic.
Despite their benefits and efficacy, the use of glucocorticoids is limited by universal, predictable, dose-dependent toxicity. Mimicking Cushing's disease, a disease wherein the adrenal glands produce excess endogenous glucocorticoids, glucocorticoid treatment is associated with side effects including immunosuppression (resulting in increased susceptibility to infections), weight gain, change in body habitus, hypertension, oedema, diabetes mellitus, cataracts, osteoporosis, poor wound healing, thinning of the skin, vascular fragility, hirsutism and other features of masculinization (in females). In children, growth retardation is also noted. These side effects are known as Cushingoid side effects.
Since the side effects of glucocorticoids are dose dependent, attempts to reduce the dosage requirement have been investigated, including combination therapies in which glucocorticoids are administered with other therapeutic agents. These combination therapies are sometimes referred to as "steroid-sparing” therapies. However, currently available combination therapies are non-specific as the other therapeutic agents do not address biological events which inhibit the effectiveness of glucocorticoids. Such combination therapies are also typically associated with serious side effects.
Furthermore, glucocorticoids are incompletely effective in a number of disease settings, leading to the concept of "steroid-resistant" diseases. Agents which amplify or enhance the effects of glucocorticoids would not only allow the reduction of dose of these agents but may also potentially render “steroid-resistant” diseases steroid-sensitive.
There is a need for effective therapies which enable a reduction in the dosage level of glucocorticoids. There is also a need for effective treatment of "steroid-resistant” diseases.
Preferably, such therapies or treatments would address factors which directly limit the effectiveness of glucocorticoids.
Therapeutic antagonism of MIF may provide “steroid-sparing” effects or be therapeutic in “steroid-resistant” diseases. Unlike other pro-inflammatory molecules, such as cytokines, the expression and/ or release of MIF can be induced by glucocorticoids ®®. Moreover,
MIF is able to directly antagonize the effects of glucocorticoids. This has been shown to be the case for macrophage TNF, IL-1, IL-6 and IL-8 secretion ®®, and for T cell proliferation and IL-2 release ®. In vivo, MIF exerts a powerful glucocorticoid-antagonist effect in models including endotoxic shock and experimental arthritis ©. In the context of an inflammatory or other disease treated with glucocorticoids, then, MIF is expressed but exerts an effect which prevents the glucocorticoid inhibition of inflammation. It can therefore be proposed that therapeutic antagonism of MIF would remove MIF’s role in inhibiting the anti-inflammatory effect of glucocorticoids, thereby allowing glucocorticoids to prevail. This would be the first example of true “steroid-sparing” therapy. In support of this hypothesis is the observation that anti-MIF antibody therapy reverses the effect of adrenalectomy in rat adjuvant arthritis ®. By neutralizing the natural glucocorticoid ‘counter-regulator’ effect of MIF, it is envisioned that with MIF antagonism, steroid dosages could be reduced or even eliminated in inflammatory disease, particularly in those diseases that are associated with the glucocorticoid resistance “*", There is a need, therefore, for therapeutic antagonists of the cytokine or biological activity of MIF.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
In a first aspect, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof
Zz y pd oy
X Y
Ry ®
R4 Ra .
Ra wherein X and X' are independently selected from —C(Rs),-, -O-, -S-, -N(Rs)-, or taken together form -C(Rs)=C(Rs)-, -C(Rs)=N-, -N=C(Rs)-, -N(Rs)-N(Rs)- or ~N=N-;
Y and Y' are independently selected from -C(Rs),-, “O-, -S-, -N(Rs)-, or taken together form -C(Rs)=C(Rs)-, -C(Rs)=N-, -N=C(Rs)-, -N(R;)-N(Rs)- or -N=N-; Zis-C(Rs),, -O-, -S- or -N(Ry)-, or forms a covalent single or double bond between X' and
Y', or Z together with X' or Y' forms —C(Rs)=C(Rs)-, -C(R5)=N-, -N=C(R;)-, -N(Rs)-N(R,)- or -N=N-; wherein when Z is ~O-, -S- or -N(R;)-, X' and Y' are ~C(Rs),-; when X is ~O-, -5- or -N(R;)-, X' is =C(Rs),~; when Y is -O-, -5- or -N(R;)-, Y' is ~C(Rs),-; or
XorY together with the carbon atom bearing the phenyl group form a double bond wherein which ever of X or Y forms part of the double bond is selected from —C(R;)- and -N-;
R, is selected from hydrogen, C,5 alkyl, C, alkenyl, C, alkynyl, (A),C(O)R,, (A),C(S)R,, (A)S(O)Rg (A)S(O)Ry (A)ORy (A)SRy, (A)N(Rs),, (A),C(=NRs)Ry; and (A),R;,, or when
X or Y together with the carbon atom bearing the phenyl group form a double bond, R,; is absent;
R; and R, are independently selected from hydrogen, C, jalkyl and (A).R;»
R; is selected from C, jalkyl, (A)nRyy, (A)qaryl and (A), heterocyclyl;
Ris selected from hydrogen, C, alkyl, C, alkenyl, C, alkynyl, (A),C(O)R,, (A),C(S)Re, (A).S(O)Rg, (A): S(O)Ry, (A), OR, (A)ySRy, (A) N(Ry), (A),C(=NRy)R,o and (A),Ryy;
Ry is selected from hydrogen, C,.xalkyl, C, alkenyl, C, alkynyl, OH, OC, palkyl,
OC,.palkenyl, OC,.jealkynyl, O(A) Ry, SH, SC,y.r0alkyl, SC. palkenyl, SC;.0alkynyl, S(A).R, 1
N(R,3),, [NH-CH(R,,)C(O)],-OH, [NH-CH(R;,)C(O)},-OC, alkyl, [sugar], and (A),R yy; R;is selected from hydrogen, Cy alkyl, C,palkenyl, C,aalkynyl, (A)Ryy, C(O)H,
C(O)C,.jealkyl, C(O)C,pealkenyl, C(O)C,.ipalkynyl, C(O)-aryl, C(OXA) Ry, C(O).H,
C(0),C,.0alkyl, C(0),Cy 0alkenyl, C(O),C; palkynyl, C(O),-aryl, C(O),(A)Ryy, C(S)H,
C(S)C,.i0alkyl, C(S)C,. alkenyl, C(S)Cy alkynyl, C(S)-aryl, C(SHA)Ry, C(S)OH,
C(S)OC,.palkyl, C(S)OC,. palkenyl, C(S)OC,. palkynyl, C(S)O-aryl, C(S)O(A)qRy;, S(O)H,
S(0),C,.0alky], S(0),C,.palkenyl, S(O)C,pealkynyl, S(O)-ary], S(O) (A)Ryy [C(O)CH(R,)NH],-H, [C(O)CH(R,)NH],-C,.jpalkyl, [C(O)CH(R,)NH],-C, palkenyl, [C(O)CH(R,)NH],-Cpq0alkynyl, [C(O)CH(R,)NH],-aryl, [C(O)CH(R,)NH],-(A);Ryy and [sugar]; 5 Each Rgis independently selected from R, and NHC(=NR;5)NH,;
Rg is selected from hydrogen and C, alkyl;
Ry, is selected from C, salkyl, NH, NH(C, salkyl), N(C,jalkyl),, OH, OC, jalkyl, SH and
SC, alkyl;
R,, is selected from OH, OC, alkyl, OC, ;alkyl-O-C, jalkyl, O-aryl, O-heterocyclyl, O[C(O)CH(R,)NHI]H, [sugar], SH, SC,alkyl, SC, salkyl-O-C, alkyl, S-aryl, S-heterocyclyl,
S[C(O)CH(R,,)NHILH, halo, N(Rs),, C(O)Rse CN, C(Ry7)s ary. 1 and heterocyclyl;
R;, is selected from OH, SH, NH,, halo, NO,, CR) OC(Ryp)5 and CN;
Each R;; is independently selected from hydrogen, C, alkyl, C, alkenyl, C; alkynyl and (A)Ryy;
Ris the characterising group of an amino acid;
Each Ry; is independently selected from hydrogen, C, calky), C,jalkoxyC; ;alkyl, aryl and heterocyclyl;
Ry, is selected from C, jalkyl, OH, C,jalkoxy, aryl, aryloxy, heterocyclyl and heterocyclyloxy;
EachRy, is independently selected from hydrogen and halogen;
A is optionally substituted methylene wherein when n > 1, any two adjacent A groups are optionally interrupted by -O-, -5- or -N(Ry3)-; where n is 0 or an integer selected from 1 to 20; m is 0 or an integer selected from 1 to 3; pis aninteger selected from 1 to 20; q is an integer selected from 1 to 10 s is an integer selected from 1 to 5; tis an integer selected from 1 or 2; and wherein each alkyl, alkenyl , alkynyl, aryl and heterocyclyl may be optionally substituted.
In a further aspect, the present invention provides a method of inhibiting cytokine or biological activity of MIF comprising contacting MIF with a cytokine or biological inhibiting amount of a compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof. :
In another aspect, the invention provides a method of treating, preventing or diagnosing a disease or condition wherein MIF cytokine or biological activity is implicated comprising the administration of a treatment, prevention or diagnostic effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof to a subject in need thereof. :
In a further aspect, there is provided the use of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament : 15 for the treatment, prevention or diagnosis of a disease or condition wherein MIF cytokine or biological activity is implicated.
In particular, the invention provides a method of treating, diagnosing or preventing autoimmune diseases, tumours, or chronic or acute inflammatory diseases, including a disease or condition selected from the group comprising: rheumatic diseases (including but not limited to rheumatoid arthritis, osteoarthritis, psoriatic arthritis) spondyloarthropathies (including but not limited to ankylosing spondylitis, reactive arthritis, Reiter's syndrome), crystal arthropathies (including but not limited to gout, pseudogout, calcium pyrophosphate deposition disease),
Lyme disease, polymyalgia rheumatica; connective tissue diseases (including but not limited to systemic lupus erythematosus, systemic sclerosis, polymyositis, dermatomyositis, Sjogren's syndrome); vasculitides (including but not limited to polyarteritis nodosa, Wegener's granulomatosis, Churg-Strauss syndrome); inflammatory conditions including consequences of trauma or ischaemia,
sarcoidosis; vascular diseases including atherosclerotic vascular disease, atherosclerosis, and vascular occlusive disease (including but not limited to atherosclerosis, ischaemic heart disease, myocardial infarction, stroke, peripheral vascular disease), and vascular stent restenosis;
ocular diseases including uveitis, corneal disease, iritis, iridocyclitis, cataracts; autoimmune diseases (including but not limited to diabetes mellitus, thyroiditis, myasthenia gravis, sclerosing cholangitis, primary biliary cirrhosis); pulmonary diseases (including but not limited to diffuse interstitial lung diseases,
prieumnoconioses, fibrosing alveolitis, asthma, bronchitis, bronchiectasis, chronic obstructive pulmonary disease, adult respiratory distress syndrome); cancers whether primary or metastatic (including but not limited to prostate cancer, colon cancer, lymphoma, lung cancer, melanoma, multiple myeloma, breast cancer, stomach cancer, leukaemia, cervical cancer and metastatic cancer);
renal diseases including glomerulonephritis, interstitial nephritis; disorders of the hypothalamic-pituitary-adrenal axis; nervous system disorders including multiple sclerosis, Alzheimer’s disease; diseases characterised by modified angiogenesis (eg diabetic retinopathy, rheumatoid arthritis, cancer), endometrial function (menstruation, implantation,
endometriosis); complications of infective disorders including endotoxic (septic) shock, exotoxic (septic) shock, infective (true septic) shock, malarial complications, other complications of infection, pelvic inflammatory disease; transplant rejection, graft-versus-host disease;
allergic diseases including allergies, atopic diseases, allergic rhinitis; bone diseases (eg osteoporosis, Paget's disease); skin diseases including psoriasis, atopic dermatitis, UV(B)-induced dermal cell activation (eg sunburn, skin cancer);
complications of diabetes mellitus, pain, testicular dysfunctions and wound healing, gastrointestinal diseases including inflammatory bowel disease (including but not limited to ulcerative colitis, Crohn's disease), peptic ulceration, gastritis, oesophagitis, liver disease (including but not limited to cirrhosis, hepatitis); comprising the administration of a treatment, diagnosis or prevention effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or prodrug thereof to a subject in need thereof.
Preferably, the disease or condition is selected from the group consisiting of rheumatoid athritis, systemic lupus erythematosus, ulcerative colitis, Crohn's disease, multiple sclerosis, psoriasis, uveitis, atherosclerotic vascular disease, asthma and chronic obstructive pulmonary disease.
A further aspect of the invention provides for the use of a compound of Formula (I) or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for the treatment of a disease or condition as above.
A further aspect of the invention provides a pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier, diluent or excipient.
In another aspect, the invention provides a method of treating or preventing a disease or condition wherein MIF cytokine or biological activity is implicated comprising: administering to a mammal a compound of formula (I) and a second therapeutic agent.
In another aspect, the present invention provides a method of prophylaxis or treatment of a disease or condition for which treatment with a glucocorticoid is indicated, said method comprising: administering to a mammal a glucocorticoid and a compound of formula (I).
In yet another aspect, the present invention provides a method of treating steroid-resistant diseases comprising: administering to a mammal a glucocorticoid and a compound of formula (I).
In a further aspect, the present invention provides a method of enhancing the effect of a glucocorticoid in mammals comprising administering a compound of formula (I) simultaneously, separately or sequentially with said glucocorticoid.
In yet a further aspect, the present invention provides a pharmaceutical composition comprising a glucocorticoid and a compound of formula (I).
In a further aspect of the invention there is provided a use of a glucocorticoid in the manufacture of a medicament for administration with a compound of formula (I) for the treatment or prophylaxis of a disease or condition for which treatment with a glucocorticoid is indicated. Inyet a further aspect of the invention there is provided a use of a compound of formula (I) in the manufacture of a medicament for administration with a glucocorticoid for the treatment or prophylaxis of a disease or condition for which treatment of a glucocorticoid is indicated.
In yet a further aspect of the invention there is provided a use of a glucocorticoid and a compound of formula (I) in the manufacture of a medicament for the treatment or prophylaxis of a disease or condition for which treatment with a glucocorticoid is indicated.
In preferred embodiments, the compounds of Formula (I) or a pharmaceutically acceptable salt or prodrug thereof are used to treat or prevent a disease or condition, particularly in a human subject.
Figure 1: graphically depicts inhibition of MIF-induced proliferation of S112 human fibroblasts by 2-(2-hydroxyethoxy)-2-(4-hydroxy-3-methylphenyl)-1,3- dioxolane (Compound 1).
Figure 2: graphically depicts inhibition of IL-1 induced COX-2 expression by 2-(2- hydroxyethoxy)-2-(4-hydroxy-3-methylphenyl)-1,3-dioxolane (Compound 1).
Figure 3: graphically depicts inhibition of IL-1 induced. COX-2 expression by 2-(2- hydroxyethoxy)-2-(4-hydroxy-3-methylphenyl)-1,3-dioxolane (Compound 1).
Figure 4: graphically depicts inhibition of IL-1 induced COX-2 expression by 2-(2- hydroxyethoxy)-2-(4'-hydroxyphenyl)-1,3-dioxolane (Compound 2).
Figure 5: graphically depicts inhibition of antigen-specific T-cell activation by 2-(2- hydroxyethoxy)-2-(4-hydroxyphenyl)-1,3-dioxolane (Compound 2).
Figure 6: graphically depicts the enhanced effect of the glucocorticoid dexamethasone in the presence of 2-(2-hydroxyethoxy)-2-(4-hydroxy-3-methylphenyl)-1,3- dioxolane (Compound 1).
Figure 7: graphically depicts the absence of cytotoxic effects of 2-(2-hydroxyethoxy)-2-(4- hydroxy-3-methylphenyl)-1,3-dioxolane (Compound 1).
Figure 8: graphically depicts the inhibition of macrophage nitrite release by 1-(3-Methylbutyl)-4-(4-methylphenyl)-1 H-pyrazole (Compound 13).
Figure 9: graphically depicts the inhibition of MIF-induced NIH-3T3 fibroblast proliferation by 2-Methyl-2-(4-methylphenyl)-1,3-dithiolane (Compound 18) and other compounds of the invention.
Figure 10: graphically depicts the inhibition of lipopolysaccharide-induced serum IL-1,
TNF, and IL-6 in mice treated with 2-Hexyl-2-(4-methylphenyl)-1,3-dithiolane (Compound 17).
As used herein, the term "alkyl" refers to monovalent straight, branched or, where appropriate, cyclic aliphatic radicals, having 1to 3,1 to 6, 1 to 10 or 1 to 20 carbon atoms, e.g. methyl, ethyl, n-propyl, iso-propyl, cyclopropyl, n-butyl, sec-butyl, t-butyl and cyclobutyl, n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, cyclopentyl, n-hexyl, 1- 2- 3- or 4- methylpentyl, 1- 2- or 3-ethylbutyl, 1 or 2- propylpropy! or cyclohexyl.
An alkyl group may be optionally substituted one or more times by halo (eg chloro, fluoro or br omo), CN, NO, CO,H, CO,C, alkyl, CO,NH,, CO,NH(C, alkyl), CO,N(C, alkyl),
OH, alkoxy, acyl, acetyl, halomethyl, trifluoromethyl, benzyloxy, phenoxy, NH,,
NH(C,qalkyl) or N (Cyealkyl),. A preferred optional substituent is a polar substituent.
Examples of alkoxy include methoxy, ethoxy, n-propoxy, iso-propoxy, cyclopropoxy, and butoxy (n-, sec- t- and cyclo) pentoxy and hexyloxy. The "alkyl" portion of an alkoxy group may be substituted as described above.
As used herein, the term "alkenyl" refers to straight, branched, or where appropriate, cyclic carbon containing radicals having one or more double bonds between carbon atoms.
Examples of such radicals include vinyl, allyl, butenyl, or longer carbon chains such as those derived from palmitoleic, oleic, linoleic, linolenic or arachidonic acids. An alkenyl group may be optionally substituted one or more times by halo (eg chloro, fluoro or bromo), CN, NO,, CO,H, CO,C, alkyl, CO,NH,, CO,NH(C, salkyl), CO,N(C, alkyl), OH, alkoxy, acyl, acetyl, halomethyl, trifluoromethyl, benzyloxy, phenoxy, NH, NH(C, alkyl) or N(Cysalkyl),. A preferred optional substituent is a polar substituent.
As used herein, the term "alkynyl" refers to straight or branched carbon containing radicals having one or more triple bonds between carbon atoms. Examples of such radicals include propargyl, butynyl and hexynyl. An alkynyl group may be optionally substituted one or more times by halo (eg chloro, fluoro or bromo), CN, NO,, CO,H, CO,C, alkyl, CO,NH,,
CO,NH(C, alkyl), CO,N(C, alkyl), OH, alkoxy, acyl, acetyl, halomethyl, trifluoromethyl, benzyloxy, phenoxy, NH, NH(C,calkyl) or N(C, ¢alkyl),. A preferred optional substituent is a polar substituent.
Examples of suitable NH(alkyl) and N(alkyl), include methylamino, ethylamino, isopropylamino, dimethylamino, n-propylamino, diethylamino and di-isopropylamino.
The term "halogen" (or "halo") refers to fluorine (fluoro), chlorine (chloro), bromine (bromo) or iodine (iodo).
The term "sugar" refers to a pyranosyl or furanosyl moiety such as those derived from glucose, galactose, mannose, allose, altrose, gluose, idose, talose, ribose, arabinose or xylose. Derivatives of such sugars include deoxy or amino pyranosyl or furanosyl sugar derivatives. Each sugar moiety is incorporated into the compound of formula (I) through a hydroxy group of the sugar moiety.
As used herein, "the characterising group of an amino acid" refers to the substituent at C, of a natural or unnatural amino acid and which defines the amino acid. For example, methyl is the characterising group of alanine, phenylmethyl is the characterising group of phenylalanine, hydroxymethyl is the characterising group of serine, hydroxyethyl is the characterising group of homoserine and n-propyl is the characterising group of norvaline.
An aryl group, as used herein, refers to Cs-Cy, aryl groups such as phenyl or naphthalene.
Aryl groups may be optionally substituted one or more times by halo (eg, chloro, fluoro or bromo), CN, f NO, CO,H, CO,C,4alkyl, CO,NH,, CO,NH(C, alkyl), CON(C,¢alkyl),, OH, alkoxy, acyl, acetyl, halomethyl, trifluoromethyl, benzyloxy, phenoxy, NH, NH(C, calkyl) or N(C,.salkyl),.
As used herein, the term "heterocyclyl" refers-to a cyclic, aliphatic or aromatic radical containing at least one heteroatom independently selected from O, N or S. Examples of suitable heterocyclyl groups include furyl, dioxolanyl, dioxanyl, dithianyl, dithiolanyl, pyridinyl, pyrimidinyl, pyrazolyl, piperidinyl, pyrrolyl, thyaphenyl, oxazolyl, imidazoly!, thiazolyl, isoxazolyl, isothiazolyl, quinolyl, isoquinolyl, indolyl, benzofurany], benzothiophenyl, triazoly], tetrazolyl, oxadiazolyl and purinyl. Heterocyclyl groups may be optionally substituted one or more times by halo (eg, chloro, fluoro or bromo), CN, NO,,
CO,H, COC, alkyl, CO,NH,, CO,NH(C, alkyl), CO,N(C,calkyl),, OH, alkoxy, acyl, acetyl, halomethy], trifluoromethyl, benzyloxy, phenoxy, NH, NH(C, calkyl) or N(C, salkyl),.
Each A is an unsubstituted methylene group (-CH,-) or an optionally substituted methylene group where one or two of the hydrogen atoms of the methylene group may be replaced by a substituent, such as halo (eg. chloro, fluoro or bromo), CN, NO,, CO.H,
CO,C,.alkyl, CO,NH,, CO,NH(C, salkyl), CO,N(C, salkyl),, OH, alkoxy, acyl, acetyl, halomethyl, trifluoromethyl, benzyloxy, phenoxy, NH,, NH(C (alkyl) or N(C,alkyl),. (A), may therefore form an optionally substituted methylene group, when nis 1, or an optionally substituted alkylene group when n is greater than 1. Alternatively, when two or more A groups appear in adjacent positions, they are optionally interrupted by ~O-, -S- or -N(R;s)-. (A), may therefore form, for example, an optionally substituted ether or polyether.
Ina first aspect, the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof
IN
1] : X Y
Ry ®
Rg Ro wherein X and X' are independently selected from ~C(Rs),-, ~O-, -S-, -N(Rs)-, or taken together form —C(Rs)=C(Rs)-, -C(Rs)=N-, -N=C(R;)-, -N(Rs)-N(Rs)- or -N=N-;
Y and Y' are independently selected from —C(Rs),-, -O-, -S-, -N(R;)-, or taken together form —C(Rs)=C(Rs)-, -C(Rs)=N-, -N=C(Rs)-, -N(Rs)-N(R5)- or -N=N-;
Zis-C(Rs),-, -O-, -5- or -N(R;)-, or forms a covalent single or double bond between X' and
Y', or Z together with X' or Y' forms -C(Rs)=C(Rs)-, -C(Rs)=N-, -N=C(Rs)-, -N(R5)-N(R)- or -
N=N-; wherein when Z is -O-, -5- or -N(R;)-, X' and Y' are -C(Rs); when X is —O-, -5- or =N(R;)-, X' is ~C(Rs),~; when Y is ~O-, -5- or -N(R;)-, Y' is -C(Rs),-; or
X or Y together with the carbon atom bearing the phenyl group form a double bond wherein which ever of X or Y forms part of the double bond is selected from -C(R;)- and
N-;
R, is selected from hydrogen, C, alkyl, C, alkenyl, C,5alkynyl, (A),C(O)R,, (A), C(S)R,, (A)S(O)R,, (A):S(O)R, (A),OR,, (ASR, (A)N(Ry), (A). C(=NRg)Ry, and (A)Ry, or when
X or Y together with the carbon atom bearing the phenyl group form a double bond, R, is absent;
R, and R, are independently selected from hydrogen, C, jalkyl and (A),R»
R, is selected from C,,alkyl, (A).Ry; (A)naryl and (A) heterocyclyl; Ryis selected from hydrogen, C, alkyl, Cyyalkenyl, Calkynyl, (A),C(O)Ry, (A),C(S)Rs (A)S(O)Ry, (A) S(O)Rg, (A); OR, (A)SRy, (A)N(Rs), (A).C(=NRg)Ryp and (A), Ry;
R, is selected from hydrogen, C, alkyl, C, alkenyl, C, palkynyl, OH, OC, alkyl,
OC, jpalkenyl, OC; palkynyl, O(A)R:y, SH, SCi.0alkyl, SC,aealkenyl, SCy.yealkynyl, S(A)Ryy,
N(R,3),, [INH-CH(R,,)C(0)],-OH, [NH-CH(R,)C(O)],-OC, salky], [sugar], and (A)Ry; R,is selected from hydrogen, C, alkyl, C,qalkenyl, C,palkynyl, (A)R;y, C(O)H,
C(O)C.10alkyl, C(O)C,.yealkenyl, C(O)Cy.poalkynyl, C(O)-aryl, C(O)(A)Ryy C(O),H,
C(O),C.ipalkyl, C(0),Cyypalkenyl, C(0),C;.10alkynyl, C(O);-aryl, C(O)A) Ru C(SH,
C(S)C,10alkyl, C(S)Cppalkenyl, C(S)C,.jpalkynyl, C(S)-aryl, C(S)(A)qRy,, C(S)OH,
C(S)OC,.pealkyl, C(S)OC, ealkenyl, C(S)OC; palkynyl, C(S)O-aryl, C(S)O(A)qRyy, S(O)H,
S(0).C,.ipalkyl, S(O),C,.i0alkenyl, S(O),C,.0alkynyl, S(O)raryl, S(O){(A)Ryy, [C(O)CH(R,,)NH],-H, [C(O)CH(R,)NH],-C, alkyl, [C(O)CH(R,s)NHJ,-C, spalkenyl, [C(O)CH(R,)NH],-C, ygalkynyl, [C(O)CH(R,)NH],-aryl, [C(O)CH(R,)NH],-(A)Ry; and [sugar];
Each Ry is independently selected from R, and NHC(=NR;5)NH,;
R, is selected from hydrogen and C, alkyl;
Ryo is selected from C, salkyl, NH,, NH(C, alkyl), N(C, alkyl), OH, OC, alkyl, SH and
SCalkyl;
Ry, is selected from OH, OC, alkyl, OC, salkyl-O-C, ;alkyl, O-aryl, O-heterocyclyl, O[C(O)CH(R,)NH],H, [sugar], SH, SC, alkyl, SC, alkyl-O-C, ;alkyl, S-aryl, S-heterocyclyl,
S[C(O)CH(R,)NH]H, halo, N(R;5),, C(O)R;¢, CN, C(Ry7),, aryl and heterocyclyl;
Ry, is selected from OH, SH, NH,, halo, NO,, C(R;);, OC(R,7); and CN;
Each Ry; is independently selected from hydrogen, C,. alkyl, C, alkenyl, C,salkynyl and (AR;
Ris the characterising group of an amino acid;
Each R;s is independently selected from hydrogen, Cy alkyl, C;salkoxyC, alkyl, aryl and heterocyclyl;
Ry is selected from C, alkyl, OH, C, salkoxy, aryl, aryloxy, heterocyclyl and heterocyclyloxy;
Each Rj, is independently selected from hydrogen and halogen;
A is optionally substituted methylene wherein when n> 1, any two adjacent A groups are optionally interrupted by —O-, -5- or -N(Rs)-; where n is 0 or an integer selected from 1 to 20; m is 0 or an integer selected from 1 to 3; pis an integer selected from 1 to 20; q is an integer selected from 1 to 10 s is an integer selected from 1 to 5; tis an integer selected from 1 or 2; and wherein each alkyl, alkenyl, alkynyl, aryl and heterocyclyl may be optionally substituted.
In another aspect, the compound of the invention is a compound of formula (II), or a pharmaceutically acceptable salt or prodrug thereof
Zz
CC)
X Y
Ry a
R4 Ro
Rs wherein X and Y are independently selected from —O-, -S-, -N(R)- and -C(Rs)~
Z is —C(Rg),- or is a covalent bond between adjacent methylene groups;
Ris selected from hydrogen, C, alkyl, C; alkenyl, Cyppalkynyl, (A),C(O)R,, (A) C(S)Rs (A) S(O)R, (A),S(OyRy, (A), OR, (A).SRy, (A)N(R,), (A).C(=NR;)Ryc and (A) Ry;
R, and R, are independently selected from hydrogen, C,alkyl and (A), Ry
R, is selected from C, alkyl, (A) Ry, (A)naryl and (A) heterocyclyl;
Rs is selected from hydrogen, C, alkyl, C;yalkenyl, C, alkynyl, (A),C(O)R,, (A) .C(S)Ry (A)S(O)Ry (A),S(O);Ry (A),ORy, (A) SRy, (A)N(Rg), (A):C(=NRs)Ryo and (A)uRy;
R; is selected from hydrogen, C, alkyl, C, alkenyl, Cy oalkynyl, OH, OC, jealkyl,
OC,.palkenyl, OC, galkynyl, O(A) Ry, SH, SCy.yealkyl, SCpqpalkenyl, SCp palkynyl, S(A)Ru,
N(R), [NH-CH(R,,)C(O)],-OH, [NH-CH(R,,)C(O)],-OC; alkyl, [sugar], and (A).Ryy;
R; is selected from hydrogen, Cy alkyl, Cyzalkenyl, C;ealkynyl, (A)Ry, C(OH,
C(O)C,. alkyl, C(O)Cyypalkenyl, C(O)C,.palkynyl, C(O)-aryl, C(O)A) Ry, C(O). H,
C(0),Cialkyl, C(0),C;.q0alkenyl, C(O),C,oalkynyl, C(O),-ary], C(O)y(A)Rys/ C(S)H,
C(S)Crpvalkyl, C(S)Cyp0alkenyl, C(S)C, joalkynyl, C(S)-aryl, C(S)(A) Ry, C(S)OH, C(S)OC, alkyl, C(S)OC, alkenyl, C(S)OC, palkynyl, C(S)O-aryl, C(S)O(A)Ry:, S(O)H,
S(0),Cy.0alkyl, S(O)C, ealkenyl, S(O)C,.poalkynyl, S(O)-aryl, S(O)(A) Ry, [C(O)CH(R,)NH],-H, [C(O)CH(R,,)NH],-C,.j0alkyl, [C(O)CH(R,,)NH],-C, jpalkenyl, [C(O)CH(R,,)NH],-C, jpalkynyl, [C(O)CH(R,)NH],-aryl, [C(O)CH(R,,)NH],-(A).Ry, and [sugar],
Each Ryis independently selected from R, and NHC(=NR)NH,;
R, is selected from hydrogen and C, salkyl;
Ryo is selected from C, alkyl, NH,, NH(C, alkyl), N(C, ;alkyl),, OH, OC; ;alkyl, SH and
SC, alkyl;
Ry; is selected from OH, OC, salkyl, OC, ;alkyl-O-C, salkyl, O-aryl, O-heterocyclyl,
O[C(O)CH(R,,)NH]H, [sugar], SH, SC, salkyl, SC, alkyl-O-C, jalkyl, S-aryl, S-heterocyclyl,
S[C(O)CH(R,)NH]H, halo, N(R;s),, C(O)R,s, CN, C(Ry;)5, aryl and heterocyclyl;
Ry, is selected from OH, SH, NH, halo, NO,, CR) OC(Ryy)s and CN;
Each R;; is independently selected from hydrogen, C, alkyl, C, alkenyl, C, alkynyl and (A) Ry;
Ry, is the characterising group of an amino acid;
Each Rs is independently selected from hydrogen, C, (alkyl, C, ;alkoxyC, salkyl, aryl and heterocyclyl;
Rye is selected from C,jalkyl, OH, C, ;alkoxy, aryl, aryloxy, heterocydyl and heterocyclyloxy;
Each Ry, is independently selected from hydrogen and halogen;
A is optionally substituted methylene wherein when n > 1, any two adjacent A groups are optionally interrupted by ~O-, -S- or -N(Rys)-; where n is 0 or an integer selected from 1 to 20;
m is 0 or an integer selected from 1 to 3; p is an integer selected from 1 to 20; q is an integer selected from 1 to 10 s is an integer selected from 1 to 5; tisan integer selected from 1 or 2; and wherein each alkyl, alkenyl, alkynyl, aryl and heterocyclyl may be optionally substituted.
In a preferred embodiment one or more of the following definitions apply:
X is -O-, -5-, -NH- or -CH,-;
Y is -O-, -5- or -NR;-; Z forms a covalent bond between adjacent methylene groups;
R, is selected from C,galkyl, C,yalkenyl, O-(A),0-C; alkyl, O-(A)g-heterocyclyl,
O-(A)y-sugar, O-(A);O[C(O)CH(R,)NH],-H, (A),OH, (A),OC, alkyl, (A).OC, alkenyl, (A),OC(0)C,.0alky), (A),OC(O)C, alkenyl, (A),0C(O)aryl, (A),O[C(O)CH(R,,)NH],-H, (A), Olsugar], (A), NHC, alkyl, (A)N(Cy50alkyl),, (A).NHC, yalkenyl, (A)N(C,nalkenyl), (A)NHC(O)C alkyl, (A),NHC(O)C, alkenyl, (A),NHC(O)aryl, (A) NH[C(O)CH(R,)NH],-H, (A),NH-[sugar],, (A)SO:H, (A),SO4C,.p0alkyl, (A),SO,C, alkenyl, (A),C(O)C,.palkyl, (A).C(O)C, alkenyl, (A),CO.H, (A),CO,C, alkyl, (A), COC, palkenyl, (A).C(O)NHC, zalkyl, (A).C(OIN(C, alkyl), (A),C(O)NHC, palkenyl, (A), C(O)NI(C, alkenyl), (A),C(O)[NHCH(R,,)C(0)],-OH, (A),C(O)[sugar]y; wherein Ais methylene optionally substituted one or two times with a group that is independently selected from C, salkyl, C, alkenyl, C,4alkynyl, halogen, OH, OC, alkyl, CO,H,
CO,C,.salkyl, NH,, NHC, alkyl, -N(Cyalkyl),, CN, NO,, aryl or heterocyclyl; Ry, is the characterising group of an amino acid, n is 0 or an integer from 1 to 20 and s is an integer from 1to5; R,is hydrogen, C,jalkyl, OH, SH, NH,, -NO,, CF, halo or -CN;
R, is hydrogen, C,-Csalkyl, -(CH,),.NH,, -(CHy)n-OH, -(CH,),,-CF,, -(CH,),-SHora5 or 6 membered heterocyclic group, wherein m is 0 or an integer from 1 to 3;
R, is hydrogen, C,jalkyl, OH, SH, NH,, NO,, CF, halo or CN;
A is unsubstituted methylene or mono-substituted methylene.
In certain preferred forms of the invention, the compounds of Formula (II) include:
Z
8
X Y
Ry
R{ Ry
Ra (m wherein
X is -O-, -S-, -NH-;
Y is -O-, -S- or -N(Rs)-;
Z forms a covalent bond between adjacent methylene groups;
R, is Cy-Cyalkyl, Cp-Cyralkenyl, C-Cppalkynyl, (A),C(O)R,, (A) C(S)Rg -(A).S(O)Re -(A)S(O)Rs (A),ORy, -(A)uSRy, -(A),N(Rg)y, (A),C(=NRg)Ry; or (A):Ry; where n, Re, Ry, Re,
Rs, Ry and R;; are defined above;
R, is hydrogen, methyl, OH, OCH, SH, NH,, NO,, CF; halo or CN;
R, is Calkyl, -(CH,), NH, -(CH,),-OH, -(CH,),.SH or heterocyclyl where m is defined above;
Ry is hydrogen, methyl, OH, OCH, SH, NH,, NO,, CF; CF; halo or CN.
More preferably the compounds of formula (II) comprise z
C
X Y
Ry
Rq Rp
Ro (m wherein
X is -O- or NH; Yis-O- or -N(Rg)- where Rpg is selected from hydrogen, C, alkyl, C;zalkenyl, C, alkenyl,
C,.0alkynyl and (CH,),R;; where Ry; and n are defined above;
Z forms a covalent bond between adjacent methylene groups;
R, is as defined for R; above;
R, is hydrogen, halomethyl, OH, OCH, SH, NH,, NO, or CN; R;is hydrogen, C,jalkyl, (CH,),,NH,, (CH,), OH or (CH,),,CF; or heterocyclyl where m is defined above;
R, is hydrogen, methyl, OH, OCH, SH, NH,, NO, or CN.
More preferably, the compounds of Formula (I) are heterocyclic compounds having the formula (III)
X Y
Ry
Ry H
Rs (Ih wherein
Xis-O-or-NH-;
Y is -O- or -N(Ry5)- where Ry, is defined above;
R, is as defined for R, above;
R, is hydrogen, NH,, OH;
R, is hydrogen, methyl, OCH,, or OH.
Ina preferred embodiment R1 is selected from (A), OR, where nis 0 and A and R; are defined above.
Further preferred embodiments include:
A compound of formula (I) wherein X is -S-; Y is -N(Rs)-; X' is -C(Rg);~; Y' is -C(Rs),~
Z forms a covalent bond between X' and Y'. Preferably, Y is -NH-; X'is -CH,-; Y' is -CH,; R, is H.
A compound of formula (I) wherein X and Y are each -O-; X' and Y' are each —-
C(Rs),~; Z forms a covalent bond between X' and Y'. Preferably, X' and Y' are each -CH,-; R, is H.
A compound of formula (I) wherein X and X' taken together form —C(R;)=N-; Y is ~C(Ry)- and taken together with the carbon atom bearing the phenyl group forms a double bond; Y' is -N(R;)-; Z forms a covalent bond between X' and Y'. Preferably,
Y is -CH-; X is ~CH-.
A compound of formula (I) wherein X and X' taken together form ~C(Rs)=N-; Z together with Y' forms ~C(R;)=C(R;)-; Y is -C(Rs)- and together with the carbon atom bearing the phenyl group forms a double bond. Preferably, X is -C(OCH,); Z together with Y' forms ~C(OCH,;)=CH-; Y is -CH-.
A compound of formula (I) wherein X' is -C(Rs),-; Y' is “C(Rs),-; Z is “C(Rs),-; X and
Y are each —O-. Preferably, X', Y' and Z are each -CH,-; R, is H.
A compound of formula (I) wherein X and Y are each -S-; X' and Y" are each —C(Rs),-; Z forms a covalent bond between X' and Y'. Preferably, X' and Y' are each -
CH,-; R, is H.
A compound of formula (I) wherein X is -S-; Y is -O-; X' and Y' are each -C(Rs),; Z forms a covalent bond between X' and Y'. Preferably, X' and Y' are each -CH,-.
A compound of formula (I) wherein X and X' taken together form —~C(Rs)=C(Rs)-; Z together with Y' forms —-C(Rs)=C(R;)-; Y is -C(Rs)- and together with the carbon atom bearing the phenyl group forms a double bond. Preferably, X and X' taken together form ~CH=CH-; Z together with Y forms -CH=CH-; Y is -CH-.
A compound of formula (I) wherein Y is -N- and taken together with the carbon atom bearing the phenyl group forms a double bond; X is -O-; X' and Y' are each ~C(Rs),~; Z forms a covalent bond between X' and Y'. Preferably, X' and Y' are each -CH,-.
A compound of formula (I) wherein X and Y are each -C(Rs),-; X' and Y' are each -
N(R;)-; Zis CRs),
A compound of formula (I) wherein X is ~O-; Y" is -N(Rs)-; X' and Y are each —C(R5),-.
A compound of formula (I) wherein X and X' are each ~C(Rs),~; Y is -N(R;)-; Y' is -C(Rs),-; Z forms a covalent bond between X' and Y'.
A compound of formula (I) wherein X is -N(Rs)-; X" is “C(Rs),; Y is -C(R;)~ Y' is ~N(R;)-; Z forms a covalent bond between X' and Y'.
A compound of formula (I) wherein X and X' are each —C(R;),- Y is -C(Rs),~; Y' is -N(Rs)-; Z is -C(Rs),-.
Preferred compounds of formula (I) include 2-(2-hydroxyethoxy)-2-(4-hydroxy-3- methylphenyl)-1,3-dioxolane; 2-(2-hydroxyethoxy)-2-(4-hydroxyphenyl)-1,3-dioxolane; 2- (2-hydroxyethoxy)-2-(3-bromo-4-hydroxy-5-methylphenyl)-1,3-dioxolane; 2-(4-
Bromophenyl)-1,3-thiazolane; 2-(4-Methoxyphenyl)-1,3-thiazolane; 4-(1,3-Thiazolidin-2- yl)benzonitrile; 2-(4-Hydroxy-3-methoxyphenyl)-1,3-thiazolane; 2-(3,4-Dimethoxyphenyl)- 1,3-thiazolane; Methyl 4-[2-(4-fluorophenyl)-1,3-dioxolan-2-ylJbutanoate; 4-[2-(4-
Fluorophenyl)-1,3-dioxolan-2-ylJbutan-1-ol; 2-(4’-Bromophenyl)-2-butyl-1,3-dioxolane; 4- (4-Methoxyphenyl)-1-(3-methylbutyl)-1/#pyrazole; 1-(3-Methylbutyl)-4-(4-methylphenyl)- 1H-pyrazole; 2,6-Dimethoxy-3-[4-(trifluoromethoxy)phenyl]pyridine); 2-[4-(2-
Thienyl)phenyl]-1,3-thiazolane; 2-Ethyl-2-(4-methoxyphenyl)-1,3-dioxolane; 2-Hexyl-2-(4- methylphenyl)-1,3-dithiolane; 2-Methyl-2-(4-methylphenyl)-1,3-dithiolane; 2-Hexyl-2-(4- methylphenyl)-1,3-dioxolane; 2-(4-Chlorophenyl)-2-methyl-1,3-dioxane; 2-(4- } Chlorophenyl)-2-methyl-1,3-dioxolane; 2-Methyl-2-(4-methylphenyl)-1,3-dioxane; 2-
Methyl-2-(4-methylphenyl)-1,3-dioxolane; 2-(4-Chlorophenyl)-2-methyl-1,3-dithiolane; 2- (4-Nitrophenyl)-2-methyl-1,3-dioxolane; 2-(4-Nitrophenyl)-2-methyl-1,3-dioxane; 2-(4-
Methoxyphenyl)-1,3-oxathiolane; 2-(3,4,5-Trimethoxyphenyl)-1,3-oxathiolane; 2-Methoxy- 4-(1,3-oxathiolan-2-yl)phenol; 4-(1,3-Oxathiolan-2-yl)benzonitrile; 2-(4-Bromophenyl)-2- ethyl-1,3-oxathiolane; 4-(5-Methyl-1,3-oxathiolan-2-yl)benzonitrile; 2-(4-Thien-2-ylphenyl)- 1,3-oxathiolane; 4-(5-Methyl-2-octyl-1,3-oxathiolan-2-yl)phenol; 2-Fluoro-5-(5-methyl-1,3- oxathiolan-2-yl)benzenecarbonitrile; 4-Methoxy-4'~(triflucromethoxy)-1,1’-biphenyl; 2,6-
Dimethoxy-3-[4-(trifluoromethyl)phenyl]pyridine; 2-(4-bromophenyl)-2-butyl-4-propyl-1,3- oxathiane; 4-(1,3-Dioxolan-2-yl)benzenecarbonitrile; 2-(3,5-Dimethoxyphenyl)-2-hexyl-1,3- dioxolane; 2-(4-Chlorophenyl)-2-ethyl-4-methyl-1,3-dioxolane; 5-(5,5-Diethyl-1,3-dioxan-2- yl)-2-fluorobenzenecarbonitrile; 2-(4-Chlorophenyl)-4,5-dihydro-1,3-oxazole; 2-(4-
Methylphenyl)-4,5-dihydro-1,3-oxazole.
More preferably the compounds are selected from the group consisting of:2-(2- hydroxyethoxy)-2-(4-hydroxy-3-methylphenyl)-1,3-dioxolane; 2-(2-hydroxyethoxy)-2-(4- hydroxyphenyl)-1,3-dioxolane; 2-(2-hydroxyethoxy)-2-(3-bromo-4-hydroxy-5- methylphenyl)-1,3-dioxclane; Methyl 4-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]butanoate; 4- [2-(4-Fluorophenyl)-1,3-dioxolan-2-yl]butan-1-ol; 2-(4’-Bromophenyl)-2-butyl-1,3- dioxolane; 4-(4-Methoxyphenyl)-1-(3-methylbutyl)-1 F-pyrazole; 1-(3-Methylbutyl)-4-(4- methylphenyl)-1A-pyrazole; 2,6-Dimethoxy-3-[4-(trifluoromethoxy)phenyl]pyridine); 2-4 (2-Thienyl)phenyl]-1,3-thiazolane; 2-Ethyl-2-(4-methoxyphenyl)-1,3-dioxolane; 2-Hexyl-2-
(4-methylphenyl)-1,3-dithiolane; 2-Hexyl-2-(4-methylphenyl)-1,3-dioxolane; 2-(4-
Bromophenyl)-2-ethyl-1,3-oxathiolane; 4-(5-Methyl-1,3-oxathiolan-2-yl)benzonitrile; 2-(4-
Thien-2-ylphenyl)-1,3-oxathiolane; 4-(5-Methyl-2-octyl-1,3-oxathiolan-2-yl)phenol; 2-
Fluoro-5-(5-methyl-1,3-oxathiolan-2-yl)benzenecarbonitrile; 4-Methoxy-4'- (trifluoromethoxy)-1,1'-biphenyl; 2,6-Dimethoxy-3-[4-(trifluoromethyl)phenyl]pyridine; 2- (4-bromophenyl)-2-butyl-4-propyl-1,3-oxathiane; 4-(1,3-Dioxolan-2-yl)benzenecarbonitrile; 2-(4-Chlorophenyl)-2-ethyl-4-methyl-1,3-dioxolane; 5-(5,5-Diethyl-1,3-dioxan-2-yl)-2- fluorobenzenecarbonitrile.
In a yet further preferred embodiment, the compound of formula (I) is selected from the group consisting of: 2-(2-hydroxyethoxy)-2-(4-hydroxy-3-methylphenyl)-1,3-dioxolane; 4- (4-Methoxyphenyl)-1-(3-methylbutyl)-1 Fpyrazole; 1-(3-Methylbutyl)-4-(4-methylphenyl)- 1H-pyrazole; 2-Hexyl-2-(4-methylphenyl)-1,3-dithiolane; 2-Methyl-2-(4-methylphenyl)-1,3- dithiolane; 2-(4-Thien-2-ylphenyl)-1,3-oxathiolane; 4-Methoxy-4'-(trifluoromethoxy)-1,1- biphenyl; 2,6-Dimethoxy-3-[4-(trifluoromethyl)phenyl]pyridine.
Examples of suitable compounds may include:
S — 0.
O oA"
HC : iy
OH : /
O_ 0 / 0 ~_-CH o_o i 0 oO CSer—Asn
OH HyC
OH
Ngo) o_O ? oH oO C~Ser—Asn—Asn—Lys
HO H3C
OH CH
= /— NE,
OH 00 Pas N de Waal oY
EN H
H OH HaC
OH
HsC
OH
/ OH 7 o_o
HN Ne ~~ HN NH yo c J 2 HsC
HC
HC I 8 OH CH,OH
OH OolH
H
Ne ~~" d_b 0 2 Ss db i nh oN er—Asn oN QO F
H OH
OCHj3 OCHs OCH3
OH OH OH
OH
=
MM av 0 Ne) 0 N I S g “OCHjg J ) OH 5 0 OCH, Ir OCHs
OH
COOH al
OH ad pad N N
CY rN
HN NH HN NH
OCHg A... : OCH;
OH OH
HN. NNN H mM H Oo. 0 » a A A
OCH OH
3 OCH, OCHa,
OH OH OH
Compounds of Formula (I) may be prepared using the methods depicted or described herein or known in the art. It will be understood that minor modifications to methods described herein or known in the art may be required to synthesize particular compounds of Formula (I). General synthetic procedures applicable to the synthesis of compounds may be found in standard references such as Comprehensive Organic Transformations, R.
C. Larock, 1989, VCH Publishers and Advanced Organic Chemistry, J. March, 4th Edition (1992), Wiley InterScience, and references therein. It will also be recognised that certain reactive groups may require protection and deprotection during the synthetic process.
Suitable protecting and deprotecting methods for reactive functional groups are known in the art for example in Protective Groups in Organic Synthesis, T. W. Green & P. Wutz, John
Wiley & Son, 3rd Edition, 1999.
Thus for certain embodiments of the invention, compounds of formula (I), where X and Y are -O-, X' and Y' are -CHj-, Z is -CH,- or forms a bond between X' and Y' and R, is alkyl, alkenyl, alkynyl or an optionally substituted alkylene with terminal functionality, eg (A),OMe where nis between 1 and 20, may be prepared by the general method shown in
Scheme 1. yA o) Ry é N 0) Oo
Ry
HO-(CH,),0H whereb=2or3
Ry Rs
Rs Ro
Rs
Rs
Scheme 1
Suitable starting materials may be commercially available or made by methods known in © 20 theart. Suitable conditions for this reaction include refluxing the starting material and the dihydroxy compound in benzene in the presence of acid, eg. tosylate. Other conditions for performing this reaction to provide selectivity in the presence of other carbonyl groups or to provide conditions suitable for use in the presence of other functional groups are provided in Protective Groups in Organic Synthesis, T.W. Green & P. Wutz, John Wiley &
Son; 3rd Edition, 1999, pages 312-329. Functionality may be introduced into the dioxolane group by using a substituted dihydroxy compound. 1,3-dithiane or 1,3-dithiolane derivatives, where X and Y are -S-, X' and Y' are -CH,-, Zis -CH,- or forms a covalent bond between X' and Y' and R, is alkyl, alkenyl, alkynyl or an optionally substituted alkylene with terminal functionality, eg.: (A),OMe where n is 1 to 20, may be prepared in a similar manner as the 1,3-dioxolane derivatives in Scheme 1. Suitable conditions for this reaction include mixing the starting material and HS-(CH,),-SH, where b is 2 or 3, in the presence of BF5-Et,O in dichloromethane at room temperature. Other conditions for performing this reaction are provided in Protective Groups in Organic
Synthesis, T.W. Green & P. Wutz, John Wiley & Son; 3rd Edition, 1999, pages 333-336. 1,3-oxathiolanes, where one of X and Y is -O- and the other is -5-, X' and Y' are -CH,-, Z is -CH,- or forms a covalent bond between X' and Y' and R is alkyl, alkenyl, alkynyl or an optionally substituted alkylene with terminal functionality, eg.: (A),OMe where n is 1 to 20, may be prepared in a similar manner as the 1,3-dioxolane derivatives in Scheme 1. Suitable conditions include mixing the starting material with HS-(CH,),-OH where b is 2 or 3, in dioxane, in the presence of ZnCl, and AcONa at room temperature. Conditions for performing this reaction are given in Protective Groups in Organic Synthesis, T.W. Green & P. Wutz, John Wiley & Son; 3rd Edition, 1999, at page 346.
Compounds where X and Y are -N(R;)-, X' and Y' are -CHj-, Z is -CH,- or forms a covalent bond between X' and Y' and R, is alkyl, alkenyl, alkynyl or an optionally substituted alkylene with terminal functionality, eg.: (A),OMe where n is 1 to 20, may be prepared as shown in Scheme 2 (12): 0
I Me—N N—~Me
C—H
A A + -
H H
OH OH
Scheme 2
Compounds where X is -N(R;)-, X' and Y' are -CH,-, Z is -CH,- or forms a covalent bond between X' and Y', Y together with the carbon atom to which the phenyl group is attached is a double bond and R, is absent may be prepared as shown in Scheme 3 (13).
I
N NH
C—OMe N
HoN—CH,CH,——NH, ——————————————
EtOH, 90%
OH OH
Scheme 3
WhenR, includes a -CO,H or -C(S)OH group, the compounds may be further derivatised to provide ketones, thioketones, esters, thioesters, amides and thioamides by standard alkylating, esterifying or amide forming methodology. When R, includes a hydroxy, thiol or amino group, these groups may be further derivatised to provide esters, thioesters, amides, ethers, thioethers and N-alkyl groups using standard acylating or alkylating methodology. Conversion of an amide to C=NH(NH,) can be achieved by aminolysis eg
NH,/ dry methanol.
In other embodiments, compounds of Formula (I), where R,, R,, R; or R, is a substituted methyl group, can be prepared by conversion of the methyl substituent into a halomethyl substituent (eg by treatment with a N-halosuccinimide such as NBS) followed by nucleophilic substitution by an appropriate nucleophile and/or insertion of additional methylene groups by, for example, Wittig reaction (see Scheme 4 where R* can be, for example, (CH,),OH, (CH,),SH, (CH,),NH,, (CH,),heterocyclyl, (CH,),aryl, (CH,),NO, where xis 0, 1 or 2. Similar reactions could be performed if R, is CH,Br to provide substituents such as (CH,),C(O)C alkyl, (CH,),0C(O)C,.jsalkyl, (CH,),0C, palkyl, (CH,).Ophenyl, (CH,),Obenzyl, (CH,),NHC, yalkyl, (CH,),N(C,.,palkyl), (CH,),NHphenyl, (CH,),NHbenzyl, (CH,),SC, »alkyl, (CH,),SC(O)C,.palkyl, (CH,),Sphenyl, (CH,),Sbenzyl, (CH,),NHsugar, (CH,),Ssugar, (CH,),Osugar, (CH,),NHC(O)C, jpalkyl, (CH,),NHC(O)phenyl, (CH,),NHC(O)benzyl, (CH,),NHCO,C, calkyl, (CH,),NHCO,pheny], or (CH,),NHCO,benzyl , where n is 0 or 1 to 20).
a N
X Y X Y
Ry > Ri
R4 Ra R4 R2
CH CH,Br nucleophile substitution and/or Wittig Reaction a
X Y
Rs Ro
CH,R"
Scheme 4
In other embodiments, compounds where R;, R,, Ry or R, are CH,halo can be prepared by reaction of a suitable carboxylic acid derivative with a reducing agent such as LiAIH,, followed by halogenation, eg treatment with thionyl chloride (Scheme 5).
X Y X Y
R, Reduction R, _——
Ry R, R4 R2
CO,H CHOH
SOCl,
A
“Sh,
R4 Ro
CH,CI
Scheme 5
Coupling of compounds wherein R;, Ry, R; or R; is CH,halo with an alkylhalide or halo(CH,),heterocyclyl in the presence of CuLi affords the corresponding compounds where the R;, Ry, R; or R, substituent is alkyl or where R, or R, are (CH,),heterocyclyl where ais 1-20 in relation to R, or 1 to 3 in relation to R;.
Reaction of CHjhalo with NH,-NH-C(=NH)-NH, in the presence of base affords access to compounds wherein R, is CH,-NH-NH-C(=NH)-NH,. Alternatively, reaction of the
CH;halo group with halo(CH,),NH-NH-C(=NH)-NH, (where p is 1 or 2), affords the group (CH,),NH-NH-C(=NH)-NH, where p is 2 or 3.
Compounds where R;, is -OH, -NR or -CH,CN can be prepared from the compound where
R; is C, as shown in Scheme 6 zZ z rd
CT i
X Y X Y
Ca(OH), [=§ —_—_— R’
Ref (14)
Ry Ra Rs Ra
Cl NHR;, OH
Cu, K,COs in
CH,CN DMF
Ref (15) | NaOCH,4
CuBr
Zz ~~ i ~N 1
X Y z
FERS xX Y ] "
X Y
R’
R4 Ro
NR2
Rg Ra 6
CH,CN Scheme
Compounds according to formula (I) in which X' and Y’ are each -N(R;)- and Z is ~CH,- can be prepared as is shown in Scheme 7. (Reference: Journal of American Chemical
Society, 123(19), 4451-4458, 2001 lo]
NH, a nN
CH,ON P lL
Hydrolysis
HoNCHO + _
Rd Ro
Rs Rg R, Rq Re
Rs Rs : 4-amino-5-phenylpyrimidi no->-phenylpyrimicing 5-phenyl-4-pyrimidinone ((elsCre (PrasCHy (fhancto (CH): CHs 1 boc
NN NSN HN" NH NSN 8
Example CHg(CHa),CH,Br Hydrogenation Z
NaH/THF 5%Pd/C
OCHg R4 Ry R4 Raz R4 Rez
OH Ro Ra Ra (A)
Several compounds can be made
R; = OCHz by varing Ry, Rs, Rg and n
Ra = OH
Re=H n=3
Scheme 7
Compounds in which X is O, Y' is -N(R;)- and Z is -CH,- can be prepared as is shown in
Scheme 8.
Ry Rq 0 0
Ra + CHzNHCH,CHOH —= Ry D
Br N
R2 Ra CHa .CH3 -CHg (ON oy he 0 | CHyCOzH 0 © 3CO2
Rs + OHgNHOHCHEOH —— eo Example
OAC 2
Ra RJ Ry OCH;
Reference: Chemische Berichte, 115(7), 2635-42, 1982 Rs © . Scheme 8
Compounds in which X and X' are each -C(R;),-, Zis abond and Y is -N(R;)- can be prepared according to scheme 9.
Cl
O-Ry ~~
HO or MeOH Fi~gN y 0. OTes (5%) He + Cl—CHoCH,CHoNH, NazCOj rr . 1 Example
R HCI step 1 * step 2 4 Ra
Rs R¢ Re Rq Ra N—(CH,),CHj
Rs Rs Ry
OCH;
Reference: J.Org.Chem.66, 6207-6208, 2001 OH
D)
Scheme 9
Compounds in which X is -N(R5)-, Y is -N(R5)- and Z is a bond can be prepared according to scheme 10. lo} ad
CHO MNRs /—NRs ~N 0 1. LiBr NH Aq NH NH + HN-G-NHRg _2:CO LAH, | example
NMP ether
R: Ra
Ra Ri Ra Rz Ra, OCHg
Rs Rs OH
References: Ger.Offen. 199940211, 23 mar 2000. E)
J.Org. Chem, 15, 1020-2, 1950.
Scheme 10
Compounds in which X and X' are =C(R;),-, Z is ~CH,- and Y" is -N(Rs)- can be prepared according to Scheme 11.
CHO
H,0 or MeOH + Cl—CH;CH,CHoNH, Nay,COg NH
Ri Ra HCl TT fia 1.Li/ THF
N= .
OR 2" ~CHaCHRCH,CI ae Rs Ra
Rs
Rg4 Ra
Rj
Reterence: J.Org.Chem.66, 6207-6208, 2001
NH MogSIGH,GI Lo N~CHzSMeg NH N-Ps N-(CH2)4CHg
DMSO DMF. Ast Example
DMF -
R4 Re Ri Ry
Rs Rs R4 Re Ag Rz2 OCH;
Ra Rs OH
Reference: Chemical & Pharmaceutical Bulletin, 39(1), 36-40, 1991 #
Scheme 11 2-Ethyl-2-(4-methoxyphenyl)-1,3-dioxolane, Compound 16, the synthesis of which is reported below, is prepared by the following the reaction scheme 12 and it would be understood by a person skilled in the art that a similar methodology can be used to prepare other appropriately substituted 1,3-dioxolanes. 0 0 o.__0O
K,C03/(Me0),S0, (HOCH,),/H" —_— —_—
OH OMe OMe
Scheme 12 2-Hexyl-2-(4-methylphenyl)-1,3-dithiolane, Compound 17, the synthesis of which is reported below, is prepared by following the reaction scheme 13 and it would be understood by a person skilled in the art that a similar methodology can be used to prepare other appropriately substituted 1,3- dithiolanes.
compounds of the invention are well known in the art and may include treatment of the compound with an appropriate carboxylic acid, anhydride or acylchloride in the presence of a suitable catalyst or base.
Suitable pharmaceutically acceptable salts include, but are not limited to, salts of pharmaceutically acceptable inorganic acids such as hydrochloric, sulphuric, phosphoric, nitric, carbonic, boric, sulfamic, and hydrobromic acids, or salts of pharmaceutically acceptable organic acids such as acetic, propionic, butyric, tartaric, maleic, hydroxymaleic, fumaric, maleic, citric, lactic, mucic, gluconic, benzoic, succinic, oxalic, phenylacetic, methanesulphonic, toluenesulphonic, benezenesulphonic, salicyclic sulphanilic, aspartic, glutamic, edetic, stearic, palmitic, oleic, lauric, pantothenic, tannic, ascorbic and valeric acids.
Base salts include, but are not limited to, those formed with pharmaceutically acceptable cations, such as sodium, potassium, lithium, calcium, magnesium, ammonium and alkylammonium.
Basic nitrogen-containing groups may be quarternised with such agents as lower alkyl halide, such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl and diethyl sulfate; and others.
It will also be recognised that some compounds of formula (I) may possess asymmetric centres and are therefore capable of existing in more than one stereoisomeric form. The invention thus also relates to compounds in substantially pure isomeric form at one or more asymmetric centres eg., greater than about 90% ee, such as about 95% or 97% ee or greater than 99% ee, as well as mixtures, including racemic mixtures, thereof. Such isomers may be prepared by asymmetric synthesis, for example using chiral intermediates, or by chiral resolution.
In a further aspect, the present invention provides a method of inhibiting cytokine or biological activity of MIF comprising contacting MIF with a cytokine or biological activity inhibiting effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
In another aspect, the invention provides a method of treating, preventing or diagnosing a disease or condition wherein MIF cytokine or biological activity is implicated comprising the administration of a treatment, prevention or diagnostic effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof to a subject in need thereof.
Os_ _H HO. _(CH,)sCH,
Mg , CeHysl r—————————-
Me Me
PCC
EE
S._-S Ox ~(CH2)sCH3 (CH2)sCH;3
ANN HSCH,CH,SH AS lj =
Me Me
Scheme 13
The term “salt, or prodrug" includes any pharmaceutically acceptable salt, ester, solvate, hydrate or any other compound which, upon administration to the recipient is capable of providing (directly or indirectly) a compound of Formula (I) as described herein. The term "pro-drug” is used in its broadest sense and encompasses those derivatives that are converted in vivo to the compounds of the invention. Such derivatives would readily occur to those skilled in the art, and include, for example, compounds where a free hydroxy group is converted into an ester, such as an acetate, or where a free amino group is converted into an amide. Procedures for acylating hydroxy or amino groups of the
In a further aspect, there is provided the use of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for the treatment, prevention or diagnosis of a disease or condition wherein MIF cytokine or biological activity is implicated.
As used herein, MIF includes human or other animal MIF and derivatives and naturally occurring variants thereof which at least partially retain MIF cytokine or biological activity.
Thus, the subject to be treated may be human or other animal such as a mammal.
Non-human subjects include, but are not limited to primates, livestock animals (eg sheep, cows, horses, pigs, goats), domestic animals (eg dogs, cats), birds and laboratory test animals (eg mice rats, guinea pigs, rabbits). MIF is also expressed in plants (thus "MIF" may also refer to plant MIF) and where appropriate, compounds of Formula (I) may be used in botanical / agricultural applications such as crop control.
Reference herein to "cytokine or biological activity" of MIF includes the cytokine or biological effect on cellular function via autocrine, endocrine, paracrine, cytokine, hormone or growth factor activity or via intracellular effects.
In a further aspect of the invention there is provided a method of treating, diagnosing, or preventing autoimmune diseases, tumours or chronic or acute inflammatory diseases comprising administration of a treatment, diagnosis or prevention effective amount of a compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof. Such diseases include: rheumatic diseases (including but not limited to rheumatoid arthritis, osteoarthritis, psoriatic arthritis) spondyloarthropathies (including but not limited to ankylosing spondylitis, reactive arthritis, Reiter's syndrome), crystal arthropathies (including but not limited to gout, pseudogout, calcium pyrophosphate deposition disease),
Lyme disease, polymyalgia rheumatica; connective tissue diseases (including but not limited to systemic lupus erythematosus, systemic sclerosis, polymyositis, dermatomyositis, Sjogren's syndrome); vasculitides (including but not limited to polyarteritis nodosa, Wegener's granulomatosis, Churg-Strauss syndrome); inflammatory conditions including consequences of trauma or ischaemia, sarcoidosis;
vascular diseases including atherosclerotic vascular disease, atherosclerosis, and vascular occlusive disease (including but not limited to atherosclerosis, ischaemic heart disease, myocardial infarction, stroke, peripheral vascular disease), and vascular stent restenosis;
ocular diseases including uveitis, corneal disease, iritis, iridocydlitis, cataracts; autoimmune diseases (including but not limited to diabetes mellitus, thyroiditis, myasthenia gravis, sclerosing cholangitis, primary biliary cirrhosis); pulmonary diseases (including but not limited to diffuse interstitial lung diseases, pneumoconioses, fibrosing alveolitis, asthma, bronchitis, bronchiectasis, chronic obstructive pulmonary disease, adult respiratory distress syndrome); cancers whether primary or metastatic (including but not limited to prostate cancer, colon cancer, lymphoma, lung cancer, melanoma, multiple myeloma, breast cancer, stomach cancer, leukaemia, cervical cancer and metastatic cancer); renal diseases including glomerulonephritis, interstitial nephritis;
disorders of the hypothalamic-pituitary-adrenal axis; nervous system disorders including multiple sclerosis, Alzheimer’s disease; diseases characterised by modified angiogenesis (eg diabetic retinopathy, rheumatoid arthritis, cancer), endometrial function (menstruation, implantation, endometriosis);
complications of infective disorders induding endotoxic (septic) shock, exotoxic (septic) shock, infective (true septic) shock, malarial complications, other complications of infection, pelvic inflammatory disease; transplant rejection, graft-versus-host disease; allergic diseases including allergies, atopic diseases, allergic rhinitis;
bone diseases (eg osteoporosis, Paget's disease); skin diseases including psoriasis, atopic dermatitis, UV(B)-induced dermal cell activation (eg sunburn, skin cancer); complications of diabetes mellitus, pain, testicular dysfunctions and wound healing, gastrointestinal diseases including inflammatory bowel disease (including but not limited to ulcerative colitis, Crohn's disease), peptic ulceration, gastritis, oesophagitis, liver disease (including but not limited to cirrhosis, hepatitis).
Particularly preferred diseases or conditions include: rheumatoid athritis, systemic lupus erythematosus, ulcerative colitis, Crohn's disease, multiple sclerosis, psoriasis, uveitis, atherosclerotic vascular disease, asthma and chronic obstructive pulmonary disease.
A further aspect of the invention provides for the use of a compound of Formula (I) or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for the treatment of a disease or condition as above.
As used herein, the term "effective amount” relates to an amount of compound which, when administered according to a desired dosing regimen, provides the desired MIF cytokine inhibiting or treatment or therapeutic activity, or disease/ condition prevention.
Dosing may occur at intervals of minutes, hours, days, weeks, months or years or continuously over any one of these periods. A cytokine or biological activity inhibiting amount is an amount which will at least partially inhibit the cytokine or biological activity of MIF. A therapeutic, or treatment, effective amount is an amount of the compound which, when administered according to a desired dosing regimen, is sufficient to at least partially attain the desired therapeutic effect, or delay the onset of, or inhibit the progression of or halt or partially or fully reverse the onset or progression of a particular disease condition being treated. A prevention effective amount is an amount of compound which when administered according to the desired dosing regimen is sufficient to at least partially prevent or delay the onset of a particular disease or condition. A diagnostic effective amount of compound is an amount sufficient to bind to MIF to enable detection of the MIF-compound complex such that diagnosis of a disease or condition is possible.
Suitable dosages may lie within the range of about 0.1 ng per kg of body weight to 1 g per kg of body weight per dosage. The dosage is preferably in the range of 1 ug to 1 g per kg of body weight per dosage, such as is in the range of 1 mg to 1 g per kg of body weight per dosage. In one embodiment, the dosage is in the range of 1 mg to 500 mg per kg of body weight per dosage. In another embodiment, the dosage is in the range of 1 mg to 250 mg per kg of body weight per dosage. In yet another preferred embodiment, the dosage is in the range of 1 mg to 100 mg per kg of body weight per dosage, such as up to 50 mg per kg of body weight per dosage. In yet another embodiment, the dosage is in the range of 1ug to 1mg per kg of body weight per dosage.
Suitable dosage amounts and dosing regimens can be determined by the attending physician or veterinarian and may depend on the desired level of inhibiting activity, the particular condition being treated, the severity of the condition as well as the general age, health and weight of the subject.
The active ingredient may be administered in a single dose or a series of doses. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a composition, preferably as a pharmaceutical composition.
Ina further aspect of the invention, there is provided a pharmaceutical composition comprising a compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient.
The formulation of such compositions is well known to those skilled in the art. The composition may contain pharmaceutically acceptable additives such as carriers, diluents or excipients. These include, where appropriate, all conventional solvents, dispersion agents, fillers, solid carriers, coating agents, antifungal and antibacterial agents, dermal penetration agents, surfactants, isotonic and absorption agents and the like. It will be understood that the compositions of the invention may also include other supplementary physiologically active agents.
The carrier must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the composition and not injurious to the subject. Compositions include those suitable for oral, rectal, inhalational, nasal, transdermal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intraspinal, intravenous and intradermal) administration. The compositions may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients.
In general, the compositions are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
Depending on the disease or condition to be treated, it may or may not be desirable for a compound of Formula (I) to cross the blood /brain barrier. Thus the compositions for use in the present invention may be formulated to be water or lipid soluble.
Compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, sachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, electuary or paste.
A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder (eg inert diluent, preservative, disintegrant (eg. sodium starch glycolate, cross-linked polyvinyl pyrrolidone, cross-linked sodium carboxymethyl cellulose)) surface-active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
Compositions suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavoured base, usually sucrose and acacia or tragacanth gum; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia gum; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
The compounds of Formula (I) may also be administered intranasally or via inhalation, for example by atomiser, aerosol or nebulizer means.
Compositions suitable for topical administration to the skin may comprise the compounds dissolved or suspended in any suitable carrier or base and may be in the form of lotions, gel, creams, pastes, ointments and the like. Suitable carriers include mineral oil, propylene glycol, polyoxyethylene, polyoxypropylene, emulsifying wax, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. Transdermal devices, such as patches, may also be used to administer the compounds of the invention. ‘ Compositions for rectal administration may be presented as a suppository with a suitable carrier base comprising, for example, cocoa butter, gelatin, glycerin or polyethylene glycol.
Compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
Compositions suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bactericides and solutes which render the composition isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The compositions may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
Preferred unit dosage compositions are those containing a daily dose or unit, daily sub-dose, as herein above described, or an appropriate fraction thereof, of the active ingredient.
It should be understood that in addition to the active ingredients particularly mentioned above, the compositions of this invention may include other agents conventional in the art having regard to the type of composition in question, for example, those suitable for oral administration may include such further agents as binders, sweeteners, thickeners, flavouring agents, disintegrating agents, coating agents, preservatives, lubricants and/or time delay agents. Suitable sweeteners include sucrose, lactose, glucose, aspartame or saccharine. Suitable disintegrating agents include corn starch, methylcellulose, polyvinylpyrrolidone, xanthan gum, bentonite, alginic acid or agar. Suitable flavouring agents include peppermint oil, oil of wintergreen, cherry, orange or raspberry flavouring.
Suitable coating agents include polymers or copolymers of acrylic acid and / or methacrylic acid and/or their esters, waxes, fatty alcohols, zein, shellac or gluten. Suitable preservatives include sodium benzoate, vitamin E, alpha-tocopherol, ascorbic acid, methyl paraben, propyl paraben or sodium bisulphite. Suitable lubricants include magnesium stearate, stearic acid, sodium oleate, sodium chloride or talc. Suitable time delay agents include glyceryl monostearate or glyceryl distearate.
It will be recognised that other therapeutically active agents such as anti-inflammatory (eg steroids such as glucocorticoids) or anti-cancer agents may be used in conjunction with a compound of Formula (I). Compounds of Formula (I) when administered in conjunction with other therapeutically active agents may exhibit an additive or synergistic effect. These may be administered simultaneously, either as a combined form (ie as a single composition containing the active agents) or as discrete dosages. Alternatively, the other therapeutically active agents may be administered sequentially or separately with the compounds of the invention. Thus, the invention also relates to kits and combinations, comprising a compound of Formula (I) and one or more other therapeutically active ingredients for use in the treatment of diseases or conditions described herein. Without being limiting, examples of agents which could be used in combination with a compound of Formula (I) include: antirheumatic drugs (including but not limited to methotrexate, leflunomide, sulphasalazine, hydroxycholorquine, gold salts); immunosuppressive drugs (including but not limited to cyclosporin, mycophenyllate mofetil, azathioprine, cyclophosphamide); anti-cytokine therapies (including but not limited to antagonists of, antibodies to, binding proteins for, or soluble receptors for tumor necrosis factor, interleukin 1, interleukin 3, interleukin 5, interleukin 6, interleukin 8, interleukin 12, interleukin 18, interleukin 17, and other pro-inflammatory cytokines as may be found relevant to pathological states); antagonists or inhibitors of mitogen-activated protein (MAP) kinases (including but not limited to antagonists or inhibitors of extracellular signal-regulated kinases (ERK), the c-Jun N-terminal kinases/ stress-activated protein kinases (JNK/SAPK), and the p38 MAP kinases, and other kinases or enzymes or proteins involved in MAP kinase-dependent cell activation); antagonists or inhibitors of the nuclear factor kappa-B (NF-B) signal transduction pathway (including but not limited to antagonists or inhibitors of I-B-kinase, interleukin receptor activated kinase, and other kinases or enzymes or proteins involved in NF-B-dependent cell activation); antibodies, protein therapeutics, or small molecule therapeutics interacting with adhesion molecules and co-stimulatory molecules (including but not limited to therapeutic agents directed against intercellular adhesion molecule-1, CD40, CD40-ligand, CD28, CD4, CD-3, selectins such as P-selectin or E-selectin); bronchodilators such as e-adrenoceptor agonists or anti-cholinergics; antagonists of eicosanoid synthesis pathways such as non-steroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, thromboxane inhibitors, or lipoxygenase inhibitors; antibodies or other agents directed against leukocyte surface antigens (including but not limited to antibodies or other agents directed against CD3,
CD4, CD5, CD19, CD20, HLA molecules); agents used for the treatment of inflammatory bowel disease (including but not limited to sulphasalazine, mesalazine, salicylic acid derivatives); anti-cancer drugs (including but not limited to cytotoxic drugs, cytolytic drugs, monoclonal antibodies).
In another aspect, the invention provides a method of treating or preventing a disease or condition wherein MIF cytokine or biological activity is implicated comprising: administering to a mammal a compound of formula (I) and a second therapeutic agent.
Inapreferred embodiment of this aspect of the invention, the second therapeutic agent is a glucocorticoid compound. :
In another aspect, the present invention provides a method of prophylaxis or treatment of a disease or condition for which treatment with a glucocorticoid is indicated, said method comprising: administering to a mammal a glucocorticoid and a compound of formula (I).
Inyet another aspect, the present invention provides a method of treating steroid-resistant diseases comprising administering to a mammal a glucocorticoid and a compound of formula (I).
In a further aspect, the present invention provides a method of enhancing the effect of a glucocorticoid in mammals comprising administering a compound of formula (I) simultaneously, separately or sequentially with said glucocorticoid.
In yet a further aspect, the present invention provides a composition comprising a glucocorticoid and a compound of formula (I).
In a further aspect of the invention there is provided a use of a glucocorticoid in the manufacture of a medicament for administration with a compound of formula (I) for the treatment or prophylaxis of a disease or condition for which treatment with a glucocorticoid is indicated.
In yet a further aspect of the invention there is provided a use of a compound of formula (I) in the manufacture of a medicament for administration with a glucocorticoid for the treatment or prophylaxis of a disease or condition for which treatment of a glucocorticoid isindicated.
In yet a further aspect of the invention there is provided a use of a glucocorticoid and a compound of formula (I) in the manufacture of a medicament for the treatment or prophylaxis of a disease or condition for which treatment with a glucocorticoid is indicated.
Preferably the amount of glucocorticoid used in the methods, uses and compositions of the invention is less than the amount which would be effective in the absence of the compound of formula (I). In the treatment of steroid-resistant diseases or conditions which are not responsive to glucocorticoids, any amount of glucocorticoid which is effective in combination with a compound of formula (I) is considered less than the amount which would be effective in the absence of a compound formula (I). Accordingly, the invention provides a steroid-sparing therapy.
In preferred embodiments of the invention, the glucocorticoid and the compound of formula (I) are used to treat or prevent a disease or condition in a mammal, preferably in a human subject.
The term "disease or condition for which treatment with a glucocorticoid is indicated” refers to diseases or conditions which are capable of being treated by administration of a glucocorticoid including but not limited to autoimmune diseases, tumours, or chronic or acute inflammatory diseases. Examples of such diseases or conditions include: rheumatic diseases (including but not limited to rheumatoid arthritis, osteoarthritis, psoriatic arthritis) spondyloarthropathies (including but not limited to ankylosing spondylitis, reactive arthritis, Reiter's syndrome), crystal arthropathies (including but not limited to gout, pseudogout, calcium pyrophosphate deposition disease),
Lyme disease, polymyalgia rheumatica; connective tissue diseases (including but not limited to systemic lupus erythematosus, systemic sclerosis, polymyositis, dermatomyositis, Sjogren's syndrome); vasculitides (including but not limited to polyarteritis nodosa, Wegener's granulomatosis, Churg-Strauss syndrome); inflammatory conditions including consequences of trauma or ischaemia, sarcoidosis; vascular diseases including atherosclerotic vascular disease, atherosclerosis, and vascular occlusive disease (including but not limited to atherosclerosis, ischaemic heart disease, myocardial infarction, stroke, peripheral vascular disease), and vascular stent restenosis; ocular diseases including uveitis, corneal disease, iritis, iridocyclitis, cataracts;
autoimmune diseases (including but not limited to diabetes mellitus, thyroiditis, myasthenia gravis, sclerosing cholangitis, primary biliary cirrhosis); pulmonary diseases (including but not limited to diffuse interstitial lung diseases, pneumoconioses, fibrosing alveolitis, asthma, bronchitis, bronchiectasis, chronic obstructive pulmonary disease, adult respiratory distress syndrome); cancers whether primary or metastatic (including but not limited to prostate cancer, colon cancer, lymphoma, lung cancer, melanoma, multiple myeloma, breast cancer, stomach cancer, leukaemia, cervical cancer and metastatic cancer); renal diseases including glomerulonephritis, interstitial nephritis;
disorders of the hypothalamic-pituitary-adrenal axis; nervous system disorders including multiple sclerosis, Alzheimer’s disease; diseases characterised by modified angiogenesis (eg diabetic retinopathy, rheumatoid arthritis, cancer), endometrial function (menstruation, implantation, endometriosis);
complications of infective disorders including endotoxic (septic) shock, exotoxic (septic) shock, infective (true septic) shock, malarial complications, other complications of infection, pelvic inflammatory disease; transplant rejection, graft-versus-host disease; allergic diseases including allergies, atopic diseases, allergic rhinitis;
bone diseases (eg osteoporosis, Paget's disease); skin diseases including psoriasis, atopic dermatitis, UV(B)-induced dermal cell activation (eg sunburn, skin cancer); complications of diabetes mellitus, pain, testicular dysfunctions and wound healing,
gastrointestinal diseases including inflammatory bowel disease (including but not limited to ulcerative colitis, Crohn's disease), peptic ulceration, gastritis, oesophagitis, liver disease (including but not limited to cirrhosis, hepatitis).
These diseases or conditions may also include steroid-resistant diseases or conditions where treatment with a glucocorticoid is indicated, but where the glucocorticoid is ineffective or is not as effective as expected.
The methods of the invention are preferably performed in a steroid-sparing manner. The term "steroid-sparing” refers to a combination therapy method that allows a reduction in the amount of glucocorticoid administered while still providing an effective therapy for the disease or condition being treated or prevented.
Steroid-resistant diseases or conditions are diseases or conditions for which treatment with a glucocorticoid is indicated, but where the glucocorticoid is ineffective or is not as effective as expected. This term encompasses diseases or conditions for which the effective dose of glucocorticoid results in unacceptable side effects and/or toxicity. Some steroid-resistant diseases or conditions may require a dosage of glucocorticoid so large that they are considered non-responsive and therefore are not able to be successfully treated with glucocorticoids. Some steroid-resistant diseases or conditions may require a large dosage of glucocorticoid to achieve only a small effect on the symptoms of the disease or condition. Furthermore, some patients, diseases or conditions present with symptoms that do not respond to treatment with a glucocorticoid, or may become less sensitive to glucocorticoid treatment over time.
Glucocorticoids are a group of steroid hormones, which are used to treat or prevent a wide range of diseases or conditions. Suitable glucocorticoids may be synthetic or naturally occurring and include but are not limited to prednisolone, prednisone, cortisone acetate, beclamethasone, fluticasone, hydrocortisone, dexamethasone, methyl prednisolone, triamcinolone, budesonide and betamethasone.
In preferred embodiments of the invention, the glucocorticoid used is selected from prednisone, prednisolone, hydrocortisone, fluticasone, beclamethasone, betamethasone, methyl prednisolone, budesonide, triamcinolone, dexamethasone and cortisone. Most preferably, the glucocorticoid is selected from prednisone, prednisolone, methyl prednisolone, fluticasone and beclamethasone. Beclamethasone and fluticasone are particularly preferred for treating asthma. Prednisone, prednisolone and methyl prednisolone are particularly preferred in the treatment of systemic or local inflammatory diseases.
The amounts of glucocorticoid and compound of formula (I) are selected such that in combination they provide complete or partial treatment or prophylaxis of a disease or condition for which a glucocorticoid is indicated. The amount of compound formula (1) is preferably an amount that will at least partially inhibit the cytokine or biological activity of
MIF. The amount of glucocorticoid is preferably less than the amount required in the absence of the compound of formula (I). The amounts of glucocorticoid and compound of formula (I) used in a treatment or therapy are selected such that in combination they at least partially attain the desired therapeutic effect, or delay onset of, or inhibit the progression of, or halt or partially or fully reverse the onset or progression of the disease or condition being treated. The amounts of glucocorticoid and compound of formula (I) used in the prophylaxis of a disease or condition are selected such that in combination they at least partially prevent or delay the onset of the disease or condition. Dosing may occur at intervals of minutes, hours, days, weeks, months or years or continuously over any one of these periods.
Suitable doses of a compound of formula (I) may lie within the range of about 0.1 ng per kg of body weight to 1 g per kg of body weight per dosage. The dosage is preferably in the range of 1 pug to 1 g per kg of body weight per dosage, such asisintherangeof Img tolg per kg of body weight per dosage. In one embodiment, the dosage is in the range of 1 mg to 500 mg per kg of body weight per dosage. In another embodiment, the dosage is in the range of 1 mg to 250 mg per kg of body weight per dosage. In yet another preferred embodiment, the dosage is in the range of 1 mg to 100 mg per kg of body weight per dosage, such as up to 50 mg per kg of body weight per dosage. In yet another embodiment, the dosage is in the range of 1ug to 1mg per kg of body weight per dosage.
Suitable dosage amounts of glucocorticoids will depend, in part, on the mode of administration and whether the dosage is being administered in a single, daily or divided dose, or as a continuous infusion. When administered orally, intravenously, intramuscularly, intralesionally or intracavity (eg. intra-articular, intrathecal, intrathoracic), dosages are typically between 1 mg to 1000 mg, preferably 1 mg to 100 mg, more preferably 1 mg to 50 mg or 1 mg to 10 mg per dose. When administered topically or by inhalation as a single, daily or divided dose, dosages are typically 1 ng to 1 ug, 1 ng to 1 mg orlpgtol ug.
Suitable dosage amounts and dosing regimens can be determined by the attending physician or veterinarian and may depend on the desired level of inhibiting activity, the particular condition being treated, the severity of the condition as well as the general age, health and weight of the subject.
The glucocorticoid and compound of formula (I) may be administered simultaneously or sequentially. The active ingredients may be administered alone but are preferably administered as a pharmaceutically acceptable composition or separate pharmaceutically acceptable compositions.
The formulation of such compositions is well known to those skilled in the art and are described above in relation to compounds of formula (I). The composition or compositions may contain pharmaceutically acceptable additives such as carriers, diluents or excipients.
These include, where appropriate, all conventional solvents, dispersion agents, fillers, solid carriers, coating agents, antifungal and antibacterial agents, dermal penetration agents, surfactants, isotonic and absorption agents and the like. It will be understood that the compositions of the invention may also include other supplementary physiologically active agents.
Preferred unit dosage compositions are those containing a daily dose or unit, daily sub-dose, as herein above described, or an appropriate fraction thereof, of the glucocorticoids and/or compound of formula (I) which inihibit the cytokine or biological activity of MIF.
The compounds of formula (1), either as the only active agent or together with another active agent, eg: a glucocorticoid, may also be presented for use in veterinary compositions.
These may be prepared by any suitable means known in the art. Examples of such compositions include those adapted for: oral administration, external application (eg drenches including aqueous and non-aqueous solutions or suspensions), tablets, boluses, powders, granules, pellets for admixture with feedstuffs, pastes for application to the tongue; parenteral administration, eg subcutaneous, intramuscular or intravenous injection as a sterile solution or suspension; and topical application eg creams, ointments, gels, lotions, etc.
By virtue of their ability to bind to or antagonize MIF, compounds of Formula (I) or salts or derivatives thereof may be used as laboratory or diagnostic or in vivo imaging reagents.
Typically, for such use the compounds would be labelled in some way, for example, radio isotope, fluorescence or colorimetric labelling, or be chelator conjugated. In particular, compounds of Formula (I) could be used as part of an assay system for MIF or as controls in screens for identifying other inhibitors. Those skilled in the art are familiar with such screens and could readily establish such screens using compounds of Formula (I). Those skilled in the art will also be familiar with the use of chelate conjugated molecules for in vivo diagnostic imaging.
Inhibitors of MIF may also be used in implantable devices such as stents. Accordingly, in a further aspect the present invention provides an implantable device, preferably a stent, comprising: (i) a reservoir containing at least one compound of formula (I); and (ii) means to release or elute the inhibitor from the reservoir
There is further provided a method for inhibiting the cytokine or biological activity of MIF in a subject comprising the step of implanting an implantable device according to the invention in the subject.
Preferably, the method is for inhibiting the cytokine or biological activity of MIF in a local region of the subject and the device is implanted within or proximate to the local region of the subject.
Ina yet further aspect, the present invention provides a method of treating, preventing or diagnosing a disease or condition wherein MIF cytokine activity is implicated comprising the step of implanting an implantable device according to the invention in a subject in need thereof.
Preferably, the disease or condition is confined to a local region of the subject and the device is implanted within or proximate to the local region.
The present invention further provides an angioplastic stent for inhibiting the onset of restenosis, which comprises an angioplastic stent operably coated with a prophylactically effective dose of a composition comprising at least one compound of formula (I).
Angioplastic stents, also known by other terms such as "intravascular stents” or simply "stents", are well known in the art. They are routinely used to prevent vascular closure due to physical anomalies such as unwanted inward growth of vascular tissue due to surgical trauma. They often have a tubular, expanding lattice-type structure appropriate for their function, and can optionally be biodegradable.
In this invention, the stent can be operably coated with at least one compound of formula (I) using any suitable means known in the art. Here, "operably coating" a stent means coating it in a way that permits the timely release of the compound(s) of formula (I)into the surrounding tissue to be treated once the coated stent is administered. Such coating methods, for example, can use the polymer polypyrrole.
The present invention further provides a method for inhibiting the onset of restenosisin a subject undergoing angioplasty, which comprises topically administering a stent according to the present invention to the subject at around the time of the angioplasty.
As used herein, administration "at around the time of angioplasty” can be performed during the procedure, or immediately before or after the procedure. The administering can be performed according to known methods such as catheter delivery.
There is further provided a method of reducing the severity of stent restenosis in the vicinity of a stent comprising the use of a stent according to the present invention.
The construction of stents that release or elute a pharmaceutical active is known to those skilled in the art. The standard approach is to use current highly refined metallic stent designs with polymer materials that release the active in a controlled manner. Several polymer materials have been used for the coating of stents to permit the elution of drugs.
These include bioerodible polymers such as poly-L lactic acid, biostable polymers such as polyurethane derivatives and slilicone-based polymers, as well as hydrogels. It will be recognised by those skilled in the art that the function of a drug-eluting stent requires the drug to be bound to the stent or its polymer or other coating in such a way as to allow steady release of drug over a period of time, and that the drug is able to be locally absorbed into cells in the vessel and stent lumen. The optimum stent coating material and delivery parameters vary according to the tissue retention of the drug, such that rapid release of a tissue-retained drug can have long lasting effects, whereas a drug retained in tissues for a shorter time would need to be released over a longer period. A person skilled in the art would be able to select appropriate materials and conformations of stent for a particular purpose and particular small molecule inhibitor.
Unless the context indicates otherwise, reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.
Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications which fall within the spirit and scope. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.
The invention will now be described with reference to the following examples which are included for the purpose of illustration only and are not intended to limit the generality of the invention hereinbefore described.
Example 1: Preparation of 2-(2-hydroxyethoxy)-2-(4-hydroxy-3-methylphenyl)-1,3-dioxolane (Compound 1)
I [1
C—H 0) 0
OH oS ——
HsC ° HaC
H
OH
Compound 1
A mixture of 3-methyl-p-hydroxybenzaldehyde (0.5 g, 3.6 mmol), ethylene glycol (0.34 g, 5.5 mmol) and p-toluenesulfonic acid (0.07 g, 0.36 mmol) in toluene was heated under reflux. After 24 h, the reaction mixture was cooled to room temperature, TLC showed no starting material. The toluene was removed in vacuo and saturated solution of sodium hydrogen carbonate (20 ml) was added to the residue, which was then extracted with ethyl acetate (3 x 20 ml). The organic layer was washed with water (20 ml), dried over anhydrous sodium sulfate and the solvent was removed in vacuo. The residue was then recrystallised from an ethyl acetate and hexane mixture to give the product as a brown solid in 24% yield. 'H NMR (CDCl,): 2.21 (s, 3H), 3.62 (t, 2H, J = 4.5 Hz), 3.70 (t, 2H, J = 42 Hz), 3.81 (t, 2H, J = 4.7 Hz), 442 (t, 2H,]=4.7 Hz2),6.74(d, 1H, J =8.4 Hz), 7.21 (d, 1H, ] =8.4 Hz) and 7.78 (s, 1H). MS: m/e 263 (M+ + Na), 179 (M+ - OCH,CH,OH), 147, 135, 118 and 107.
BC NMR (CDCl): 15.7, 61.1, 63.5, 69.1, 72.4, 114.0, 120.5, 124.5, 128.4, 135.6, 159.8 and 167.1.
Example 2: Preparation of 2-(2-hydroxyethoxy)-2-(4-hydroxyphenyl)-1,3-dioxolane (Compound 2) [1
C—H 0. 0}
OH oS ——————
OH
OH
Compound 2
To a solution of p-hydroxybenzaldehyde (1g, 8.18 mmol) in anhydrous toluene (100 mL) was added ethylene glycol (0.68 mL, 12.28 mmol), pyridinium toluene sulphonate (0.2 g, 0.88 mmol) and p-toluene sulphonic acid monohydrate (0.16 g, 0.88 mmol). The solution was refluxed overnight before concentrating the solvent to furnish an amber gum.
Saturated sodium bicarbonate (50 mL) was then added to the reaction mixture, and extracted with ethyl acetate (3x 50 mL). The organic extracts were dried over magnesium sulphate, filtered, and concentrated to furnish a dark brown gum. The gum was chromatographed on silica (ether/ methanol, 9.5:0.5) to furnish the title compound as a dark brown solid (173 mg, 9%). 'H NMR (CDCl,): 7.88 (d, 2H, 2x ArCH, J 8.7 Hz), 7.49 (bs, 1H, phenolic hydroxyl), 6.82 (d, 2H, 2x ArCH, J 8.7 Hz), 4.46, 3.84 (2x appt, 2x 2H, 2x ethoxy CH,, Jvic 4.5 Hz), 3.74 (m, 2H, dioxolan CH,), 3.66 (appt, 2H, dioxolan CH,, Jvic 4.8 Hz);
LRMS (ESI): m/z 227 [M+H+]; Cy; H140s: 226.23
Example 3: Preparation of 2-(2-hydroxyethoxy)-2-(3-bromo-4-hydroxy-5-methylphenyl)-1,3-dioxolane (compound 3) 0. 0 0) 0]
OH OH o SN o SN
NBS
LE a
HzC HaC Br
OH OH
Compound 3
A mixture of compound 1 (109 mg; 0.4 mmol), N-bromosuccinamide (80 mg; 0.4 mmol) and AIBN (7.3 mg; 0.045 mmol) in dry carbon tetrachloride was refluxed for 5 hrs, TLC did not show any of the starting material. The reaction mixture was cooled to room temperature and then concentrated to dryness. The residue was dissolved in ethyl acetate (2 x 10 ml). The clear solution was washed with distilled water (5 x 10 ml), dried over anhydrous Na,SO, and evaporated to dryness. This gave a 47% yield of compound 3.
HNMR (CDCl): 2.32 (s, 3H), 3.65 (t, 2H, ] = 4.4 Hz), 3.74 (t, 2H, ] = 4.3 Hz), 3.83 (t, 2H, J= 4.7 Hz), 4.46 (t, 2H, ] = 4.8 Hz), 7.80 (s, 1H) and 8.02 (s, 1H).
Example 4: Preparation of 2-(4-Bromophenyl)-1,3-thiazolane (compound 4) ,
Br
Compound 4
Melting Point Ref : UK patent GB2010827 A.
To a solution of 4-bromobenzaldehyde (2.5 g, 13.5 mmol) in EtOH (15 ml) was added a solution of cysteamine HCl (0.5 g, 4.4 mmol) in water (5 ml) dropwise with stirring. The solution was then stirred at RT for 18 h before the bulk of the EtOH was removed by rotary evaporator. The residue was diluted with water (15 ml) and extracted with ether (3x20 ml) to remove excess aldehyde. The acidic aqueous layer was then basified with the slow addition of solid sodium carbonate (0.3 g) to give a heavy white precipitate, which was filtered and washed carefully with water (3x10 ml). The solid was dried in a vacuum desiccator to give 2-(4-bromophenyl)-1,3-thiazolane (4) as a white crystalline solid (0.73 g, 68%), mp 107° (lit. mp, 105-107°). 'H nmr (ds-dmso, 300 MHz) 2.4, br s, NH; 3.05-3.2, m,
H4,4,5; 3.5-3.6, m, H5; 5.55, s, H2; 7.38, d (8.4 Hz), ArH; 7.47, d (8.4), ArH. ESI (+ve) MS m/z 287/285 (M+MeCN+H, 30%), 246/244 (M+H, 100).
Example5: Preparation of 2-(4-Methoxyphenyl)-1,3-thiazolane (compound 5) ,
OMe
Compound 5
Melting Point Ref : US patent 4616025
To a solution of p-methoxybenzaldehyde (1.81 g, 13.3 mmol) in ethanol (15 ml) was added dropwise a solution of cysteamine HCl (0.5 g, 4.4 mmol) in water (5 ml) and the solution stirred at RT for 18 h. The bulk of the ethanol was removed by rotary evaporator and the residue was diluted with water (15 ml) and extracted with diethyl ether (3x20 ml) to remove excess aldehyde. The aqueous layer was basified by addition of solid sodium carbonate (0.3 g) causing the product to precipitate out of solution. The precipitatewas filtered, washed carefully with water (3x20 ml) and dried in a vacuum desiccator to give 2-(4-methoxyphenyl)-1,3-thiazolane (5) as a white solid (0.55 g, 69%), mp 94-95° (lit mp, 93-94°). 'H nmr (CDCl, 300 MHz) 2.51, s, NH; 3.05-3.20, m, H4,4,5; 3.64, m, H5; 3.80, s,
OMe; 5.23, 5, H2; 6.87, d (8.7 Hz), H3'5'; 7.44, d (8.7), H2',H6'. ESI (+ve) MS m/z 196 (M+H,
Example 6: Preparation of 4-(1,3-Thiazolidin-2-yl)benzonitrile (compound 6)
CN
Compound 6
To a solution of 4-cyanobenzaldehyde (0.86 g, 6.6 mmol) in ethanol (15 ml) was added a solution of cysteamine HCl (0.5 g, 4.4 mmol) in water (5 mi) and the solution stirred at RT for 18 h. The bulk of the ethanol was removed by rotary evaporator and the residue was treated with water (15 ml) and extracted with diethyl ether (3x20 ml) to remove excess aldehyde. The aqueous layer was basified with solid sodium carbonate (0.3 g) resulting in the formation of an oil. The mixture was extracted with ether (2x25 ml), washed with brine (1x50 ml), dried (MgSO,) and evaporated to give a clear oil that solidified on standing (0.62 g). Column chromatography (silica gel, 100% chloroform) afforded pure 4-(1,3-thiazolidin-2-yl)benzonitrile (6) (0.56 g, 67%) as clear oil that solidified on standing, mp 57-58°. 'H nmr (CDCl, 300 MHz) 3.05-3.15, m, H4,4; 3.2-3.35, m, H5; 3.4-3.5, m,H5; 5.64, s, H2;7.63, app. s, H2',3'5,6". ESI (+ve) MS m/z 191 (M+H, 100%).
Example 7: Preparation of 2-(4-Hydroxy-3-methoxyphenyl)-13-thiazolane (compound
S NH
‘OMe
OH
Compound 7
Melting Point Ref: Chem. Pharm. Bull. 1988, 36, 1110-1116.
To a solution of vanillin (2.0 g, 13.2 mmol) in ethanol (15 ml) was added dropwise a solution of cysteamine HCI (0.5 g, 4.4 mmol) in water (5 ml) and the solution stirred at RT for 16.5 h. The bulk of the ethanol was removed by rotary evaporator and the residue was diluted with water (15 ml) and extracted with diethyl ether (3x20 ml) to remove excess aldehyde. The aqueous layer was basified by addition of solid sodium carbonate (0.3 g) causing the product to precipitate out of solution. The precipitate was filtered, washed carefully with water (3x20 ml) and dried in a vacuum desiccator to give 2-(4-hydroxy-3-methoxyphenyl)-1,3-thiazolane (7) as a white solid (0.62 g, 67%), mp 158-161° (lit mp, 182-183°). 'H nmr (ds-dmso, 300 MHz) 2.8-3.0, m, H4,4,5; 3.12, br s, NH; 3.4-3.6, m, H5; 3.76, s, OMe; 5.34, s, H2; 6.70, d (8.0 Hz), H5'; 6.84, dd (1.8, 8.1 Hz), H6'; 7.04, d (1.8 Hz), H2; 8.91, s, OH. ESI (+ve) MS m/z 212 (M+H, 100%).
Example 8: Preparation of 2-(3,4-Dimethoxyphenyl)-1,3-thiazolane (compound 8)
S._ _NH ‘OMe
One
Compound 8
To a solution of 3,4-dimethoxybenzaldehyde (2.19 g, 13.2 mmol) in ethanol (15 ml) was added dropwise a solution of cysteamine HCI (0.5 g, 4.4 mmol) in water (5 ml) and the solution stirred at RT for 40 h. The bulk of the ethanol was removed by rotary evaporator and the residue was diluted with water (15 ml) and extracted with diethyl ether (3x20 ml) to remove excess aldehyde. The aqueous layer was basified with solid sodium carbonate (0.3 g) resulting in the formation of an oil. The mixture was extracted with ether (2x25 ml), washed with brine (1x50 ml), dried (MgSO,) and evaporated to give a clear oil that solidified on standing (0.77 g). The material was triturated with hexane (3x5 ml) to give 2-(3,4-dimethoxyphenyl)-1,3-thiazolane (8) as a friable white solid (0.65 g, 66%), mp 54-56°. 'H nmr (d,-dmso, 300 MHz) 2.8-3.2, m, H4,4,5; 3.5, m, H5; 3.73, s, OMe; 3.74, s, Ome; 5.37, d (10.2 Hz), H2; 6.87, d (8.1 Hz), HS; 6.96, dd (1.7,8.1 Hz), He; 7.06, d (1.5 Hz), H2. ESI (+ve)
MS m/z 226 (M+H, 100%).
Example9: Preparation of Methyl 4-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]butanoate (compound 9) 0)
Oo oO
OMe
F
Compound 9
Methyl 5-(4-fluorophenyl)-5-oxopentanoate
To a solution of 5-(4-fluorophenyl)-5-oxopentanoic acid (3.0 g, 14.3 mmol) in dry MeOH (50 ml) was added concentrated sulfuric acid (50 mg) and the mixture refluxed under nitrogen for 16 h. The bulk of the MeOH was removed by rotary evaporator and the residue treated with sodium bicarbonate solution (5%, 100 mi) and extracted with ethyl acetate (3x50 ml).
The organic extract was washed with water (1x100 ml), brine (1x100 ml), dried (Na,SO;) and evaporated to give methyl 5-(4-fluorophenyl)-5-oxopentanoate (2.69 g, 84%) as a white crystalline solid.
Methyl 4-[2-(4-fluorophenyl)-1.3-dioxolan-2-yllbutanoate (9)
To a solution of 5-(4-fluorophenyl)-5-oxopentanoate (2.26 g, 10 mmol) in toluene (60 ml) was added ethylene glycol (1.95 ml, 35 mmol) and p-toluenesulfonic acid monohydrate (60 mg, 0.32 mmol) and the mixture refluxed in a Dean-Stark apparatus under nitrogen for 17 h. The toluene was removed by rotary evaporator and the residue treated with sodium bicarbonate solution (5%, 50 ml) and extracted with ether (2x50 ml). The ether extract was washed with brine (1x50 ml), dried (Na,SO,) and evaporated to give methyl 4-[2-(4-fluorophenyl)-1,3-dioxolan-2-ylJbutanoate (9) as a pale yellow oil (2.47 g, 91%). *H nmr (CDCl, 300 MHz) 1.6-1.7, m, H3; 1.9, m, H4; 2.30, t (7.5 Hz), H2; 3.64, s, OMe; 3.7-3.8, m, CH,0; 3.95-4.05, m, CH,0; 7.01, m, H3,5’; 7.41, m, H2",6’. ESI (+ve) MS m/z 269 (M+H,
Example 10: Preparation of 4-[2-(4-Fluorophenyl)-1,3-dioxolan-2-yljbutan-1-ol (compound 10) 0) 0
F
5 Compound 10
To a suspension of lithium aluminium hydride (0.167 g, 4.4 mmol) in dry tetrahydrofuran (10 ml) was added dropwise a solution of methyl 4-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]butanoate (9) (0.50 g, 1.86 mmol) in dry tetrahydrofuran (10 ml) with stirring under nitrogen. Once the addition was complete stirring was continued at RT for 2 h following by refluxing under nitrogen for 1 h. Water was cautiously added to destroy excess hydride then the reaction mixture tipped into sodium carbonate solution (1.7%, 150 ml) and extracted with ethyl acetate (2x50 ml). The ethyl acetate extract was washed with brine (1x50 ml), dried (Na,SO,) and evaporated to give a yellow oil (0.394 g). Purification by column chromatography (silica gel, 80:3 chloroform/n-propanol) afforded 4-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]butan-1-ol (10) (0.252 g, 56%) as a clear colourless oil. "H nmr (CDCl, 300 MHz) 1.35-1. 50, m, H3; 1.55, quin (6.9 Hz), H2; 1.90, m, H4; 3.60, m, H1; 3.76, m, CH,0; 4.01, m, CH,0; 7.01, m, H3,5; 7.41, m, H2',6’. ESI (+ve) MS m/z 179 (M-C,H;0,, 90%).
Example 11: Preparation of 2-(4'-Bromophenyl)-2-butyl-1,3-dioxolane (compound 11) &
Br
Compound 11
To a solution of 4’-bromovalerophenone (2.41 g, 10 mmol) in benzene (60 ml) was added ethylene glycol (2.0 ml, 36 mmol), p-toluenesulfonic acid monohydrate (100 mg, 0.53 mmol) and the mixture refluxed under nitrogen in a Dean-Stark apparatus for 16 h. The reaction mixture was washed with sodium bicarbonate solution (5%, 50 ml), brine (1x50 ml), dried (Na,SO,) and evaporated to give 2-(4-bromophenyl)-2-butyl-1,3-dioxolane (11) as a clear oil (2.61 g, 92%). 'H nmr (CDCl, 300 MHz) 0.88, t (6.9 Hz), H4”;1.2-1.4, m,
H2",3”;1.88, m, H1”; 3.7-3.8, m, CH,0; 4.0-4.1, m, CH,0; 7.34, d (8.4 Hz), H2’,6"; 7.49, d (8.4
Hz), H3',5'. ESI (+ve) MS m/z285/287 (M+H, 8%).
Example 12: Preparation of 4-(4-Methoxyphenyl)-1-(3-methylbutyl)-1H-pyrazole (compound 12)
N—
OMe : Compound 12
To p-bromoanisole (0.25 g, 1.33 mmol) was added a solution of 1-(3-methylbutyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1F-pyrazole (0.41 g, 1.55 mmol) in tetrahydrofuran (10 ml), potassium carbonate (0.29 g, 2.1 mmol) and [1,1-bis(diphenylphosphino)ferrocene] dichloropalladium (II) (12 mg, 0.023 mmol) and the mixture refluxed under nitrogen for 17 h. Water (50 ml) was added to the reaction mixture and stirring continued at RT for 15 min followed by extraction with ether (2x50 ml), drying (MgSO,) and evaporation of the ether extract to give a brown oil (0.414 g). Purification by column chromatography (silica gel, 100% chloroform) afforded 4-(4-methoxyphenyl)-1-(3-methylbutyl)-1--pyrazole (12) as a waxy pale yellow solid (37 mg, 11%). ‘H nmr (CDCl, 300 MHz) 0.97, d (6.6 Hz), 2xMe; 1.64, sept (6.6 Hz), H3"; 1.80, dt (7.2 Hz), H2”; 3.82, s, OMe; 4.15, t (7.5 Hz), H1”; 6.90, d (8.7 Hz), H3',5"; 7.39, d (8.7 Hz),
H2' 6’; 7.54, s, H3 or H5; 7.69, s, H5 or H3. ESI (+ve) MS m/z245 (M+H, 100%).
Example 13: Preparation of 1-(3-Methylbutyl)-4-(4-methylphenyl)-1A-pyrazole (compound 13)
N—N : C
Me
Compound 13
To a solution of p-bromotoluene (0.66 g, 3.86 mmol) in tetrahydrofuran (20 ml) was added a solution of 1-(3-methylbutyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole (0.41 g, 1.55 mmol) in tetrahydrofuran (10 ml), potassium carbonate (0.42 g, 3.0 mmol), [1,1-bis(diphenylphosphino)ferrocene] dichloropalladium (II) (40 mg, 0.077 mmol) and water (40 pl) and the mixture refluxed under nitrogen for 43 h. Water (50 ml) was added to the reaction mixture and stirring continued at RT for 10 min followed by extraction with ether (2x50 ml). The ether extract was then dried (MgSO,) and evaporated to give a brown oil (0.56 g) that solidified on standing. Purification by column chromatography (silica gel, 100% chloroform) afforded 1-(3-methylbutyl)-4-(4-methylphenyl)-1 A-pyrazole (13) as a waxy pale yellow solid (0.216 g, 53%). 'H nmr (CDCl, 300 MHz) 0.97, d (6.3 Hz), 2xMe; 1.62, m, H3”;1.80, dt (7.3 Hz), H2"; 2.35, 5, 4'-Me; 4.16, t (7.5 Hz), H1"; 7.16, d (8.1 Hz),
H3',5;7.37, d (8.1 Hz), H2',6’; 7.59, s, H3 or H5; 7.74, s, H5 or H3. ESI (+ve) MS m/z229 (M+H, 100%).
Example 14: Preparation of 2,6-Dimethoxy-3-[4-(trifluoromethoxy)phenyllpyridine (compound 14)
OMe no
MeO =
OCF;
Compound 14
To a solution of 1-bromo-4-(trifluoromethoxy)benzene (0.92 g, 3.86 mmol) in tetrahydrofuran (20 mi) was added a solution of 2,6-dimethoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (0.40 g, 1.50 mmol) in tetrahydrofuran (10 ml), potassium carbonate (0.42 g, 3.0 mmol), [1,1-bis(diphenylphosphino)ferrocene] dichloropalladium (II) (40 mg, 0.077 mmol) and water (40 pl) and the mixture refluxed under nitrogen for 43 h. Water (50 ml) was added to: the reaction mixture and stirring continued at RT for 10 min followed by extraction with ether (2x50 ml). The ether extract was then dried (MgSO,) and evaporated to give a dark mobile oil (0.504 g). Purification by column chromatography (silica gel, 3:1 hexane/ dichloromethane) afforded 2,6-dimethoxy-3-[4-(trifluoromethoxy)phenyl}pyridine (14) as a clear, colourless oil (0.372 g, 83%). 'H nmr (CDCl, 300 MHz) 3.97, s, 2x OMe; 6.40, d (8.1 Hz), H5; 7.24, d (8.4 Hz), H3',5’; 7.55, m, H2,2’,6'. ESI (+ve) MS m/z 300 (M+H,
Example 15: Preparation of 2-[4-(2-Thienyl)phenyl]-1,3-thiazolane (compound 15)
S NH
S—
S
Compound 15
To a solution of 4-(2-thienyl)benzaldehyde (500.0 mg, 2.66 mmol) in EtOH (5.0 mL) was added a solution of cysteamine HCI (101.0 mg, 0.89 mmol) in water (2.0 mL) dropwise with stirring. The solution was then stirred at room temperature for 18 hours before the bulk of the EtOH was removed by rotary evaporator. The resulting residue was diluted with water (15.0 mL) and extracted with ether (3x30.0 mL) to remove excess aldehyde. The acidic aqueous layer was then basified with the slow addition of solid sodium carbonate (300.0 mg) to afford a white precipitate, which was filtered and washed carefully with water (3 x 20.0 mL). The solid was dried under reduced pressure to afford 2-[4-(2-thienyl)phenyl]-1,3-thiazolane (15) as a yellow powder (30 mg, 4.6%). 'H nmr (CDCl, 300 MHz) 3.14, m, H4,4,5; 3.64, m, H5; 5.95, s, H2; 7.08, m, thienyl-H; 7.31, m, 2 x thienyl-H; 7.50, d (8.1 Hz), 2 x phenyl-H; 7.59, d (8.4 Hz), 2 x phenyl-H. ESI (+ve) MS m/z 248 (M+H, 100%).
Example 16: Preparation of 2-Ethyl-2-(4-methoxyphenyl)-1,3-dioxolane (compound 16)
OMe
Compound 16 4'-Methoxypropiophenone
To a solution of 4'-hydroxypropiophenone (1.0 g, 6.67 mmol) in acetonitrile (50.0 mL) was added potassium carbonate (7.17 g, 66.7 mmol) and the mixture heated to reflux for 90 min.
After this time the reaction mixture was allowed to cool to room temperature and dimethyl sulphate (1.05 mL, 11.1 mmol) was added and the reaction mixture was heated to reflux for a further 19h. After cooling the acetonitrile was evaporated under reduced pressure and the residue taken up in water and extracted with dichloromethane. The dichloromethane extract was dried (MgSO,) and evaporated under reduced pressure to give 4’-methoxypropiophenone as a yellow oil, (970 mg, 89 %) 'H nmr (d¢-DMSO, 300 MHz) 1.06, t (7.2 Hz), CHj; 2.95, q (7.2 Hz), CH,; 3.83, s, OMe; 7.02, d (6.9 Hz), H3',5"; 7.93, d (6.9
Hz), H2 6. ESI(+ve) MS m/z 165 (M+H, 100%). 2-Ethyl-2-(4-methoxyphenyl)-1,3-dioxolane (16)
To a solution of 4'-methoxypropiophenone (250.0 mg, 1.52 mmol) in toluene (20.0 mL) was added ethylene glycol (255.0 UL, 4.57 mmol) and p-toluenesulfonic acid monohydrate (13.0 mg, 0.04 mmol) and the reaction mixture refluxed overnight using a Dean-Stark apparatus.
The reaction mixture was cooled to room temperature, then washed with saturated aqueous sodium bicarbonate solution followed by water. The toluene solution was then dried (MgSO,) and evaporated under reduced pressure to afford 2-ethyl-2-(4-methoxyphenyl)-1,3-dioxolane (16) as a yellow oil (184 mg, 58%). 'H nmr (CDCl, 300 MHz) 0.76, t (6.6 Hz), CHj; 1.78, q (6.9 Hz), CH; 3.65, m, CH,O, 3.73, 5, 4-OMe;
3.95, m, CH,0; 6.88, d (7.2 Hz), H3',5'; 7.02, d, (7.5 Hz), H2',6'. ESI (+ve) MS m/z209 (M+H, 100%).
Example 17: Preparation of 2-Hexyl-2-(4-methylphenyl)-1,3-dithiolane (compound 17) 8
Me
Compound 17 a-Hexyl-4-methyl-benzenemethanol (Ref: Liang, X.; Bols, M. J. Chem. Soc, Perkin Trans. 12002, 503-508.) 1-Iodohexane was added dropwise to a stirred suspension of magnesium turnings (987 mg, 40.6 mmol, 2.0 equiv.) in anhydrous diethyl ether (40 mL), cooled in an ice-water bath and under an atmosphere of dry nitrogen. The addition was followed by a vigorous exotherm after which a cloudy suspension resulted. Stirring was continued at ambient temperature for 2 hours before recooling to 0 °C. 4-Tolualdehyde (1.21 mL, 10.2 mmol, 0.5 eq.) was added dropwise and the reaction mixture was stirred at ambient temperature for 2 hours prior to careful quenching with saturated aqueous ammonium chloride solution (20 mL).
The biphasic mixture was stirred for 10 minutes, the organic phase was isolated and the aqueous phase was twice extracted with diethyl ether. The organic phases were combined, dried over anhydrous magnesium sulfate and concentrated in vacuo to afford a colourless oil which was purified by flash chromatography on silica gel, eluting with hexane-ethyl . acetate (4:1) to give the desired benzylic alcohol (2.10 g, 100%). 'H nmr (200 MHz, CDCl;) 0.83-1.79 (m, 13H, (CH,);CHs;), 2.34 (s, 3H, ArCH;), 4.61 (t, ] = 3.8 Hz, 2H, CHOH), 7.14 (d, ] =4.0Hz, 2H, 2 x ArH), 7.23 (d, J = 4.2 Hz, 2H, 2 x ArH). 1-(4-Methylphenyl)-1-heptanone
To a stirred solution of a-hexyl-4-methyl-benzenemethanol (2.10 g, 10.2 mmol.) in anhydrous dichloromethane (45 mL) under an atmosphere of dry nitrogen was added pyridinium chlorochromate (3.08 g, 14.3 mmol., 1.4 eq.). Stirring was continued at room temperature for 3 hours after which time analysis by thin layer chromatography revealed complete conversion of the starting alcohol. Following evaporation of the reaction solvent the desired ketone (1.929 g, 93%) was isolated by flash chromatography on silica gel, eluting with hexane-ethyl acetate (4:1). 'H nmr (200 MHz, CDCl,) 0.86-1.76 (m, 3H, (CH,)sCH;), 2.41 (s, 3H, ArCHa), 2.93 (t, ] = 3.6 Hz, 2H, COCH,), 7.25 (d, J =4.2 Hz, 2H, 2 x
ArH), 7.86 (d, J = 4.2 Hz, 2H, 2 x ArH). 2-Hexyl-2-(4-methylpheny!}-1,3-dithiolane (17) (Ref: Banik et al. Tetrahedron Lett. 2001, 42, 4425-4427.) :
To a stirred solution of 1-(4-methylphenyl)-1-heptanone (500 mg, 2.45 mmol) and 1,2-ethanedithiol (250 pL, 2.94 mmol., 1.2 eq.) in anhydrous tetrahydrofuran (5.0 mL) under an atmosphere of dry nitrogen was added iodine (62 mg, 0.245 mmol, 0.10 eq.). The reaction mixture was stirred at ambient temperature for several days after which time analysis by thin layer chromatography revealed a mixture of starting material and a new less polar compound which stained positively towards phosphomolybdic acid.
Evaporation of the solvent gave a strong smelling crude oil which was purified by flash chromatography on silica gel, eluting with hexane-dichloromethane (2:1) to afford the desired dithiolane (17; 300 mg, 44% isolated) as a colourless oil. *H nmr (200 MHz, CDCl;) 0.80-0.86 (m, 3H, CH,CHS,), 1.21-1.29 [m, 10H, (CH,)s], 2.32 (s, 3H, ArCH,), 3.16-3.41 (m, 4H,
SCH,),7.01(d,]=4.0 Hz 2H, 2 x ArH), 7.56 (d, ] = 4.1 Hz, 2H, 2 x ArH).
Example 18: Preparation of 2-Methyl-2-(4-methylphenyl)-1,3-dithiolane (compound 18)
Me
Compound 18 (Ref: Banik et al. Tetrahedron Lett. 2001, 42, 4425-4427.)
To a stirred solution of the 4-methylacetophenone (1.34 mL, 10.0 mmol) and 1,2- ethanedithiol (838 pL, 10.0 mmol., 1.0 eq.) in anhydrous tetrahydrofuran (20.0 mL) under an atmosphere of dry nitrogen was added iodine (253 mg, 1.0 mmol., 0.10 equiv.). The reaction mixture was stirred at ambient temperature for five days after which time analysis
Dy thin layer chromatography revealed a mixture of starting material and a new less-polar compound which stained positively towards phosphomolybdic acid. Evaporation of the solvent gave a strong smelling crude oil which was purified by flash chromatography on silica gel, eluting with hexane-ethyl acetate (4:1) to afford the desired dithiolane (558 mg, 27% isolated) as a pale yellow oil (a low melting solid). 'H nmr (200 MHz, CDCl;) 2.14 (s, 3H, CH,), 2.33 (s, 3H, ArCHs), 3.32-3.53 (m, 4H, SCH,CH,S), 7.12 (d, J = 8.5 Hz, 2H, 2 x
ArH), 7.63 (dd, /=8.5, 1.9 Hz, 2H, 2 x ArH).
Example 19: Preparation of 2-Hexyl-2-(4-methylphenyl)-1,3-dioxolane (compound 19) 8
Me
Compound 19 (Ref: A. Srikishna and R. Viswajanani, Tetrahedron, 1995, 51, 3339.)
A mixture of 1-(4-methylphenyl)-1-heptanone (200 mg, 0.980 mmol), p-toluenesulfonic acid (17 mg, 0.098 mmol) and ethylene glycol (0.16 mL, 2.9 mmol) in dry toluene (10 mL) was heated at reflux with a Dean-Stark apparatus under nitrogen for 24 h. The mixture was allowed to cool to room temperature and the solvent was evaporated in vacuo. The residue was taken up in ether (20 mL) and the solution was washed with saturated sodium carbonate solution (2 x 10 mL) and brine (1 x 10 mL), then dried (Na,SO,) and concentrated under reduced pressure. Flash column chromatography of the residue, eluting with dichloromethane/ hexane (1:2) afforded 2-hexyl-2-(4-methylphenyl)-1,3-dioxolane (19) as a tan-coloured oil (162 mg, 67 %). 'H nmr (200 MHz, CDCl,) 0.80-0.92 (m, 3H, CH, CH), 1.18-1.40 [m, 8H, (CH,),), 1.84-1.89 (m, 2H, CCH,), 2.34 (s, 3H, ArCH,), 3.73-3.81 (m, 2H,
OCH,), 3.94-4.02 (m, 2H, OCH,), 7.13 (d, /= 8.2 Hz, 2H, 2 x ArH), 7.32 (d, /= 8.2 Hz, 2H, 2 x
Example 20: Preparation of 2-(4-Chlorophenyl)-2-methyl-1,3-dioxane (compound 20)
Cl
Compound 20 (Ref. B. Karimi, G. R. Ebrahimian and H. Sheradj, Org. Lett, 1999, 1, 1737.)
To a stirred mixture of 4-chloroacetophenone (1.3 mL, 10 mmol), triethylformate (2.0 mL, 12 mmol), 1,3-propanediol (2.2 mL, 30 mmol) and dry methanol (1.2 mL) in dry CH,Cl, (50 mL) was added NBS (53 mg, 0.30 mmol). The mixture was protected from light and stirred atroom temperature under an inert atmosphere of nitrogen for 70 h. After the mixture was washed with saturated aqueous sodium bicarbonate solution (20 mL), the aqueous phase was extracted with dichloromethane (3 x 30 mL). The combined organic solution was washed with water (2 x 20 mL), brine (1 x 20 mL), then dried (Na,50,) and concentrated under reduced pressure. Flash column chromatography of the residue, eluting with 37% aqueous ammonia:ether:hexane (0.02:1:6) afforded 2-(4-chlorophenyl)-2-methyl-1,3-dioxane (20) as a colourless oil (1.1 g, 52%). 'H nmr (200
MHz, CDCl) 1.49 (s, 3H, CH,), 1.98-2.25 (m, 2H, OCH, CHL H,0), 3.65-4.10 (m, 4H,
OCHLCH, CHL), 7.30-7.50 (m, 4H, 4 x ArH) .
Example 21: Preparation of 2-(4-Chlorophenyl)-2-methyl-1,3-dioxolane (compound 21) :
Cl
Compound 21
To a stirred mixture of 4-chloroacetophenone (1.3 mL, 10 mmol), triethylformate (2.0 mL, 12 mmol), ethylene glycol (1.7 mL, 30 mmol) and dry methanol (1.2 mL) in dry dichloromethane (50 mL) was added NBS (53 mg, 0.30 mmol). The mixture was protected from light and stirred at room temperature under an inert atmosphere of nitrogen for 70 h.
After the mixture was washed with saturated sodium bicarbonate solution (20 mL), the aqueous phase was extracted with dichloromethane (3 x 30 mL). The combined organic solution was washed with water (2 x 20 mL), brine (1 x 20 mL), then dried (Na,SQ,) and concentrated under reduced pressure. Flash column chromatography of the residue, eluting with 37% aqueous ammonia:ether:hexane (0.02:1:6) afforded 2-(4-chlorophenyl)-2-methyl-1,3-dioxolane (21) as a colourless oil (1.1 g, 51%). 'H nmr (300
MHz, CDCl) 1.63 (s, 3H, CH,), 3.72-3.82 (m, 2H, OCH,), 3.98-4.09 (m, 2H, OCH,), 7.42 (d, / =8.6Hz 2H, 2x ArH), 7.30 (d, /=8.6 Hz, 2H, 2 x ArH).
Example 22: Preparation of 2-Methyl-2-(4-methylphenyl)-1,3-dioxane (compound 22)
Me
Compound 22
To a stirred mixture of 4-methylacetophenone (1.3 mL, 10 mmol), triethylformate (2.0 mL, 12 mmol), 1,3-propanediol (2.2 mL, 30 mmol) and dry methanol (1.2 mL) in dry dichloromethane (50 mL) was added NBS (53 mg, 0.30 mmol). The mixture was protected from light and stirred at room temperature under an inert atmosphere of nitrogen for 70 h.
After the mixture was washed with saturated sodium bicarbonate solution (20 mL), the aqueous phase was extracted with dichloromethane (3 x 30 mL). The combined organic solution was washed with water (2 x 20 mL), brine (1 x 20 mL), then dried (Na,50,) and concentrated under reduced pressure. Flash column chromatography of the residue, eluting with 37% aqueous ammonia:ether:hexane (0.02:1:6) afforded 2-methyl-2-(4-methylphenyl)-1,3-dioxane (22) as a colourless oil (480 mg, 24%). 'H nmr (200 MHz, CDCl) 1.50 (s, 3H, CH,), 1.96-2.25 (m, 2H, OCH, CHLCH,0), 2.37 (s, 3H, ArCH,), 3.70-4.00 (m, 4H, OCHLCH,CHf),7.23 (d, J=8.3 Hz, 2H, 2 x ArH), 7.33 (d, /=8.3 Hz, 2H, 2 x ArH).
Example 23: Preparation of 2-Methyl-2-(4-methylphenyl)-1,3-dioxolane (compound 23)
Me
Compound 23
A mixture of 4-methylacetophenone (1.00 g, 7.45 mmol), p-toluenesulfonic acid (133 mg, 0.745 mmol) and ethylene glycol (1.20 mL, 22.4 mmol) in dry toluene (20 mL) was heated at reflux with a Dean-Stark apparatus under nitrogen for 24 h. The mixture was allowed to cool to room temperature and the solvent was evaporated in vacuo. The residue was taken up in ether (20 mL) and the solution was washed with saturated sodium bicarbonate solution (2 x 10 mL) and brine (1 x 10 mL), then dried (Na,SO,) and concentrated under reduced pressure. Flash column chromatography of the residue, eluting with 37% aqueous ammonia:ether:hexane (0.02:1:6) afforded 2-methyl-2-(4-methylphenyl)-1,3-dioxolane (23) as a colourless oil (1.05 g, 59 %). 'H nmr (200 MHz, CDCl,) 1.65 (s, 3H, CH}), 2.35 (s, 3H,
ArCH,), 3,74-3.86 (m, 2H, OCH), 3.94-4.06 (m, 2H, OCH,), 7.15 (d, /=8.2 Hz, 2H, 2 x ArH), 7.37(d, J=8.2Hz, 2H, 2 x ArH).
Example 24: Preparation of 2-(4-Chlorophenyl)-2-methyl-1,3-dithiolane (compound 24)
Cl
Compound 24 (Ref. S. Samajdar, M. K. Basu, F. FE. Becker and B. K. Banik, Tetrahedron Lett, 2001, 42, 4425.)
A mixture of 4-chloroacetophenone (1.3 mL, 10 mmol), iodine (250 mg, 1 mmol), 1,2-ethanedithiol (0.85 mL, 10 mmol) in dry tetrahydrofuran (20 mL) was heated at reflux under an atmosphere of nitrogen for 16 h. The mixture was allowed to cool to room temperature and concentrated in vacuo and the residue taken up in ether (20 mL). The organic solution was washed with water (2 x 10 mL) and brine (1 x 10 mL), then dried (N2,5S0,) and evaporated under reduced pressure. Flash column chromatography of the residue, eluting with 37% aqueous ammonia:ether:hexane (0.02:1:6) afforded 2-(4-chlorophenyl)-2-methyl-1,3-dithiolane (24) as a colourless oil (1.11 g, 48%). 'H nmr (300 MHz, CDCl) 2.13 (s, 3H, CHa), 3.31-3.53 (m, 4H, SCH,CH,S), 7.27 (d, J=8.7 Hz, 2H, 2 x ArH), 7.69 (d, J=8.7 Hz, 2H, 2 x ArH).
Example 25: Preparation of 2-(4-Nitrophenyl)-2-methyl-1,3-dioxolane (compound 25)
NO,
Compound 25
A mixture of 4-nitroacetophenone (1.65 g, 10.0 mmol), p-toluenesulfonic acid (172 mg, 1.00 mmol) and ethylene glycol (1.7 mL, 30 mmol) in dry toluene (20 mL) was heated at reflux with a Dean-Stark apparatus under nitrogen for 24 h. The mixture was allowed to cool to room temperature and the solvent was evaporated in vacuo. The residue was taken up in ether (20 mL) and the solution was washed with saturated sodium bicarbonate solution (2 x 10 mL) and brine (1 x 10 mL), then dried (Na,SO,) and concentrated under reduced pressure. Recrystallisation from ether and hexanes afforded 2-(4-nitrophenyl)-2-methyl-1,3-dioxolane (25) as a pale yellow crystals (1.52 g, 73 %; yield based from the first crop of crystals). 'H nmr (300 MHz, CDCl,) 1.66 (s, 3H, CH), 3.71-3.83 (m, 2H, OCH,), 4.02-4.13 (m, 2H, OCH,), 7.63-7.73 (d, J= 8.8 Hz, 2H, 2 x ArH), 8.16-8.26 (d,
J=88Hz, 2H, 2 x ArH).
- :
Example 26: Preparation of 2-(4-Nitrophenyl)-2-methyl-1,3-dioxane (compound 26)
NO,
Compound 26
A mixture of 4-nitroacetophenone (1.65 g, 10.0 mmol), p-toluenesulfonic acid (172 mg, 1.00 mmol) and 1,3-propanediol (2.3 mL, 30 mmol) in dry toluene (20 mL) was heated at reflux with a Dean-Stark apparatus under nitrogen for 24 h. The mixture was allowed to cool to room temperature and the solvent was evaporated in vacuo. The residue was taken up in ether (20 mL) and the solution was washed with saturated sodium bicarbonate solution (2 x 10 mL) and brine (1 x 10 mL), then dried (Na,SO,) and concentrated under reduced pressure. Recrystallisation from ether and hexane afforded 2-(4-nitrophenyl)-2-methyl-1,3-dioxane (26) as a pale yellow crystals (1.60 g, 72 %; yield based from the first crop of crystals). 'H nmr (300 MHz, CDCl,) 1.52 (s, 3H, CH;), 2.08-2.22 (m, 2H, OCH, CH,CH,0), 3.65-3.80 (m, 2H, OCH,), 3.88-4.00 (m, 2H, OCH), 7.63 (d, /=8.9
Hz, 2H, 2 x ArH), 8.26 (d, J= 8.9 Hz, 2H, 2 x ArH).
oo
Example 27: Preparation of 2-(4-Methoxyphenyl)-1,3-oxathiolane (compound 27)
OMe
Compound 27
A mixture of anisaldehyde (273 mg, 2.00 mmol), freshly distilled 2-mercaptoethanol (625 mg, 8.00 mmol), sodium sulfate (852 mg, 6.00 mmol) and freshly fused zinc chloride (818 mg, 6.00 mmol) in dry 1,4-dioxane (1 ml) was stirred under nitrogen at room temperature for 16 h. Water (10 ml) and ethyl acetate (20 ml) were added and the phases separated.
The ethyl acetate layer was washed with more water (10 ml) followed by saturated aqueous sodium chloride solution (10 ml). The solution was then dried (Na,SO)), filtered and the solvent removed in vacuoto give a colourless oil (528 mg). To 260 mg of the oil were added toluene (20 mi) and p-toluenesulfonic acid monohydrate (5 mg, 26 pmol) and the mixture was refluxed for 3 h. After cooling the toluene was removed in vacuo and the residual oil subjected to flash chromatography (ether/hexane gradient) to give 2-(4-methoxyphenyl)-1,3-oxathiolane (27) (74 mg, 39%) as a colourless oil. 'H nmr (d,-dmso, 300 MHz) § 3.18 (m, 2H); 3.81 (m, 1H); 4.45 (m, 1H); 5.98, (s, 1H); 6.90 (d, /8.7 Hz, 2H); 7.36 (d, 8.7 Hz, 2H). ESI (+ve) MS m/z197 (M+H, 100%).
Example 28: Preparation of 2-(3,4,5-Trimethoxyphenyl)-1,3-oxathiolane (compound 28) : S 0
MeO’ ‘OMe
OMe
Compound 28
A mixture of 3,4,5-trimethoxybenzaldehde (393 mg, 2.00 mmol), freshly distilled 2-mercaptoethanol (469 mg, 6.00 mmol), sodium sulfate (568 mg, 4.00 mmol) and freshly fused zinc chloride (545 mg, 4.00 mmol) in dry 1,4-dioxane (1 ml) was stirred under nitrogen at room temperature for 16 h. Water (10 ml) and ethyl acetate (20 ml) were added and the phases separated. The ethyl acetate layer was washed with more water (10 ml) followed by saturated aqueous sodium chloride solution (10 ml). The solution was then dried (sodium sulfate), filtered and the solvent removed in vacuoto give a colourless oil (513 mg). To the oil was added toluene (20 ml), p-toluenesulfonic acid monohydrate (5 mg, 26 umol) and the mixture was refluxed for 2 h. After cooling, the toluene was removed in vacuo and the residual oil subjected to flash chromatography (ether/hexane gradient) to give 2-(3,4,5-trimethoxyphenyl)-1,3-oxathiolane (28) (174 mg, 34%) as a colourless oil. 'H nmr (d,-dmso, 300 MHz) 8 3.17 (m, 2H); 3.64 (s, 3H); 3.75 (s, 6H); 3.84 (m, 1H); 4.48 (m, 1H); 5.98, (s, 1H); 6.72 (s, 2H). ESI (+ve) MS m/z257 (M+H, 100%).
Example 29: Preparation of 2-Methoxy-4-(1,3-oxathiolan-2-yl)phenol (compound 29) 0) S
OMe
OH
Compound 29
A mixture of vanillin (304 mg, 2.00 mmol), freshly distilled 2-mercaptoethanol (469 mg, 6.00 mmol), sodium sulfate (568 mg, 4.00 mmol) and freshly fused zinc chloride (545 mg, 4.00 mmol) in dry 1,4-dioxane (1 ml) was stirred under nitrogen at room temperature for 16 h. Water (10 ml) and ethyl acetate (20 ml) were added and the phases separated. The ethyl acetate layer was washed with more water (10 ml) followed by saturated aqueous sodium chloride solution (10 ml). The solution was then dried (sodium sulfate), filtered and the solvent removed in vacuo to give a colourless oil (507 mg). To the oil was added toluene (20 ml) and p-toluenesulfonic acid monohydrate (6 mg, 31 pmol) and the mixture was refluxed for 1 h. After cooling the toluene was removed in vacuo and the residual oil subjected to flash chromatography (ether/ hexane gradient) to give 2-methoxy-4-(1,3-oxathiolan-2-yl)phenol (29) (34 mg, 8%) as a colourless oil which solidified upon standing. 'H nmr (ds-dmso, 300 MHz) § 3.17 (m, 2H); 3.74 (s, 3H); 3.78 (m, 1H); 4.45 (m, 1H); 5.93, (s, 1H); 6.72 (d, /7.8 Hz, 1H); 6.84 (dd, /7.8, 1.8 Hz, 1H); 6.97 (d, / 1.8
Hz, 1H). ESI (+ve) MS m/z 213 (M+H, 65%).
Example 30: Preparation of 4-(1,3-Oxathiolan-2-yl)benzonitrile (compound 30) :
CN
Compound 30
A mixture of 4-cyanobenzaldehyde (262 mg, 2.00 mmol), freshly distilled 2-mercaptoethanol (469 mg, 6.00 mmol), sodium sulfate (568 mg, 4.00 mmol) and freshly fused zinc chloride (545 mg, 4.00 mmol) in dry 1,4-dioxane (1 ml) was stirred under nitrogen at room temperature for 16 h. Water (10 ml) and ethyl acetate (20 ml) were added and the phases separated. The ethyl acetate layer was washed with more water (10 ml) followed by saturated aqueous sodium chloride solution (10 ml). The solution was then dried (sodium sulfate), filtered and the solvent removed in vacuo to give a colourless oil (512 mg). To the oil was added toluene (25 ml) and p-toluenesulfonic acid monohydrate (6 mg, 31 pmol) and the mixture was refluxed for 1 h. After cooling, the toluene was removed in vacuo and the residual oil subjected to flash chromatography (ether/hexane gradient) to give 4-(1,3-oxathiolan-2-yl)benzonitrile (30) (106 mg, 28%) as a colourless oil. 'H nmr (de-dmso, 300 MHz) § 3.20 (m, 2H); 3.92 (m, 1H); 4.49 (m, 1H); 6.16, (s, 1H); 7.59 (d, /8.1 Hz, 2H); 7.82 (d, /8.1 Hz, 2H).
Example 31: Preparation of 2-(4-Bromophenyl)-2-ethyl-1,3-oxathiolane (compound 31)
Br
Compound 31
A mixture of p-bromopropiophenone (426 mg, 2.00 mmol), freshly distilled 2-mercaptoethanol (469 mg, 6.00 mmol), sodium sulfate (568 mg, 4.00 mmol) and freshly fused zinc chloride (545 mg, 4.00 mmol) in dry 1,4-dioxane (1 ml) was stirred under nitrogen at room temperature for 16 h. Water (10 ml) and ethyl acetate (20 ml) were added and the phases separated. The ethyl acetate layer was washed with more water (10 ml) followed by saturated aqueous sodium chloride solution (10 ml). The solution was then dried (sodium sulfate), filtered and the solvent removed in vacuo to give a colourless oil (560 mg). The oil was subjected to flash chromatography (ether / hexane gradient) to give 2-(4-bromophenyl)-2-ethyl-1,3-oxathiolane (31) (214 mg, 39%) as a colourless oil. *H nmr (ds-dmso, 300 MHz) § 0.77 (t, /7.2 Hz, 3H); 2.05 (q, /7.2 Hz, 2H); 3.07 (m, 2H); 3.86 (m, 1H); 4.30 (m, 1H); 7.31 (d, /8.7 Hz, 2H); 7.51 (d, /8.4 Hz, 2H).
So
Example 32: Preparation of 4-(5-Methyl-1,3-oxathiolan-2-yl)benzonitrile (compound 32)
Me
CN
Compound 32
A mixture of 4-cyanobenzaldehyde (131 mg, 1.00 mmol), 1-mercapto-2-propanol (276 mg, 3.00 mmol), sodium sulfate (284 mg, 2.00 mmol) and freshly fused zinc chloride (273 mg, 2.00 mmol) in dry 1,4-dioxane (1 ml) was stirred under nitrogen at room temperature for 16 h. Water (10 ml) and ethyl acetate (20 ml) were added and the phases separated. The ethyl acetate layer was washed with more water (10 ml) followed by saturated aqueous sodium chloride solution (10 ml). The solution was then dried (sodium sulfate), filtered and the solvent removed in vacuoto give a colourless oil (284 mg). To the oil was added toluene (25 ml) and p-toluenesulfonic acid monohydrate (6 mg, 31 pmol) and the mixture was refluxed for 70 min. After cooling the toluene was removed in vacuo and the residual oil subjected to flash chromatography (ether/ hexane gradient) to give a diasteromeric mixture of 4-(5-methyl-1,3-oxathiolan-2-yl)benzonitrile (32) (76 mg, 37%) as a colourless oil. 'H nmr (d,-dmso, 300 MHz) § 1.32 & 1.43 (each d, /6.0 Hz, total 3H); 2.83 & 3.29 (each m, total 2H); 4.21 & 4.60 (each m, total 1H); 6.17 & 6.30 (each s, total 1H); 7.58 (m, 2H); 7.82 (m, 2H).
Example 33: Preparation of 2-(4-Thien-2-ylphenyl)-1,3-oxathiolane (compound 33)
S oO =
S
—
Compound 33
A mixture of 4-(2-thienyl)benzaldehyde (188 mg, 2.00 mmol), freshly distilled 2-mercaptoethanol (234 mg, 3.00 mmol), sodium sulfate (284 mg, 2.00 mmol) and freshly fused zinc chloride (273 mg, 2.00 mmol) in dry 1,4-dioxane (1 ml) was stirred under nitrogen at room temperature for 16 h. Water (10 ml) and ethyl acetate (20 ml) were added and the phases separated. The ethyl acetate layer was washed with more water (10 ml) followed by saturated aqueous sodium chloride solution (10 ml). The solution was then dried (sodium sulfate), filtered and the solvent removed in vacuo to give a yellow-green solid (323 mg). A solution of the solid and p-toluenesulfonic acid monohydrate (6 mg, 31 pmol) in toluene (25 ml) was refluxed for 70 min. After cooling, the toluene was removed in vacuo and the residual solid subjected to flash chromatography (ether/hexane gradient) to give 2-(4-thien-2-ylphenyl)-1,3-oxathiolane (33) (49 mg, 20%) as a white powder. 'H nmr (d,-dmso, 300 MHz) 8 3.21 (m, 2H); 3.88 (m, 1H); 4.49 (m, 1H); 6.07, (s, 1H); 7.13 (dd, /5.1, 4.8 Hz, 1H); 7.45 (d, /8.4 Hz, 2H); 7.51 (dd, J4.8, 1.1 Hz, 1H); 7.54 (dd, /5.1, 1.1 Hz, 1H); 7.64 (d, 8.4 Hz, 2H). ESI (+ve) MS m/z249 (M+H, 70%).
Example 34: Preparation of 4-(5-Methyl-2-octyl-1,3-oxathiolan-2-yl)phenol (compound 8
OH
Compound 34
A mixture of 4-hydroxynonanophenone (468 mg, 2.00 mmol), 1-mercapto-2-propanol (553 mg, 6.00 mmol), sodium sulfate (568 mg, 4.00 mmol) and freshly fused zinc chloride (545 mg, 4.00 mmol) in dry 1,4-dioxane (1 ml) was stirred under nitrogen at room temperature for 16 h. Water (10 ml) and ethyl acetate (20 ml) were added and the phases separated.
The ethyl acetate layer was washed with more water (10 ml) followed by saturated aqueous sodium chloride solution (10 ml). The solution was then dried (sodium sulfate), filtered and the solvent removed in vacuo to give a colourless oil (688 mg). A portion of the oil (410 mg) was subjected to flash chromatography (ether/ hexane gradient) to give a mixture of the two diastereoisomers of 4-(5-methyl-2-octyl-1,3-oxathiolan-2-yl)phenol (34) (117 mg, 32%) as a colourless oil. H nmr (ds-dmso, 300 MHz) 8 0.82 (t, /6.6 Hz, 3H); 1.16 (br. s, 12H); 1.33 (m, 2H); 1.96 (m, 2H); 2.6 & 3.1 (each m, total 2H); 3.99 & 4.11 (each m, total 1H); 6.67 (m, 2H); 7.16 (m, 2H). ESI (+ve) MS m/z 309 (M+H, 25%).
Example 35: Preparation of 2-Fluoro-5-(5-methyl-1,3-oxathiolan-2-yl)benzenecarbonitrile (compound 35) 0) S
CN
F
Compound 35
A mixture of 2-fluoro-5-formylbenzonitrile (298 mg, 2.00 mmol), 1-mercapto-2-propanol (553 mg, 6.00 mmol), sodium sulfate (568 mg, 4.00 mmol) and freshly fused zinc chloride (545 mg, 4.00 mmol) in dry 1,4-dioxane (1 ml) was stirred under nitrogen at room temperature for 16 h. Water (10 ml) and ethyl acetate (20 ml) were added and the phases separated. The ethyl acetate layer was washed with more water (10 ml) followed by saturated aqueous sodium chloride solution (10 ml). The solution was then dried (sodium sulfate), filtered and the solvent removed in vacuoto give a colourless oil (717 mg). To this oil was added toluene (25 ml) and p-toluenesulfonic acid monohydrate (8 mg, 41 umol) and the mixture was refluxed for 1.5 h. After cooling the toluene was removed in vacuo and the residual oil subjected to flash chromatography (ether/ hexane gradient) to give a mixture of the two diastereoisomers of 2-fluoro-5-(5-methyl-1,3-oxathiolan-2-yl)benzenecarbonitrile (35) (295 mg, 66%) as a colourless oil. H nmr (dg-dmso, 300 MHz) § 1.31 & 1.42 (each d, /6.0 Hz, total 3H); 2.85 & 3.30 (each m, total 2H); 4.18 & 4.61 (each m, total 1H); 6.11 & 6.25 (each s, total 1H); 7.51 (m, 1H); 7.83 (m, 1H); 7.93 (m, 1H).
Example 36: 4-Methoxy-4'~(trifluoromethoxy)-1,1’-biphenyl (compound 36)
OMe
Compound 36
To a solution of 1-bromo-4-(trifluoromethoxy)benzene (0.90 g, 3.7 mmol) in tetrahydrofuran (20 ml) was added a solution of 2-(4-methoxyphenyl)-4,4,5,5-tetramethy]- 1,3,2-dioxaborolane (0.36 g, 1.54 mmol) in tetrahydrofuran (10 ml), potassium carbonate (0.42 g, 3.0 mmol), [1,1-bis(diphenylphosphino)ferrocene] dichloropalladium (0) (40 mg, 0.077 mmol) and water (0.20 ml) and the mixture refluxed under nitrogen for 19h. The reaction mixture was tipped into water (150 ml) and extracted with ether (2x50 ml), the ether extract then dried (MgSO,) and evaporated to give a tan semi-solid (0.801 g).
Purification by column chromatography (silica gel, 4:1 hexane/ chloroform) afforded 4- methoxy-4'-(trifluoromethoxy)-1,1-bipheny! (36) as a white solid (0.33 g, 80%). "H nmr (CDCl, 300 MHz) 3.86, s, 4-OMe; 6.99, d (8.7 Hz), H3,5; 7.26, d (8.1 Hz), H3',5’; 7.49, d (8.7
Hz), H2,6 or H2,6’; 7.55, d (8.7 Hz), H2',6’ or H2,6. APCI (+ve) MS m/z268 (M*, 80%).
Example 37: 2,6-Dimethoxy-3-[4-(trifluoromethyl)phenyllpyridine (compound 37)
OMe
N™
P
MeO
CF,
Compound 37
To a solution of 4-bromobenzotriflouride (0.85 g, 3.78 mmol) in tetrahydrofuran (20 mi) was added a solution of 2,6-dimethoxy-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2- yl)pyridine (0.41 g, 1.55 mmol) in tetrahydrofuran (10 ml), potassium carbonate (0.42 g, 3.0 mmol), [1,1-bis(diphenylphosphino)ferrocene] dichloropailadium (I) (40 mg, 0.077 mmol) and water (0.2 ml) and the mixture refluxed under nitrogen for 19 h. The reaction mixture . was tipped into water (150 ml) and extracted with ether (2x50 ml), the ether extract then dried (MgSO,) and evaporated to give a light brown oil (0.537 g). Purification by column chromatography (silica gel, 2:1 hexane/ chloroform) afforded 2,6-dimethoxy-3-{4- (triftuoromethyl)phenyllpyridine (37) as a clear, colourless oil (0.359 g, 82%). 'H nmr (CDCl, 300 MHz) 4.00, s, 2x OMe; 6.44, d (8.1 Hz), H5; 7.60, d (8.1 Hz), H4;7.66, m,
H2',3',5,6'. ESI (+ve) MS m/z284 (M+H, 100%).
Example 38 and 39: Diastereomers of 2-(4-bromophenyl)-2-butyl-4-propyl-1,3- oxathiane (compound 38) and (compound 39) &
Br
Compound 38/39
A mixture of 4-bromovalerophenone (482 mg, 2.00 mmol), 3-mercapto-1-hexanol (805 mg, 6.00 mmol), sodium sulfate (568 mg, 4.00 mmol) and freshly fused zinc chloride (545 mg, 4.00 mmol) in dry 1,4-dioxane (1 ml) was stirred under nitrogen at room temperature for 16 h. Water (10 ml) and ethyl acetate (20 ml) were added and the phases separated. The ethyl acetate layer was washed with more water (3x10 ml) followed by saturated aqueous sodium chloride solution (10 ml). The solution was then dried (sodium sulfate), filtered and the solvent removed in vacuo to give a colourless oil (1.112g). To 467 mg of this oil were added toluene (25 ml) and p-toluenesulfonic acid monohydrate (7.5 mg, 39 pmol) and the mixture was refluxed for 5 h. After cooling, the toluene was removed in vacuo and the residual oil subjected to flash chromatography (ether / hexane gradient) to give a colourless oil (254 mg), consisting of the starting ketone and the two diasteroisomers of 2-(4- bromophenyl)-2-butyl-4-propyl-1,3-oxathiane (38/39). Further flash chromatography (dichloromethane/ hexane gradient) gave in order of elution, the first diastereomer (38) as a colourless oil (36 mg), followed by the second diastereomer (39), also as a colourless oil (43 mg). The 'H nunr data for the separated diastereomers is given below. (38) 'H nmr (di-dmso, 300 MHz) § 0.76 (t, ] 7.2 Hz, 3H); 0.85 (t, J] 6.9 Hz, 3H); 0.9-1.5 (complex, 9H); 1.83 (dd, J 13.5, 2.7 Hz, 1H); 2.00 (ddd, J 15.0, 11.4, 4.2 Hz, 1H); 276 (ddd, J - 15.0, 11.7, 4.2 Hz, 1H); 3.35 (m, 1H); 3.89 (dt, J 11.7, 1.8 Hz, 1H); 3.98 (m, 1H); 7.38 (d, J 8.7
Hz, 2H); 7.52 (d, ] 8.7 Hz, 2H).
(39) 'H nmr (d--dmso, 300 MHz) § 0.74 (t, J 7.2 Hz, 3H); 0.84 (t, ] 6.9 Hz, 3H); 0.9-1.3 (complex, 4H); 1.3-1.9 (complex, 8H); 2.61 (m, 1H); 3.40 (apparent dt, J 12.3, 2.4 Hz); 3.83 (ddd, J 12.3, 3.6, 1.5 Hz); 7.49 (d, ] 8.7 Hz, 2H); 7.60 (d, J] 8.7 Hz, 2H).
Example 40: 4-(1,3-Dioxolan-2-yl)benzenecarbonitrile (compound 40)
CN
Compound 40 4-Cyanobenzaldehyde (500 mg, 3.81 mmol), ethylene glycol (828 mg, 13.34 mmol) and a catalytic amount of p-toluenesulfonic acid monohydrate were refluxed in toluene (25 mL) overnight in a Dean-Stark apparatus. The reaction mixture was then concentrated and the residue dissolved in chloroform (50 ml) and washed with saturated sodium bicarbonate solution (2x 25 mL) and brine (1x 25 mL). The organic phase was then dried (Na,50,) and evaporated to give 4-(1,3-dioxolan-2-yl)benzenecarbonitrile (40) as an oil which solidified to a white solid (633 mg, 95%). 'H NMR (CDCl, 300 MHz): 8 4.04, t (1.8 Hz), OCH); 4.07, t (2.0 Hz), OCH,; 5.82, s, H2; 7.64, d (1.4 Hz), 2xArH; 7.73, d (1.3 Hz), 2xArH. ESI (+ve) MS: m/z176 (M+H, 12%).
Example 41: 2-(3,5-Dimethoxyphenyl)-2-hexyl-1,3-dioxolane (compound 41)
MeO OMe
Compound 41 5 1-(3,5-Dimethoxyphenyl)heptan-1-one (200 mg, 0.80 mmol), ethylene glycol (173 mg, 2.80 mmol) and a catalytic amount of p-toluenesulfonic acid monohydrate were refluxed in toluene (25 mL) overnight in a Dean-Stark apparatus. The reaction mixture was then concentrated and the residue dissolved in chloroform (50 mL) and washed with saturated sodium bicarbonate solution (2x 25 mL) then brine (1x 25 mL). The organic phase was dried (Na,SO,) and evaporated to give 2-(3,5-dimethoxyphenyl)-2-hexyl-1,3-dioxolane (41) as a light yellow oil (213 mg, 90%). '"H NMR (CDCl, 300 MHz): 5 0.94, t (6.5 Hz), CHj; 1.31, m, methylene envelope; 1.89, m, CH,; 3.79-3.83, m, 2x OMe, OCH); 4.04, m, OCH); 6.46, m,
H4’; 6.63, m, H2,6'. ESI (+ve) MS: m/z295 (M+H, 62%).
Example 42: 2-(4-Chlorophenyl)-2-ethyl-4-methyl-1,3-dioxolane (compound 42)
Cl
Compound 42 _p-Chloropropriophenone (250 mg, 1.48 mmol), propylene glycol (395 mg, 5.19 mmol) and a catalytic amount of p-toluenesulfonic acid monohydrate were refluxed in toluene (25 mL) overnight in a Dean-Stark apparatus. The reaction mixture was then concentrated and the residue dissolved in chloroform (50 mL) and washed with saturated sodium bicarbonate solution (2x 25 mL) then brine (1x 25 mL). The organic phase was dried (Na,SO,) and evaporated to give a 2:1 diasteromeric mixture of 2-(4-chlorophenyl)-2-ethyl-4-methyl-1,3- dioxolane (42) as an oil (329 mg, 98%). 'H NMR (CDCl, 300 MHz): 3 0.88, t (7.4 Hz),
CH,CH; (minor); 0.92, t (7.4 Hz), CH,CH, (major); 1.19, d (6.1 Hz), C4-Me (minor); 1.32, d (6.0 Hz), C4-Me (major); 1.87, m, CH,CHj (both); 3.27, t (8.0 Hz), H5 (minor); 3.53, t (7.2
Hz), H5 (major); 3.92, t (7.3 Hz), H5 (major); 4.05, app q (6.3 Hz), H4 (major); 4.20, dd (5.8, 8.1 Hz), H5 (minor); 4.33, m, H4 (minor), 7.3-7.5, m, 4xArH (both). ESI (+ve) MS: m/z244 (M+NH,7%).
Example 43: 5-(5,5-Diethyl-1,3-dioxan-2-yl)-2-fluorobenzenecarbonitrile (compound 43)
Pa 0) (0)
CN
F
Compound 43 2-Fluoro-5-formylbenzonitrile (250 mg, 1.68 mmol), 2,2-diethyl-1,3-propanediol (776 mg, 5.87 mmol) and a catalytic amount of p-toluenesulfonic acid monohydrate were refluxed in toluene (25 mL) overnight in a Dean-Stark apparatus. The reaction mixture was then concentrated and the residue dissolved in chloroform (50 mL) and washed with saturated sodium bicarbonate solution (2x 25 mL) then brine (1x 25 mL). The organic phase was dried (Na,SO,) and evaporated to give an oil. The oil was then chromatographed on silica gel (4:1 hexane/ ethyl acetate) to give 5-(5,5-diethyl-1,3-dioxan-2-yl)-2- fluorobenzenecarbonitrile (43) as a light yellow oil (401 mg, 91%). 'H NMR (MeOD, 300
MHz): § 0.90, t (7.7 Hz), CH,CH;; 0.97, t (7.5 Hz), CH,CH,; 1.25, q (7.6 Hz), CH,CHj; 1.86, q (7.6 Hz), CH,CH;; 3.72, d (11.5 Hz), CH,0; 4.02, d (11.4 Hz), CH,0; 5.52, s, H2; 7.42, t (9.3
Hz), H3; 7.86, m, H4,6. ESI (+ve) MS: m/z264 (M+H, 11%).
Example 44 2-(4-Chlorophenyl)-4,5-dihydro-1,3-oxazole (compound 44)
N
Cl
Compound 44 p-Chlorobenzoic acid (0.5 g, 3.19 mmol) was suspended in thionyl chloride (25 mL) and refluxed overnight. The excess thionyl chloride was removed in vacuo to furnish the acid chloride as a light brown solid. The solid was then dissolved in dichloromethane (25 mL), cooled on an ice bath and ethanolamine (0.40 mL, 6.4 mmol) added to the mixture, followed by the addition of triethylamine (2.3 mL, 16 mmol) and the mixture was then stirred overnight at room temperature. The mixture was then diluted with chloroform (50 mL) and washed with IM hydrochloric acid (2x 25 mL) and brine (1x 25 mL) before concentrating the solvent to give the crude amide as an oil, which solidified to an off-white solid. Without further purification the crude amide was then dissolved in ethyl acetate (10 mL) to which was added dropwise, a solution of thionyl chloride (0.7 mL, 6.4 mmol) in ethyl acetate (3 mL) and the mixture stirred overnight at room temperature before concentrating to furnish the solid chloro-amide. After dissolving in dichloromethane (10 mL) and addition of DBU (1 mL, 6.4 mmol) the mixture was refluxed overnight.
Concentration of the solvent and flash chromatography of the resulting gum furnished 2- (4¢-chlorophenyl)-4,5-dihydro-1,3-oxazole (44) as a white crystalline solid (327 mg, 56 % overall yield). 'H NMR (d-MeOH, 300 MHz): § 4.09, t (9.6 Hz), H4; 4.57, t (9.5 Hz), HS; 7.54, d (8.6 Hz), 2xArH; 7.95, d (8.6 Hz), 2xArH. ESI (+ve) MS: m/2z182/184 (M+H, 100%/ 32%).
Example 45: 2-(4-Methylphenyl)-4,5-dihydro-1,3-oxazole (compound 45)
N vie : Compound 45 p-Toluicacid (0.5 g, 3.67 mmol) was suspended in thionyl chloride (25 mL) and refluxed overnight. The excess thionyl chloride was removed in vacuo to furnish the acid chloride as a light brown solid. The solid was then dissolved in dichloromethane (25 mL), cooled on an ice bath and ethanolamine (0.45 mL, 7.3 mmol) added to the mixture, followed by the addition of triethylamine (2.6 mL, 18.4 mmol) and the mixture was then stirred overnight at room temperature. The mixture was then diluted with chloroform (50 mL) and washed with IM hydrochloric acid (2x 25 mL) and brine (1x 25 mL) before concentrating the solvent to give the crude amide as an oil, which solidified to an off-white solid. Without further purification the crude amide was then dissolved in ethyl acetate (10 mL) to which was added dropwise, a solution of thionyl chloride (0.8 mL, 7.3 mmol) in ethyl acetate (3 mL) and the mixture stirred overnight at room temperature before concentrating to give the chloro-amide as a brown solid. After dissolving in dichloromethane (10 mL) and addition of DBU (1.1 mL, 7.3 mmol) the mixture was refluxed overnight. Concentration of the solvent and flash chromatography of the resulting gum furnished 2-(4-methylphenyl)- 4,5-dihydro-1,3-oxazole (45) as a white crystalline solid (236 mg, 40 % overall yield). 'H NMR (d,-MeOH, 300 MHz): § 2.45, s, Me; 4.07, t (9.6 Hz), H4; 4.54, t (9.5 Hz), H5; 7.33, d (7.9 Hz), 2xArH; 7.86, d (7.9 Hz), 2xArH. ESI (+ve) MS: m/z 162 (M+H, 100%).
BIOLOGICAL EXAMPLES .
Biological Example 1: MIF-induced human fibroblast proliferation.
Methods
The activity of a compound of formula (I) was studied in a bioassay utilising MIF-induced proliferation of human dermal fibroblasts. The proliferation of human fibroblasts has been demonstrated to be a phenomenon inducible by MIF "9. $112 human dermal fibroblasts were propagated in RPMI/ 10% foetal calf serum (FCS). Prior to experimentation, cells were seeded at 10° cells/ml in RPMI/0.1% BSA for 18 hours. Cells were treated with recombinant human macrophage migration inhibitory factor (MIF) 50 ng/ml and/or a compound of the invention at a concentration of 1 nM. The compound was combined with
MIF at time point 30 minutes, prior to adding to cell culture at time point zero. At time point zero, culture medium was replaced with RPMI/10% FCS and treatments administered. At time point 30 hours, cells were pulsed with 1 uCi *H-thymidine. At time point 48 hours, cells were harvested using a semi-automated cell harvester. The radioactivity incorporated into DNA was determined by liquid scintillation counting, with results expressed as *H-thymidine incorporation.
Significant inhibition of MIF-induced proliferation was determined by the demonstration of a significant P value (< 0.05) using the Mann-Whitney U-test.
Results 2-(2-hydroxyethoxy)-2-(4-hydroxy-3-methylphenyl)-1,3-dioxolane (Compound 1) (cpd 1), when used in the method above, significantly inhibited the induction of S112 human fibroblast proliferation (P < 0.05), as shown in Table 1 and Figure 1. Treatment of cells with
MIF (+MIF) induced proliferation, but this was prevented by pre-incubating MIF with
Compound 1 (1 nM) (+MIF +cpd 1) (*P < 0.05). These data are consistent with these compounds exerting inhibitory effects on the biological activity of MIF.
Table 1.
Untreated cells MIF-treated cells MIF-treated cells + pd1 at 1 nM os on 07
Number of experiments *P<0.05
Biological Example 2: MIF-dependent IL-1 induced fibroblast cyclooxygenase-2 expression.
Methods
The activity of the compounds of formula (I) were further studied in a bioassay utilising
MIF-dependent activation of human dermal fibroblasts. Sampey ef a/have shown that induction of the expression of cyclooxygenase-2 (COX-2) by the cytokine interleukin 1 (IL- 1) is dependent upon the presence of MIF, i.e. can be prevented using specific anti-MIF monoclonal antibody “7. IL-1-induced COX-2 expression is therefore a MIF-dependent event. $112 human dermal fibroblasts were propagated in RPMI/10% foetal calf serum (FCS).
Prior to experimentation, cells were seeded at 2x10° cells/ml in RPM1/0.1% BSA for 18 hours. Cells were treated with compound at 1-100 uM and 30 minutes later with recombinant human IL-1 (0.1 ng/ml). After 6 hours, cells were collected and intracellular
COX-2 protein determined by permeabilisation flow cytometry, as described by Sampey et al"®, Cells permeabilised with 0.2% saponin were sequentially labelled with a mouse anti- human COX-2 monoclonal antibody and with sheep-anti-mouse F(ab)2 fragment labelled with fluoroscein isothiocyanate. Cellular fluorescence was determined using a flow cytometer. At least 5000 events were counted for each reading, each of which was performed in duplicate, and the results expressed in mean fluorescence intensity (MFI) after subtraction of negative control-labelled cell fluorescence.
In Table 2 and Figure 2, the effect of each concentration of 2-(2-hydroxyethoxy)-2-(4- hydroxy-3-methylphenyl)-1,3-dioxolane (Compound 1) was determined by subtracting the IL-1+compound-treated cell MFI from the IL-1-treated cell MF], and expressed as %
inhibition. Significant inhibition of IL-induced COX-2 expression was determined by the demonstration of a significant P value (P< 0.05) using Student's test.
Results
As shown in Figure 2, cells treated with Compound 1 exhibited a significant reduction in
COX-2 expression as measured by flow cytometry ( P < 0.01). Statistically significant inhibition of the induction of COX-2 expression by IL-1 in human S112 fibroblast cells was demonstrated when cells were treated with Compound 1 (cpd 1) 50 pM (*P < 0.01).
As shown in Table 2 and Figure 3, cells treated with 2-(2-hydroxyethoxy)-2-(4-hydroxy-3- methylphenyl)-1,3-dioxolane (Compound 1) exhibited a dose-dependent reduction in
COX-2 expression as measured by flow cytometry. These data are consistent with these compounds exerting inhibitory effects on the biological activity of MIF.
Table 2. oncentration of Mean % ompound 1 inhibition COX2 (WM) expression Standard error Number of experiments oo | owes | oes | 4
TE EE
A EE YE ow | owes |e | 6 "VE EY *P <0.05
In Figure 4, the effect of 2-(2-hydroxyethoxy)-2-(4-hydroxyphenyl)-1,3-dioxolane (Compound 2) is expressed as mean fluorescence intensity (MFI), after deducting the MFI of control-labelled cells. Significant inhibition of IL-induced COX-2 expression was determined by the demonstration of a significant P value (P< 0.05) using Student's test.
Significant inhibition of IL-induced COX-2 expression in human S112 fibroblast cells was demonstrated in cells treated with Compound 2 (IL-1+cpd?2) compared to cells treated with
IL-1(*P <0.05).
Biological Example 3: MIF-dependent antigen-specific T cell activation.
Methods
The activity of compounds of formula (I) was further studied in a bioassay utilising MIF- dependent activation of murine T cell activation. The activation of T lymphocytes in response to exposure to a recall antigen is known to be dependent on the presence of MIF, i.e. can be prevented using specific anti-MIF monoclonal antibody”. Antigen-induced T cell activation is therefore a MIF-dependent phenomenon.
Splenocytes were obtained by Hank's buffered saline flushing of spleens obtained from
C57Bl/6 mice previously immunized with methylated bovine serum albumin (mBSA,
Sigma Chemical Co., Castle Hill, Australia). Mice were immunized on day 0 with 200 ug mBSA emulsified in 0.2 ml of Freund's complete adjuvant (FCA) injected subcutaneously into the flank skin. On day 7, the mice received 100ug mBSA/0.1 ml FCA by intradermal injection at the base of the tail. Spleens were removed on day 14 after first immunisation and a single cell suspension was prepared in DMEM containing 5% FCS and 0.05% 2- mercaptoethanol. 1 x 10° cells /2001 were cultured in triplicate in the presence of mBSA (10 ug / ml) with or without the addition of 2-(2-hydroxyethoxy)-2-(4-hydroxyphenyl)-1,3- dioxolane (Compound 2) at a concentration of 100 nM — 10 pM, 30 minutes before the addition of mBSA. The T cell proliferation response was determined by measuring the amount of [*H] thymidine incorporation during the final 18 hr. The cells were harvested and radioactivity incorporation into the DNA was measured with a Wallac 1409 liquid scintillation counter (Pharmacia, Turku, Finland). Significant inhibition of T cell activation was determined by the demonstration of a significant P value (P< 0.05) using Student's test.
Results.
Treatment of spleen cells with 2-(2-hydroxyethoxy)-2-(4-hydroxyphenyl)-1,3-dioxolane (Compound 2) (cpd2) resulted in a significant dose-dependent reduction in antigen-specific
T cell activation, compared to cells exposed to mBSA without Compound 2 (*P < 0.05) (Figure 5). These data are consistent with these compounds exerting inhibitory effects on the biological activity of MIF.
Biological Example 4: Combination of MIF-antagonist with glucocorticoid: effects on MIF-dependent IL-1 induced fibroblast cyclooxygenase-2 expression.
A particular aspect of the biological function of MIF relates to its ability to antagonise the anti-inflammatory effects of glucocorticoids such as dexamethasone, as recently reviewed by Morand et al. ®. This property of MIF suggests that MIF antagonists might exert “steroid-sparing” effects, that is, their use in combination with glucocorticoids might permit the achievement of a greater therapeutic effect with a given dose of glucocorticoids.
Thus, in the presence of MIF antagonists, low doses of glucocorticoids could exert a therapeutic effect otherwise requiring a higher dose of glucocorticoids. As the adverse effects of glucocorticoids are in general dose-dependent, the ability to reduce the requirement for glucocorticoids is clinically desirable.
The potential for a MIF antagonist to be “steroid-sparing”, therefore, could be demonstrated by the observation of enhanced effectiveness of a given dose of glucocorticoids in the presence of a MIF antagonist.
Methods
The above in vitro assay (Biological Example 2) for analysing the effect of MIF antagonists on IL-1 induced COX-2 expression was performed using 2-(2-hydroxyethoxy)-2-(4'- hydroxy-3'-methylphenyl)-1,3-dioxolane (Compound 1) (50 uM), dexamethasone (1 AM) or a combination of dexamethasone (1 nM) and Compound 1 (50 uM). COX-2 expression was expressed as the mean fluorescence intensity (MFI) as measured by flow cytometry, after deduction of the MFI for control-labelled samples, as described by Sampey ef al. ®. The results are shown in Table 3 and Figure 6.
Results
Significant enhancement of the inhibitory effects of the glucocorticoid dexamethasone was determined by the demonstration of a significant P value (P< 0.05) using Student's test, compared to the effect of dexamethasone alone. Compared to the inhibition of IL-1- induced COX-2 expression achieved with 1 nM dexamethasone alone (IL-1+DEX), a significantly greater inhibition of IL-1-induced COX-2 expression was observed when cells were treated with 1 nM dexamethasone together with Compound 1 50 pM (IL- 1+DEX+cpd1) (P < 0.05). These data are consistent with these compounds exerting inhibitory effects on the biological activity of MIF.
Table 3.
I I+ EU IU F—
Mean COX-2 0.7400 49.37 15.13 6.013* expression (MFI)
Standard 0.4413 2.412 1.770 2.906 error :
FE EU VU EE
*P<0.05
Biological Example 5: Lack of cytotoxicity.
A valuable characteristic of a therapeutic material is a lack of toxicity. The compounds of formula (I) may have low toxicity towards cells. To examine this in vitro, the ability of 2-(2- hydroxyethoxy)-2-(4-hydroxy-3-methylphenyl)-1,3-dioxolane (Compound 1) to induce apoptosis (“programmed cell death) was investigated. A lack of cytotoxicity would be evidenced by the finding of equivalent proportions of apoptotic and viable cells in control- and compound-treated cells.
Methods
To examine the cytotoxicity of compounds of formula (I), S112 human dermal fibroblasts were exposed to a therapeutic concentration (50 uM) of 2-(2-hydroxyethoxy)-2-(4-hydroxy-3-methylphenyl)-1,3-dioxolane (Compound 1) or vehicle (control) and analysed for apoptosis by flow cytometric analysis of annexin V and propidium iodide staining, as described by Leech et al. ". Toxicity was assessed by analysis of apoptosis using flow cytometric detection of cell surface Annexin V binding and propidium iodide staining. At least 5000 events were analysed for each experiment. Cells positive for both Annexin V and propidium iodide were designated as apoptotic and cells negative for both Annexin V and propidium iodide were designated as viable. Results are expressed as the percentage (%) of cells with each of these labels.
Results.
The results of cytotoxicity analysis are shown in Figure 7. No significant increase (ns) in apoptotic cell numbers, and no significant decrease (ns) in viable cell numbers, was observed in cells treated with 2-(2-hydroxyethoxy)-2-(4-hydroxy-3-methylphenyl)-1,3-dioxolane (Compound 1) compared to control-treated cells.
Biological Example 6: MIF-dependent nitrite production in peritoneal macrophages
MIF is able to induce or facilitate the expression and release of a wide variety of pro- inflammatory and/or destructive molecules, including the release of macrophage nitric oxide (NO) ®. A compound with the ability to inhibit the cytokine or biological function of
MIF might be expected to inhibit the activation of NO production by macrophages.
Methods
C57BL6/J male mice were injected intraperitoneally with 2ml of thioglycolate. Three days later peritpneal macrophages were collected by lavaging the peritoneum with 3ml of cold
Hank's buffered saline solution. Cells from several mice were pooled, washed and re- suspended in DMEM supplemented with 5%FCS. Cells were plated in 96 well plastic tissue culture plates at 1x10° cells/ well. Cells were treated in triplicate wells with compound or vehicle for 1 hour in a 5% CQO, incubator at 37 °C. Cells were then treated with LPS (10 ng/ml) and recombinant human interferon-y (10 units/ml) and incubated for 24 hours.
After 24 hours, 50 pl of supernatant from each well was carefully removed and transferred to ELISA plates. The production of NO was measured by analysing the concentration of nitrite in culture supernatants, as measured by the Greiss assay “. The results were calculated as the percentage inhibition of nitrite concentration in compound-treated cell culture supernatants, compared to that of vehicle-treated cells.
Results
Treatment of cells with 1-(3-Methylbutyl)-4-(4-methylphenyl)-1 HF pyrazole (Compound 13) 0.5-100 uM resulted in a dose-responsive inhibition of LPS-IFN--induced nitrite production (Figure 8).
Table 4 displays the results for other compounds tested in this assay. Marked reductions in nitrite concentration were observed in the supernatants of cells treated with thee compounds. These data are consistent with these compounds exerting inhibitory effects on the biological activity of MIF.
Significant inhibition of nitrite production was determined by the demonstration of a significant P value (P< 0.05) using the Mann-Whitney U-test.
TABLE 4 (+SD) (uM) sl me | ow
I EE
0 sew
P<0.05
Biological Example 7: MIF-induced proliferation in mouse fibroblasts
Methods
The activity of compounds was studied in a bioassay utilising MIF-induced proliferation of mouse NIH 3T3 fibroblasts. The proliferation of NIH3T3 fibroblasts has been demonstrated to be a phenomenon inducible by MIF ®, and MIF-induced proliferation has been linked to the pathology of diseases such as rheumatoid arthritis *. NIH 3T3 cells were propagated in DMEM/ 10% foetal calf serum (FCS). Prior to experimentation, cells were seeded at 10 cells/well in 96-well plates in DMEM/ 10% FCS for 18 hours. The media was then replaced with DMEM/0.1% FCS and the cells incubated for a further 18 hr. At time point -1 hr, culture medium was replaced with DMEM/ 0.1% FCS and cells were treated with a compound of the invention at a final concentration of 10 uM or vehicle. At time point zero, cells were treated with MIF at a final concentration of 50 ng/ml. At time point 6 hr the cells were pulsed with 1 Ci/ well of *H-thymidine. At time point 24 hours, cells were harvested using a semi-automated cell harvester. The radioactivity incorporated into DNA was determined by liquid scintillation counting, with results expressed as *H-thymidine incorporation (cpm). Statistical significance was analysed using the Mann-Whitney test.
Results
Compounds of the invention were inhibitory of MIF-induced proliferation. Treatment of cells with MIF induced a significant increase in proliferation (P = 0.006). Treatment with 2-Methyl-2-(4-methylphenyl)-1,3-dithiolane (Compound 18) 10 uM resulted in significant inhibition of MIF-induced proliferation (*P<0.05) (Figure 9a). In a further experiment, treatment of cells with MIF again induced a significant increase in proliferation (P = 0.004).
Other compounds of the invention resulted in significant inhibition of MIF-induced proliferation (*P<0.05) (Figure 9b).
Table 5 displays the results for other compounds tested using this methodology.
Reductions in MIF-induced proliferation were observed in cells treated with all compounds listed; where indicated these results were statistically significant. These data are consistent with these compounds exerting direct inhibitory effects on the biological activity of MIF.
TABLE 5
Mean cpm | Std. Error | P value (compared to nil) oy | so
Mean cpm | Std. Error | P value (compared ompound (10x!*¢M) to MIF + vehicle) lew ae es | ew , 1071 89.58 0.0253 oe | uw | as _ ws | wss os | est 00255 wwe | ow 955.6 88.32 0.0253 be | owes | wes 933.2 216.5 0.0253 1209 51.21 0.0257 bh 1214 87.57 0.0485 new Jee 2 wo [en “
TE I I
SE TO ET
"I PE TE
EE I YE ws | wes | oom
EA a ewe | ws
PE I PP ET
Biological Example 8: Mouse endotoxic shock model
The activity of compounds was studied in the murine endotoxic shock model. In this model, features of shock, characterised by increased serum levels of cytokines such as IL-1, tumor necrosis factor (TNF), and interleukin 6 (IL-6), are induced by the injection of bacterial lipoloysaccharide (LPS). The in vivo production of IL-1, IL-6, and TNF in response to endotoxin has been previously shown to be dependent on MIF ®. Treatment of mice with a compound with inhibitory effects on the biological or cytokine activity of MIF could be expected to produce inhibition of serum IL-1, TNF, and/or IL-6 levels.
Methods
Groups of four mice were used in each experiment. Endotoxaemia was induced by intra- peritoneal injection of lipopolysaccharide (LPS) (5 mg/kg) in 300 pl saline. Mice injected with saline alone were used as a control group. Treatments were administered by intra- peritoneal injection at intervals 24 hours and 1 hour before intra-peritoneal LPS injection.
Mice were treated with saline, compounds dissolved in DMSO/ saline vehicle at a dose of 5-15 mg/kg body weight, or vehicle (containing matching concentrations of DMSO).
After 1.5 hours mice were humanely killed by CO2 inhalation then neck dislocation.
Serum was obtained from blood obtained by cardiac puncture prior to death and measured for the concentration of cytokines including IL-1, TNF, and/or IL-6, by ELISA. Statistical significance was analysed using the Mann-Whitney test.
Results
Treatment with 2-Hexyl-2-(4-methylphenyl)-1,3-dithiolane (Compound 17) was assessed.
The mean + standard error of serum IL-1, IL-6, and TNF concentrations at a time-point 1.5h after administration of LPS are presented in Figure 10. Compared to saline, LPS injection induced a significant cytokinaemia for each of IL-1, IL-6, and TNF (P<0.05). Treatment with 2-Hexyl-2-(4-methylphenyl)-1,3-dithiolane (Compound 17) (shown as cpd 17) at 5 and 15 mg/kg (as shown in brackets) was associated with marked inhibition of LPS-induced serum IL-1 (Figure 10a), IL-6 (Figure 10b), and TNF (Figure 10c). In the case of IL-1, the inhibition was statistically significant (*P<0.05). These data are consistent with this compound exerting inhibitory effects on the biological activity of MIF.
The effect of additional compounds is presented in Table 6, in which the mean + standard error of serum IL-1, IL-6, and TNF concentrations are presented. 4-(4-Methoxyphenyl)-1-(3-methylbutyl)-1 F-pyrazole (Compound 12), 1-(3-Methylbutyl)-4-(4-methylphenyl)-1F£pyrazole (Compound 13), and 2-(4¢-Thien-2-ylphenyl)-1,3-oxathiolane (Compound 33) were tested. An inhibitory effect of treatment with Compounds 12, 13, and 33 on serum IL-1 was observed at a dose of 5 mg/kg. An inhibitory effect of treatment with Compounds 12, 13, and 33 on serum IL-6 and TNF was observed at a dose of 15 mg/kg. These data are consistent with these compounds exerting inhibitory effects on the biological activity of MIF.
TABLE 6 vehicle 12 13 33 5mg/kg 5 mg/kg 5 mg/kg vehicle 12 13 33 mg/kg 15 mg/kg 15 mg/kg
References (1) David, J. Proc. Natl. Acad. Sci., USA, (1966), 56, 72-77. (2) Weiser, W.Y,, etal., Proc. Natl. Acad. Sci., USA, (1989), 86, 7522-7526. 3) Leech M, Metz-CN, Smith M, Weedon H, Holdsworth SR, Bucala R, et al.
Macrophage migration inhibitory factor (MIF) in rheumatoid arthritis: Evidence for pro-inflammatory function and regulation by glucocorticoids. Arthritis &
Rheumatism 1999; 42:1601-1608. (4) Morand EF, Bucala R, Leech M. Macrophage migration inhibitory factor (MIF): An emerging therapeutic target in rheumatoid arthritis. Arthritis & Rheumatism 2003; 48:291-299. (5) Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995; 377:68-71. 6) Donnelly SC, Haslett C, Reid PT, Grant IS, Wallace WAH, Metz CN, I. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nature Medicine 1997; 3:320-323. (7) Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M, et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation.
Proceedings of the National Academy of Sciences USA 1996; 3:7849-7854. (8) Santos LL, Hall P, Metz CN, Bucala R, Morand EF. Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: Interaction with glucocorticoids. Clin. Exp.Immunol. 2001; 123:309-314. (9) Leech M, Santos LL, Metz C, Holdsworth SR, Bucala R, Morand EF. Control of macrophage migration inhibitory factor (MIF) by endogenous glucocorticoids in rat adjuvant arthritis. Arthritis & Rheumatism 2000; 43:827-833. (10) Bucala R. MIF rediscovered: cytokine, pituitary hormone, and glucocorticoid-induced regulator of the immune response. FASEB.]. 1996; 10:1607-1613. (11) Sabroe I, Pease JE, Williams TJ. Asthma and MIF: innately Thl and Th2. Clin Exp
Allergy 2000; 30(9):1194-6.
(12) Eur. J. Med. Chem - Chim. Ther., 17(3), 235-43, (1982). (13) Synthetic Communications, 30(6), 1083-1094, (2000). (14) J. Am. Pharm. Assoc., 38, 9-11, (1949). (15) J. Org. Chem, 63 (12), 4116-4119, (1998). (16) LaceyD, Sampey A, Mitchell R, Bucala R, Santos L, Leech M. Morand EF. Control of fibroblast-like synoviocyte proliferation by macrophage migration inhibitory factor (MIF). Arthritis Rheum 48:103-9, 2003. (17) Sampey A, Hall P, Morand EF. Regulation of Synoviocyte PLA2 and COX2 By
Macrophage Migration Inhibitory Factor. Arthritis Rheum 44:1273-1280, 2001. (18) Sampey A, Morand EF. Annexin inhibition of human synoviocyte phospholipase
A2 but not cyclooxygenase-2 activity. Mediators of Inflammation 9:125-132, 2000. (19) Leech M, Lacey D, Xue JR, Santos L, Hutchinson P, Wolvetang E, David JR, Bucala
R, Morand EF. Macrophage migration inhibitory factor (MIF) regulates p53 in inflammatory arthritis. Arthritis Rheum 2003. (20) Juttner S, Bernhagen J, Metz CN, Rollinghoff M, Bucala R, Gessner A. Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF. J.Immunol. 1998;161:2383- 2390. (21) Santos LL, Morand EF, Holdsworth SR. Suppression of adjuvant arthritis and synovial macrophage inducible nitric oxide by N-iminoethyl-l-ornithine, a nitric oxide synthase inhibitor. Inflammation 1997,21:299-311. (22) Mitchell RA, Metz CN, Peng T, Bucala R. Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. Journal of Biological Chemistry 1999;274:18100-18106. (23) Bozza M, Satoskar AB, Lin G, Lu B, Humbles AA, Gerard C, et al. Targeted disruption of Migration Inhibitory Factor gene reveals its critical role in sepsis.
Journal of Experimental Medicine 1999;189:341-346.
Claims (52)
1. A compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof PERN 1 X Y Ry ® Rq Ro Ra wherein X and X' are independently selected from —C(Rs),-, =O-, -S-, -N(Rs)-, or taken together form —C(Rs}=C(Rs)-, -C(Rs)=N-, -N=C(R;)-, -N(Rs)-N(Rs)- or -N=N-; Y and Y' are independently selected from ~C(Rs),-, ~O-, -S-, -N(Rs)-, or taken together form —C(R5)=C(R;)-, -C(R5)=N-, -N=C(R5)-, -N(R;5)-N(R;)- or -N=N-; Z is =C(Rs),-, -O-, -S- or -N(R;)-, or forms a covalent single or double bond between X'and Y', or Z together with X' or Y' forms —C(Rs)=C(Rs)-, -C(Rs)=N-, -N=C(Rs)-, -N(R)-N(R;)- or -N=N-; wherein when Z is -O-, -5- or -N(R;)-, X' and Y' are -C(Rs),~; when X is ~O-, -5- or -N(R;)-, X' is =C(Rs),~; when Y is -O-, -5- or -N(R;)-, Y' is =C(Rs),~; or X or Y together with the carbon atom bearing the phenyl group form a double bond wherein which ever of X or Y forms part of the double bond is selected from -C(R;)- and -N-; R, is selected from hydrogen, C, alkyl, C, alkenyl, C, alkynyl, (A),C(O)R,, (A),C(S)Rs, (A)S(O)R,, (A),S(O):Re, (A),OR;, (A):SRy, (A)N(Rg), (A),C(=NRg)R,, and
(A).R,,, or when X or Y together with the carbon atom bearing the phenyl group form a double bond, R, is absent; R, and R, are independently selected from hydrogen, C, alkyl and (A) Ry R, is selected from C, alkyl, (A),R,, (A).aryl and (A), heterocyclyl;
R; is selected from hydrogen, C, jalkyl, C, alkenyl, C, alkynyl, (A),C(O)R,,
(A), C(S)R,, (A) S(O)Rg, (A), S(O);Rg, (A),ORy, (A),SR;, (A) N(Rs), (A),C(=NRy)R,; and (A)R yy;
Ry is selected from hydrogen, C, alkyl, C, alkenyl, C, alkynyl, OH, OC, ealkyl, OC, jpalkenyl, 0G; alkynyl, O(A)Ryy SH, SC,.0alkyl, SC; ealkeny], SC, 0alkynyl,
S(A)qRy, N(R,3),, [NH-CH(R,,)C(0)],-OH, [NH-CH(R,,)C(O)],-OC, ;alkyl, [sugar], and (A)Ryy;
R, is selected from hydrogen, C, alkyl, C; alkenyl, C;p0alkynyl, (A)Ry;, C(O)H, C(O)C.r0alkyl, C(O)C,pealkenyl, C(O)C,0alkynyl, C(O)-aryl, C(O)XA)Rn, C(O)H, C(0),Cy10alkyl, C(0),Cza0alkenyl, C(0),Cy.10alkynyl, C(O)yaryl, C(O)y(A)R1y, C(SH,
C(S)C,.yealkyl, C(S)C,poalkenyl, C(S)C; alkynyl, C(S)-aryl, CS) (A)Ry, C(S)OH, C(S)OC,.palkyl, C(S)OC, soalkenyl, C(S)OC,.palkynyl, C(S)O-aryl, C(S)YO(A) Ry, S(O)H, S(0)Cy.1ealkyl, S(0).C,.palkeny], S(0),C,.ealkynyl, S(O)-aryl, S(O)(A)R1/ [C(O)CH(R,)NH],-H, [C(O)CH(R,)NH],-C, jpalky], [C(O)CH(R,,)NH],-C,.jpalkeny], [C(O)CH(R,,)NH],-C,.jpalkynyl, [C(O)CH(R,)NH],-aryl, [C(O)CH(R.)NH],-(A) Ry,
and [sugar]. each Rq is independently selected from R, and NHC(=NR,;)NH,;
R, is selected from hydrogen and C, alkyl; Ro is selected from C, ¢alkyl, NH, NH(C, alkyl), N(C, alkyl), OH, OC, salkyl, SH and SC, jalkyl;
R,, is selected from OH, OC, alkyl, OC, 4alkyl-O-C, jalkyl, O-aryl, O-heterocydlyl, O[C(O)CH(R,y)NH],H, [sugar], SH, SC, alkyl, SC, ;alkyl-O-C, ;alkyl, S-aryl, S-heterocyelyl, S[C(O)CH(R,,)NH],H, halo, N(R;5),, C(O)R;¢, CN, C(Ry7), aryl and heterocyclyl;
R,, is selected from OH, SH, NH,, halo, NO,, C(R,7);, OC(R;); and CN;
each R;; is independently selected from hydrogen, C, salkyl, C,¢alkenyl, C, alkynyl and (A)Ryy Ry, is the characterising group of an amino acid; each R; is independently selected from hydrogen, C, salkyl, C;;alkoxyC, alkyl, aryl and heterocydyl; Rye is selected from C, alkyl, OH, C, ;alkoxy, aryl, aryloxy, heterocyclyl and heterocyclyloxy; each R,; is independently selected from hydrogen and halogen; A is optionally substituted methylene wherein when n > 1, any two adjacent A groups are optionally interrupted by —O-, -S- or -N(Rys)-; where n is 0 or an integer selected from 1 to 20; m is 0 or an integer selected from 1 to 3; p is an integer selected from 1 to 20; q is an integer selected from 1 to 10 s is an integer selected from 1 to 5; tis an integer selected from 1 or 2; and wherein each alkyl, alkenyl, alkynyl, aryl and heterocyclyl may be optionally substituted.
2. A compound according to claim 1 of formula (II), or a pharmaceutically acceptable salt or prodrug thereof a X Y Ry Im Rg R, Ra wherein X and Y are independently selected from —O-, -S-, -N(R;)- and ~C(Rs),-; Z is ~C(Rs),- or is a covalent bond between adjacent methylene groups; R, is selected from hydrogen, C, alkyl, C,zpalkenyl, C; alkynyl, (A).C(O)Ry (A) C(S)Ry, (A). S(O)Ry, (A) S(O).Ry, (A), ORy, (A),SRy, (A)N(Ry), (A);C(=NRs)R;, and (A)Ryy; R, and R, are independently selected from hydrogen, C, ;alkyl and (A).Ry; R, is selected from C, alkyl, (A), Ry, (A),aryl and (A) heterocyclyl; Rs is selected from hydrogen, C alkyl, C,patkenyl, Cy alkynyl, (A),C(O)R,,
(A).C(S)Rs, (A)S(O)R, (A) S(O)R, (A), ORy, (A)SRy, (A)N(Rg), (A) C(=NRg)R,, and (A)Ryy; R; is selected from hydrogen, C,palkyl, C, alkenyl, C; alkynyl, OH, OC, calkyl,
OC,.ealkenyl, OC, alkynyl, O(A)Ryy, SH, SCy.i0alkyl, SCyy0alkenyl, SC; alkynyl, S(A) Ry NR), [NH-CH(R,,)C(O)],-OH, [NH-CH(R,,)C(0)],-OC,,alky 1, [sugar], and (A)Ryy; R, is selected from hydrogen, C,alkyl, C, alkenyl, C; alkynyl, (A)R,;, C(O)H, C(O)Cy.ppalkyl, C(O)C, palkenyl, C(O)C;.palkynyl, C(O)-aryl, C(O}A)Ry, C(O)H, C(0),Cy.p0alkyl, C(0),Cpoalkenyl, C(O),Caaoalkynyl, C(O)aryl, C(O) (A)gR1y, C(S)H, C(S)Cy102lkyl, C(S)C,. alkenyl, C(S)Cy alkynyl, C(S)-aryl, C(SXA),Ryy, C(S)OH, C(S)OC,. alkyl, C(S)OC,.palkenyl, C(SYOC,. palkynyl, C(S)O-aryl, C(S)O(A) Ry, S(0)H, S(O)Ci.i0alkyl, S(O)Cy.j0alkenyl, S(O)C,.palkynyl, S(O)-aryl, S(O)(A)Ry,
[C(O)CH(R,,)NH],-H, [C(O)CH(R,,)NH],-C, jpalkyl, [C(O)CH(R;,)NH],-C, jpalkeny], [C(O)CH(R,,)NH],-C,.ealkynyl, [C(O)CH(R,,)NH],-aryl, [C(O)CH(R,,)NH],-(A)R;; and [sugar]; each R, is independently selected from R; and NHC(=NR;s)NH,; R, is selected from hydrogen and C, salkyl;
Ry, is selected from C, alkyl, NH,, NH(C, alkyl), N(C, salkyl),, OH, OC, ;alkyl, SH and SC, ;alkyl; R;, is selected from OH, OC, salkyl, OC, jalkyl-O-C, alkyl, O-aryl, O-heterocydlyl, O[C(O)CH(R,,)NHLH, [sugar], SH, SCyalkyl, SC, alkyl-O-C, jalkyl, S-aryl,
S-heterocyclyl, S[C(O)CH(R,,)NH]H, halo, N(Rys),, C(O)Rye CN, CRy)s aryl and heterocyclyl; Ry, is selected from OH, SH, NH,, halo, NO,, C(R;;); OC(R;7); and CN; each R;; is independently selected from hydrogen, C;.alkyl, C, ¢alkenyl, C, alkynyl and (A)Ryy;
Ry, is the characterising group of an amino acid; each R;s is independently selected from hydrogen, C,.alkyl, C,alkoxyC, jalkyl, aryl and heterocyclyl; Ry, is selected from C, zalkyl, OH, C, jalkoxy, aryl, aryloxy, heterocyclyl and heterocyclyloxy;
each Ry, is independently selected from hydrogen and halogen; A is optionally substituted methylene wherein when n > 1, any two adjacent A groups are optionally interrupted by -O-, -S- or -N(Rys)-; where n is 0 or an integer selected from 1 to 20; m is 0 or an integer selected from 1 to 3;
p is an integer selected from 1 to 20; q is an integer selected from 1 to 10 sis an integer selected from 1 to 5; tis an integer selected from 1 or 2; and : wherein each alkyl, alkenyl , alkynyl, aryl and heterocyclyl may be optionally substituted.
3 A compound according to claim 2 wherein Xis -O-, -5-, -NH- or -CH-; Y is -O-, -5- or -NR;-; Z forms a covalent bond between adjacent methylene groups; R, is selected from C,yalkyl, Ci alkenyl, O-(A),0-C, salkyl, O-(A),-heterocyclyl, O-(A)q-sugar, O-(A),O[C(O)CH(R,)NH],-H, (A),OH, (A),OC, alkyl, (A), OC; palkenyl, (A),0C(O)C, alkyl, (A), OC(O)C, palkenyl, (A),0C(O)aryl, (A),O[C(O)CH(R,,)NH],-H, (A),Olsugar],, (A).NHC, yalkyl, (A),N(C, palkyl), (A)uNHC, alkenyl, (A).N(C,.palkenyl),, (A),NHC(O)C, alkyl, (A),NHC(O)C, yalkeny], (A),NHC(O)aryl, (A),NH[C(O)CH(R,JNH],-H, (A),NH-[sugar 1s (A).SO,H, (A). SOC, alkyl, (A),SO,C; pealkenyl, (A) C(O)Cra0alkyl, (A)uC(O)C, alkenyl, (A),CO,H, (A),CO,Cy palkyl,
(A).CO,C,.0alkenyl, (A),C(OINHC, yalkyl, (A),C(O)N(C, alkyl), (A)C(O)NHC, alkenyl, (A),C(OIN(C, alkenyl), (A).C(O)INHCH(R,,)C(O)],-OH, (A),C(O)[sugar],; wherein A is methylene optionally substituted one or two times with a group that is independently selected from C, alkyl, C,¢alkenyl, C, alkynyl, halogen, OH, OC, alkyl, COH, CO,C, alkyl, NH, NHC, ;alky}, -N(C, ;alkyl),, CN, NO,, aryl or heterocyclyl; Ry, is the characterising group of an amino acid, nis 0 or an integer from 1 to 20 and s is an integer from 1 to 5; R; is hydrogen, C, alkyl, OH, SH, NH,, -NO,, CF; halo or -CN; R, is hydrogen, C,-Csalkyl, -(CH,),NH,, -(CH,),,-OH, -(CH,),,-CF;, -(CH,),-SHor a 5 or 6 membered heterocyclic group, wherein m is 0 or an integer from 1 to 3; R, is hydrogen, C, ;alkyl, OH, SH, NH,, NO,, CF,, halo or CN; A is unsubstituted methylene or mono-substituted methylene.
4. A compound according to claim 2 wherein
Xis -O-, -S-, -NH-; Y is -O-, -S- or -N(R;)-; Z forms a covalent bond between adjacent methylene groups; R, is C;-Cyalkyl, C,-Cyealkenyl, C,-Cyealkynyl, (A),C(O)Ry, -(A),C(S)R,, -(A) SOR, (A):S(O):Ry, -(A)ORy, -(A),SRy, -(A)N(Re),, (A), C(=NRs)Ry, or (A),Ry; where n, Rg, R;, Ry, Ry, Ry and R;; are defined above; R, is hydrogen, methyl, OH, OCH, SH, NH,, NO,, CF,, halo or CN; R; is Cy zalkyl, -(CH,),NH,, -(CH,),-OH, -(CH,),.SH or heterocyclyl where m is defined above; R, is hydrogen, methyl, OH, OCH,, SH, NH,, NO,, CF, CF;, halo or CN.
5. A compound according to claim 2 wherein Xis -O- or NH; Y is -O- or -N(Rg)- where Ry; is selected from hydrogen, Cy alkyl, C, alkenyl,
C,.0alkenyl, Cj oalkynyl and (CH,),R;, where R;, and n are defined above; Z forms a covalent bond between adjacent methylene groups; R, is hydrogen, halomethyl, OH, OCH, SH, NH,, NO, or CN; R, is hydrogen, C,alkyl, (CH), NH,, (CH,),OH or (CH,),.CF; or heterocyclyl where m is defined above; R, is hydrogen, methyl, OH, OCH, SH, NH,, NO, or CN.
6. A compound according, to claim 1 of formula (III)
[0 X Y Ry Rs H Re (IID wherein Xis -O- or -NH-; Y is -O- or -N(R;s)- where Ry is defined above; R; is hydrogen, NH,, OH; R, is hydrogen, methyl, OCH, or OH.
7. A compound according to claim 6 wherein R, is selected from (A),OR; where nis 0.
8. A compound according to claim 1 wherein Xis -5-; Y is -N(Rs)-; X' is —=C(Rs);- Y' is —-C(Rs)~ z forms a covalent bond between X' and Y'.
9. A compound according to claim 8 wherein Y is -NH-; X'is =CHy; Y'is ~-CH;;
R,is H.
10. A compound according to claim 1 wherein X and Y are each -O-; X' and Y' are each =C(Rg),-; Z forms a covalent bond between X' and Y'.
11. A compound according to claim 10 wherein X'and Y' are each -CH,-; R, is H.
12. A compound according to claim 1 wherein X and X' taken together form —C(Rs)=N-; Y is —C(R;)- and taken together with the carbon atom bearing the phenyl group forms a double bond; Y'is -N(R:)-; Z forms a covalent bond between X and Y'.
13. A compound according to claim 12 wherein Y is -CH-; X is -CH-.
14. A compound according to claim 1 wherein X and X' taken together form -C(Rs)=N-; Z together with Y' forms -C(R;)=C(R;)-; Y is -C(R;)- and together with the carbon atom bearing the phenyl group forms a double bond.
15. A compound according to claim 14 wherein X is -C(OCH,);
Z together with Y' forms ~C(OCH,)=CH-; Y is -CH-.
16. A compound according to claim 1 wherein X'is =C(Rg) Y' is -C(R)y; Z is -C(Rg),-; X and Y are each -O-.
17. A compound according to claim 16 wherein X', Y' and Z are each ~-CH,-; R, is H.
18. A compound according to claim 1 wherein X and Y are each -S-; X'and Y' are each ~C(Rs),~; Z forms a covalent bond between X' and Y'.
19. A compound according to claim 18 wherein X'and Y' are each -CH,-; R; is H.
20. A compound according to claim 1 wherein X is =S-; Y is -O-; X'and Y' are each —-C(Rs),~; Z forms a covalent bond between X' and Y'.
21. A compound according to claim 20 wherein X' and Y' are each -CH,-.
22. A compound according to claim 1 wherein X and X' taken together form —C(Rs)=C(Rs)-; Z together with Y' forms -C(Rs)=C(R;)-; Y is -C(Rs)- and together with the carbon atom bearing the phenyl group forms a double bond.
23. A compound according to claim 22 wherein X and X' taken together form -CH=CH-; Z together with Y forms -CH=CH-; Y is -CH-.
24. A compound according to claim 1 wherein Y is -N- and taken together with the carbon atom bearing the phenyl group forms a double bond; Xis -O-; X'and Y' are each -C(R:),- Z forms a covalent bond between X' and Y'.
25. A compound according to claim 24 wherein X' and Y' are each ~CH,-.
26. A compound according to claim 1 wherein X and Y are each -C(R;),-; X'and Y' are each -N(R;)-; Z is C(Rs),. :
27. A compound according to claim 1 wherein Xis -O-;
Y' is -N(Rs)-; X' and Y are each —C(R;),-.
28. A compound according to claim 1 wherein X and X' are each ~C(Rs),~; Y is -N(R)-; Y' is CRs), Z forms a covalent bond between X' and Y'.
29. A compound according to claim 1 wherein X is -N(Rs)-; X' is —-C(Rs)y; Y is -C(Ra)y Y' is -N(Rs)-; Z forms a covalent bond between X' and Y'.
30. A compound according to claim 1 wherein X and X' are each —-C(R),- Y is —C(Rs),-; Y' is -N(R)-; Z is -C(Rs),-
31. A compound according to claim 1 selected from the group consisting of: 2-(2-hydroxyethoxy)-2-(4-hydroxy-3-methylphenytl)-1,3-dioxolane; 2-(2-hydroxyethoxy)-2-(4-hydroxyphenyl)-1,3-dioxolane; 2-(2-hydroxyethoxy)-2-(3-bromo-4-hydroxy-5-methylphenyl)-1,3-dioxolane;
2-(4-Bromophenyl)-1,3-thiazolane; 2-(4-Methoxyphenyl)-1,3-thiazolane; 4-(1,3-Thiazolidin-2-yl)benzonitrile; 2-(4-Hydroxy-3-methoxyphenyl)-1,3-thiazolane; 2-(3,4-Dimethoxyphenyl)-1,3-thiazolane; Methy! 4-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]butanoate; 4-[2-(4-Fluorophenyl)-1,3-dioxolan-2-yl]butan-1-ol; 2-(4’-Bromophenyl)-2-butyl-1,3-dioxolane; 4-(4-Methoxyphenyl)-1-(3-methylbutyl)-1 A -pyrazole;
1-(3-Methylbutyl)-4-(4-methylphenyl)-1H-pyrazole; 2,6-Dimethoxy-3-[4-(trifluoromethoxy)phenyl pyridine); 2-[4-(2-Thienyl)phenyl]-1,3-thiazolane; 2-Ethyl-2-(4-methoxyphenyl)-1,3-dioxolane; 2-Hexyl-2-(4-methylphenyl)-1,3-dithiolane;
2-Methyl-2-(4-methylphenyl)-1,3-dithiolane; 2-Hexyl-2-(4-methylphenyl)-1,3-dioxolane; 2-(4-Chlorophenyl)-2-methyl-1,3-dioxane; 2-(4-Chlorophenyl)-2-methyl-1,3-dioxolane; 2-Methyl-2-(4-methylphenyl)-1,3-dioxane;
2-Methyl-2-(4-methylphenyl)-1,3-dioxolane; 2-(4-Chlorophenyl)-2-methyl-1,3-dithiolane; 2-(4-Nitrophenyl)-2-methyl-1,3-dioxolane;
2-(4-Nitrophenyl)-2-methyl-1,3-dioxane; 2-(4-Methoxyphenyl)-1,3-oxathiolane; 2-(3,4,5-Trimethoxyphenyl)-1,3-oxathiolane; 2-Methoxy-4-(1,3-oxathiolan-2-yl)phenol; 4-(1,3-Oxathiolan-2-yl)benzonitrile; 2-(4-Bromophenyl)-2-ethyl-1,3-oxathiolane; 4-(5-Methyl-1,3-oxathiolan-2-yl)benzonitrile; 2-(4-Thien-2-ylphenyl)-1,3-oxathiolane; 4-(5-Methyl-2-octyl-1,3-oxathiolan-2-yl)phenol; 2-Fluoro-5-(5-methyl-1,3-oxathiolan-2-yl)benzenecarbonitrile; 4-Methoxy-4'-(trifluoromethoxy)-1,1"-bipheny]; 2,6-Dimethoxy-3-[4-(trifluoromethyl)phenyl]pyridine; 2-(4-bromophenyl)-2-butyl-4-propyl-1,3-oxathiane; 4-(1,3-Dioxolan-2-yl)benzenecarbonitrile; 2-(3,5-Dimethoxyphenyl)-2-hexyl-1,3-dioxolane; 2-(4-Chlorophenyl)-2-ethyl-4-methyl-1,3-dioxolane; 5-(5,5-Diethyl-1,3-dioxan-2-yl)-2-fluorobenzenecarbonitrile; 2-(4-Chlorophenyl)-4,5-dihydro-1,3-oxazole; : 2-(4-Methylphenyl)-4,5-dihydro-1,3-oxazole.
32. A compound according to claim 31 selected from the group consisting of: 2-(2-hydroxyethoxy)-2-(4-hydroxy-3-methylphenyl)-1,3-dioxolane; 2-(2-hydroxyethoxy)-2-(4-hydroxyphenyl)-1,3-dioxolane;
2-(2-hydroxyethoxy)-2-(3-bromo-4-hydroxy-5-methylphenyl)-1,3-dioxolane; Methyl! 4-[2-(4-fluorophenyl)-1,3-dioxolan-2-yl]butanoate; 4-[2-(4-Fluorophenyl)-1,3-dioxolan-2-ylJoutan-1-ol; 2-(4'-Bromophenyl)-2-butyl-1,3-dioxolane;
4-(4-Methoxyphenyl)-1-(3-methylbutyl)-1H-pyrazole; 1-(3-Methylbutyl)-4-(4-methylphenyl)-14-pyrazole; 2,6-Dimethoxy-3-[4-(trifluoromethoxy)phenyl] pyridine); 2-[4-(2-Thienyl)phenyl]-1,3-thiazolane; 2-Ethyl-2-(4-methoxyphenyl)-1,3-dioxolane;
2-Hexyl-2-(4-methylphenyl)-1,3-dithiolane; 2-Hexyl-2-(4-methylphenyl)-1,3-dioxolane; 2-(4-Bromophenyl)-2-ethyl-1,3-oxathiolane; 4-(5-Methy!-1,3-oxathiolan-2-yl)benzonitrile; 2-(4-Thien-2-ylphenyl)-1,3-oxathiolane;
4-(5-Methyl-2-octyl-1,3-oxathiolan-2-yl)phenol; 2-Fluoro-5-(5-methyl-1,3-oxathiolan-2-yl)benzenecarbonitrile; 4-Methoxy-4'-(trifluoromethoxy)-1,1"-biphenyl; 2,6-Dimethoxy-3-[4-(trifluoromethyl)phenyl]pyridine; 2-(4-bromophenyl)-2-butyl-4-propyl-1,3-oxathiane;
4-(1,3-Dioxolan-2-yl)benzenecarbonitrile; 2-(4-Chlorophenyl)-2-ethyl-4-methyl-1,3-dioxolane; 5-(5,5-Diethyl-1,3-dioxan-2-yl)-2-fluorobenzenecarbonitrile.
- v .
33. A compound according to claim 1 selected from the group consisting of: 2-(2-hydroxyethoxy)-2-(4-hydroxy-3-methylphenyl)-13-dioxolane; 4-(4-Methoxyphenyl)-1-(3-methylbutyl)-1H-pyrazole; 1-(3-Methylbutyl)-4-(4-methylphenyl)-1H-pyrazole; 2-Hexyl-2-(4-methylphenyl)-1,3-dithiolane; 2-Methyl-2-(4-methylphenyl)-1,3-dithiolane; 2-(4-Thien-2-ylphenyl)-1,3-oxathiolane; 4-Methoxy-4'- (trifluoromethoxy)-1,1’- biphenyl; 2,6-Dimethoxy-3-[4-(trifluoromethyl)phenyl]pyridine.
34. The use of a compound according to any one of claims 1 to 33 in the manufacture of a medicament for use in a method for inhibiting cytokine or biological activity of MIF..
35. A compound according to any one of claims 1 to 33 for use in a method for inhibiting cytokine or biological activity of MIF, said method comprising contacting MIF with a cytokine or biological inhibiting amount of said compound.
36. The use of a compound according to any one of claims 1 to 33 in the manufacture of a medicament for the treatment, prevention or diagnosis of a disease or condition wherein MIF cytokine or biological activity is implicated.
37. A compound according to any one of claims 1 to 33 for use in a method of treating, preventing or diagnosing a disease or condition wherein MIF cytokine or biological activity is implicated, said method comprising the administration of a treatment, prevention or diagnostic effective amount of said compound.
38. The use of a compound according to claim 36 wherein the disease or condition is selected from the group consisting of autoimmune diseases, tumours or chronic or acute inflammatory diseases.
39. A compound according to claim 35 wherein the disease or condition is selected from the group consisting of autoimmune diseases, tumours or chronic or acute inflammatory diseases. AMENDED SHEET
\
40. The use of a compound according to claim 38 wherein the disease or condition is selected from the group consisting of: rheumatoid athritis, systemic lupus eryhtematosus, ulcerative colitis, Crohn's disease, multiple sclerosis, psoriasis, uveitis, atherosclerotic vascular disease, asthma and chronic obstructive pulmonary disease.
41. A compound according to claim 39 wherein the disease or condition is selected from the group consisting of: rheumatoid athritis, systemic lupus eryhtematosus, ulcerative colitis, Crohn's disease, multiple sclerosis, psoriasis, uveitis, atherosclerotic vascular disease, asthma and chronic obstructive pulmonary disease.
42. A compound according to claim 37 wherein the subject is a human subject.
43. A pharmaceutical composition comprising a compound according to any one of claims 1 to 33 and a pharmaceutically acceptable carrier, diluent or excipient
44. A pharmaceutical composition according to claim 43 further comprising a glucocorticoid.
45. A compound according to any one of claims 1 to 33 for use in a method of treating or preventing a disease or condition wherein MIF cytokine or biological activity is implicated comprising: administering to a mammal said compound or a pharmaceutically acceptable salt or prodrug thereof and a second therapeutic agent.
46. A compound according to claim 45 wherein the second therapeutic agent isa glucocorticoid.
47. The use of a compound according to any one of claims 1 to 33 in the manufacture of a medicament for use in a method of prophylaxis or treatment of a disease or condition for which treatment with a glucocorticoid is indicated.
48. A compound according to any one of claims 1 to 33 for use in a method of prophylaxis or treatment of a disease or condition for which treatment with a glucocorticaid is indicated, said method comprising: administering to a mammal a glucocorticoid and said compound or a pharmaceutically acceptable salt or prodrug thereof.
49. The use of a compound according to any one of claims 1 to 33 for the manufacture of a medicament for use in a method of treating a steroid-resistant disease or condition. AMENDED SHEET
' :
1¢ . -128-
50. A compound according to any one of claims 1 to 33 for use in a method of treating a steroid-resistant disease or condition comprising: administering to a mammal a glucocorticoid and said compound or a pharmaceutically acceptable salt or prodrug thereof.
51. The use of a compound according to any one of claims 1 to 33 in the manufacture of a medicament for use in a method of enhancing the effect of a glucocorticoid in mammals.
52. A compound according to any one of claims 1 to 33 for use in a method of enhancing the effect of a glucocorticoid in mammals, said method comprising administering said compound simultaneously, separately or sequentially with said glucocorticoid. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003901579A AU2003901579A0 (en) | 2003-04-07 | 2003-04-07 | Therapeutic molecules and methods-3 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200508847B true ZA200508847B (en) | 2006-10-25 |
Family
ID=31500622
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200508847A ZA200508847B (en) | 2003-04-07 | 2005-11-01 | Novel methods for the treatment of inflammatory diseases |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003901579A0 (en) |
ZA (1) | ZA200508847B (en) |
-
2003
- 2003-04-07 AU AU2003901579A patent/AU2003901579A0/en not_active Abandoned
-
2005
- 2005-11-01 ZA ZA200508847A patent/ZA200508847B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2003901579A0 (en) | 2003-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100324001A1 (en) | Novel Methods for the Treatment of Inflammatory Diseases | |
US20100323999A1 (en) | Therapeutic Molecules and Methods-1 | |
EP2342179B1 (en) | Compounds for inhibiting semicarbazide-sensitive amine oxidase (ssao) / vascular adhesion protein-1 (vap-1) and uses thereof for treatment and prevention of diseases | |
JP2009509986A5 (en) | ||
US20060106102A1 (en) | Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif) | |
KR102588426B1 (en) | Substituted dihydropyrrolopyrazole derivatives | |
US20090130165A1 (en) | MIF Inhibitors | |
US6713510B2 (en) | 6-Methoxy-2-naphthylacetic acid prodrugs | |
ZA200508847B (en) | Novel methods for the treatment of inflammatory diseases | |
NIŢULESCU et al. | Synthesis and pharmacological evaluation of some new pyrazole derivatives | |
US6552078B2 (en) | 6-methoxy-2-naphthylacetic acid prodrugs | |
JP2024532406A (en) | Triazolone compounds and their medical uses | |
AU1576101A (en) | 6-methoxy-2-naphthylacetic acid prodrugs | |
ZA200409845B (en) | Therapeutic molecules and methods-1 |